TANIA M. BUBELA - CURRICULUM VITAE · TANIA M. BUBELA - CURRICULUM VITAE Dean and Professor Faculty...

TANIA M. BUBELA - CURRICULUM VITAE Dean and Professor Faculty of Health Sciences Simon Fraser University Blusson Hall, 11328 Simon Fraser University 8888 University Drive Burnaby, B.C. Canada V5A 1S6

AREAS OF INTEREST

Intellectual property, biotechnology, technology transfer, innovation and knowledge management, health law, science/health communication and media studies.

EDUCATION

2003 Juris Doctor with Distinction (Gold Medalist), University of Alberta 1990-1995 Doctor of Philosophy, University of Sydney, Sydney Australia 1985-1988 Bachelor of Science (Honours), Australian National University, Canberra Australia

PROFESSIONAL EXPERIENCE

2017- Dean, Faculty of Health Sciences, Simon Fraser University 2017- Professor, Faculty of Health Sciences, Simon Fraser University 2015-2017 Professor, School of Public Health, University of Alberta 2014-2016 Associate Dean for Research, School of Public Health, University of Alberta 2011-2015 Associate Professor, School of Public Health, University of Alberta 2008-2011 Assistant Professor, School of Public Health, University of Alberta 2004- 2008 Assistant Professor, Marketing, Business Economics and Law, Alberta School of Business 2004 Student at Law, Field Law, Edmonton Alberta 2003-2004 Law Clerk to the Honourable Louise Arbour, Supreme Court of Canada 2000-2004 Researcher, Health Law Institute, Faculty of Law, University of Alberta 2002 Summer Internship, Alberta Court of Appeal Research Assistant, Committee on Discovery and Evidence, Alberta Law Reform Institute 1997-1999 Faculty (Tutor stream), Biology Group, University of Toronto at Mississauga 1996-1997 Post-Doctoral Fellow, Department of Zoology, University of Toronto and Centre for Biodiversity

and Conservation Biology, Royal Ontario Museum. 1995-1996 Sessional Lecturer, Division of Life Sciences, University of Toronto at Scarborough 1995 Guest Lecturer, Ecology Field Course, Churchill, Manitoba, University of Toronto 1990-1995 Ph. D. Researcher: First field trial for fertility control of red foxes 1992 Technical Officer, Environmental Survey and Research, NSW National Parks and Wildlife Service 1992-1993 Undergraduate Teaching Assistant, University of Sydney 1990: Guest Lecturer, School of Applied Science, University of Canberra 1989-1990 Research Assistant, Department of Botany and Zoology, Australian National University, Canberra 1989 Technical Officer, Burramys Project, NSW National Parks and Wildlife Service

of 74

ACADEMIC DISTINCTIONS AND AWARDS

2018 Fellow, Canadian Academy of Health Sciences 2017 Fulbright Scholar Award (12,500 $) (Declined due to new position as Dean of the Faculty of

Health Sciences, Simon Fraser University) 2015-2016 Vice President Research Fellow, University of Alberta (10,000 $) 2014-2015 McCalla Professorship, University of Alberta (20,000 $) 2010 Research Fellow, Science at Creative Commons 2003 The Horace Harvey (Gold) Medal in Law for the graduating student with the highest standing in

the work prescribed for the JD degree. 2003 The Mr Justice W G Morrow Memorial Prize. 2003 The Sheldon M Chumir Memorial Essay Prize in Human Rights. 2003 The Master L D Hyndman Memorial Prize for the highest mark in the third year class for a paper

in the course on Professional Responsibility. 2001, 2002 Blake, Cassels and Graydon Second Year Scholarship (renewed 2002) 2002 Honourable Mr. Justice Arnold F Moir Scholarship for outstanding academic achievement in

second year law 2001, 2002 The Jason Lang Scholarship: Alberta Learning - academic achievement first and second year law 2001 The Chief Justice S Bruce Smith Prize for highest standing in first year law 2000-2003 Dean’s List for first, second, and third year law 1992-1994 Ph.D. Scholarship, Collaborative Research Centre for Biological Control of Vertebrate Pest

Populations 1993 Travel award, visiting student, Department of Biology, University of British Columbia

PROFESSIONAL AFFILIATIONS AND TRAINING

Certificate of Completion: 2019 PHSA San’yas Indigenous Cultural Safety Training Program Leadership Certificate: 2016 Adaptive Leadership Course. Certificate of Completion: Cost Effectiveness Modeling Course. University of Alberta. April 29-May 3, 2013 Expert: The Innovation Partnership; www.theinnovationpartnership.org Research Fellow: Health Law Institute, University of Alberta Member: Senior Women Academic Administrators of Canada Member: University of Alberta Academic Women’s Association Member: Centre for Intellectual Property Policy, Faculty of Law, McGill University Member: Technology Commercialization Centre, School of Business, University of Alberta Member 2005-2017 Law Society of Alberta (2005 Call) Member: Canadian Bar Association

of 74

ACADEMIC LEADERSHIP AND SERVICE

LEADERSHIP AT SIMON FRASER UNIVERISTY FROM 2017 Strategic Planning

As an interdisciplinary scholar in ethical, legal and social implications of the development of novel health biotechnologies, with a strong background in the life sciences, I bring training and expertise in interdisciplinary research to all service activities. In 2017, I began to lead two integrated strategic planning initiatives in the Faculty of Health Sciences (FHS) at Simon Fraser University: the first focused on developing a Research Strategic Plan that exemplifies the FHS interdisciplinary and social justice vision and the second that integrates its research strengths into teaching and service commitments. Our strategic planning initiatives build on the SFU Vision of being “the leading engaged university defined by its dynamic integration of innovative education, cutting-edge research and far-reaching community engagement.” They therefore integrate and focus on the intersection of SFU’s three core themes:

• Engaging Students: To equip students with the knowledge, skills and experiences that prepare them for life in an ever-changing and challenging world.

• Engaging Research: To be a world leader in knowledge mobilization, building on a strong foundation of fundamental research.

• Engaging Communities: To be Canada’s most community-engaged research university.

In a faculty-wide consultation, FHS identified six six health-related research challenge areas, one health sciences education-focused challenge area and four cross-cutting themes that envision FHS research that can help shape future states that ameliorate health-related challenges facing global societies. Faculty will be incentivised to form teams and collaborate within these challenge areas and compete for provincial, national and international funding. The cross-cutting themes are: local to global research impacts; social inequities; philosophy of science and ethics; and responsiveness to the Truth and Reconciliation Commission to improve the health and wellness of Indigenous peoples and communities in Canada. The six research challenge areas are: (1) transforming mental health and substance use policies and interventions informed by evidence and a social determinants of health approach; (2) anticipating and responding to changing threats and burdens of HIV and other infectious diseases to improve the health of human populations; (3) analyzing and influencing equity, health and wellbeing through policy and systems; (4) intersecting social, environmental and biological influences and interventions affecting health and well-being across the human life span; (5) harnessing Big Data and technological and social innovation to influence individual and population health; and (6) Responding to the challenge of humans irreversibly changing the planet.

The development of these challenge areas then informs our academic plan that incorporates curricular design that integrates research and teaching and informs engagement with our students and external/community partners. Our goal is to build communities that integrate research and learning and teaching within the challenge areas,

LEADERSHIP AND SERVICE ACTIVITIES PRIOR TO 2017

From 2014-2016, I served as Associate Dean for Research in the School of Public Health, a position that required me to play a research advocacy role on behalf of the faculty on University and Provincial committees as well as providing a strong mentoring role for junior faculty in seeking funding and publishing. I supported and drafted nominations for faculty for Canada Research Chairs, Canadian Academies, and Martha Cook Piper Research Awards. Based on my experience, in 2015-2016, I was asked to undertake a university-wide consultation to evaluate processes and policies of the University of Alberta’s Research Services Office as a Vice President

of 74 Research Fellow. In addition, in 2016, I served as a representative of the University of Alberta in development of a provincial science policy.

Many of my leadership and service activities directly engaged my legal expertise, especially when they relate dto regulation of research, such as the University of Alberta’s Health Research Ethics Board or Biosafety Committee, or to the plain-language drafting of policies and guidelines. My substantive and methodological expertise enabled me to be a broad-minded and fair reviewer of diverse applications in health research from the ethics, law, humanities and other social science communities. I was continuously invited (although on occasion unable to participate) to be a member or scientific officer of the CIHR Humanities, Law, Ethics, and Social Sciences Committee. Since the restructuring of CIHR, I have reviewed for Stage 1 of the Foundation Scheme, for the Project Scheme, served as Virtual Chair for the Project Scheme and was appointed to a term as Scientific Officer for the flagship Foundation Scheme. My expertise in knowledge translation with multiple stakeholder communities mademe an excellent communicator with the media as well as lay and policy audiences. My research and consultation work on innovation and research metrics has informed the development of new FEC guidelines and supporting online reporting and database infrastructure for the School of Public Health. I served on the SPH FEC committee for a two-year term. In addition, I assist all research teams I work with on issues related to governance and knowledge translation, as well as legal issues such as Intellectual Property Agreements, Material Transfer Agreements and regulatory applications.

My leadership and service activities benefited students and peers in multiple ways. My active engagement in service activities served as a role model in collegiality and service for my students. To further benefit students, I worked with them to understand the peer-review process for journal publications and funding proposals, in which my graduate students have all been highly successful. My experience with peer-review has enhanced my own abilities to publish in top-tier journals and to be successful in funding awards. I taught both activities within the required School of Public Health PHD Course in Science Communication in Public Health, and as an additional service to the University of Alberta community, I opened the classes on funding applications and journal submissions to all interested participants. I was also part of interdisciplinary panels with nursing on publishing for impact. I engaged with researchers across campus and provincial health funders to translate my experience with peer review, consultations with international funding agencies, and success in grant writing to advise on how to improve University of Alberta’s success in national funding programs, especially interdisciplinary team grants. I represented the School of Public Health on the CIHR Open-Operating Grant Program (OOGP) Reforms Committee to develop interpretation guidelines as part of the new reforms to the Open Suite of Programs and peer review process, assess potential impacts of the reforms for Pillars 3 and 4 researchers and to develop response strategies. I presented the new development to my colleagues in the School of Public Health and to the research community at the University of Alberta more broadly. Starting in 2015, I was appointed to the CIHR College of Reviewers. My work with the media has also informed the media communications module in Science Communication in Public Health. Communicating with diverse audiences one of seven core competencies identified by The Public Health Agency of Canada necessary for practice in the Canadian public health system.

SERVICE AND LEADERSHIP, FACULTY OF HEALTH SCIENCES (FHS), SIMON FRASER UNIVERSITY 2018 - Chair, Faculty Executive Committee 2018 Revised FHS Constitution 2018 Developed Faculty of Health Sciences Academic Plan, 2018-2023 2018 Developed FHS Research Strategic Plan, 2018-2023

SERVICE AND LEADERSHIP, SIMON FRASER UNIVERSITY 2018 - 2019 Member, Search Committee, SFU President 2018 - Member, Steering Committee, SFU Centre for Dialogue 2019 - Member, Advisory Committee, Carnegie Community Engagement Classification 2018 - Member, Senate Committee on University Priorities (SCUP) 2018 - Member, Enterprise Risk Management Working Group 2018 - Co-Chair, Indigenous Pathways Planning Group

of 74 Jan-Feb 2018 Member, Search Committee, Vice President Research and International Jan 19, 2018 Participant, Strategic planning retreat for SFU Innovates 2017 - Senator, Simon Fraser University 2017 - Ex officio member, Senate Committee on Enrollment Management and Planning 2017 - Member, Deans Council 2017 - Member, Research Systems Stewardship Committee

SERVICE AND LEADERSHIP ON EXTERNAL COMMITTEES/ADVISORY BOARDS, PROVINCIAL 2019 - Member, Board of Directors, Institute for Health System Transformation and

Sustainability. http://ihsts.ca/ 2019 - Member, External Advisory Committee, Centre for Health Evaluation and Outcome

Sciences (CHÉOS), St. Paul’s Hospital, Vancouver, British Columbia. http://www.cheos.ubc.ca/

2019 - Member, Advisory Council, Clinical Trials BC. BC Academic Health Science Network, Vancouver, British Columbia. https://www.clinicaltrialsbc.ca/

2018 - Member, Steering Committee, Surrey City Lab 2018, 2019 Reviewer Scholar Awards, BC Children’s Hospital Research Institute 2017 - Member, Health Research Council of British Columbia 2017 - Member, Scientific Advisory Board, British Columbia Cancer Agency Immunotherapy

Program 2016 Member, Provincial Working Group on Precision Health, Alberta 2016 University of Alberta representative on “Science Enterprise and Research - Outcome

Mapping" initiative for the Province of Alberta to inform the development of a provincial science strategy, including for 'omics research and infrastructure. Initiative lead by Dr. Daphne Cheel, Executive Director, Science and Research Branch, Alberta Innovation and Advanced Education, Government of Alberta. Panel included representatives from Provincial innovation and health departments, health funders, and the Universities of Alberta, Calgary and Lethbridge.

2015-2016 Board Member, Alberta PROMs and EQ-5D Research and Support Unit (APERSU).

SERVICE AND LEADERSHIP ON EXTERNAL COMMITTEES/ADVISORY BOARDS, NATIONAL 2019- Chair, Board of Directors, The Centre for Phenogenomics (TCP), Toronto.

http://phenogenomics.ca/ 2019- Chair, CIHR Health Ethics, Law and Humanities Committee 2017- Member, CIHR College of Reviewers. 2016- Member, Advisory Board of Directors, The Centre for Phenogenomics (TCP), Toronto. 2016 Scientific Officer, CIHR Foundation Scheme – appointed to Executive for 3 years 2016 Virtual Chair, CIHR Project Scheme 2015- Reviewer for CIHR Foundation and Project Schemes. 2014 - 2015 CIHR-Institute of Genomics Sounding Board. One of 30 leading researchers and

stakeholders in an invited network of experts in GE3LS and Health Services & Policy Research in Genetics/Genomics.

2013 - 2014 Member of the CIHR Open-Operating Grant Program (OOGP) Reforms Committee. Representing the School of Public Health on this national committee to develop interpretation guidelines as part of the new reforms to the Open Suite of Programs and peer review process, assess potential impacts of the reforms for Pillars 3 and 4 researchers and to develop response strategies.

2012 - 2018 Appointed to the CIHR Stem Cell Oversight Committee (SCOC) 2012 - 2014 Scientific Officer, CIHR Humanities, Law, Ethics and Social Science Committee January 2011 - 2014 Member, CIHR Humanities, Law, Ethics and Social Science Committee November 2011 Scientific Officer, CIHR Humanities, Law, Ethics and Social Science Committee

of 74 October 2010 - 2012 Elected to the Board of the Canadian Coalition for Global Health Research (CCGHR) 2010 Member, CIHR Health Ethics, Law and Humanities Committee July 2009 - 2012 Co-Chair Canadian Coalition for Global Health Research (CCGHR) Policy Influence

Program February – May 2009 Team to assist the Canadian Coalition for Global Health Research (CCGHR)’s Board of

Directors prepare a 5-year strategic plan—concept area “Policy Engagement” 2007 - 2016 Member, Training and Education Committee for the Stem Cell Network 2007 Member of the Steering Committee for the Stem Cell Network Annual General Meeting

held in Toronto in November 2007. 2006 – 2008 Member, CIHR Health Ethics, Law and Humanities Committee

Mentor for Trainee Member of the Committee 2006 – 2009 Member, Assistant Deputy Minister (ADM) Committee on International Polar Year (IPY),

Data Management Subcommittee

SERVICE AND LEADERSHIP ON EXTERNAL COMMITTEES/ADVISORY BOARDS, INTERNATIONAL 2016- Panel of External Advisors, Knockout Mouse Project (KOMP2) and the Davis, Toronto,

Charles River, CHORI (DTCC) Consortium. The Consortium works to produce and phenotype 2,500 knockout mouse lines from gene targeted ES cells generated by the first phase of the KOMP.

2016- Associate Editor, Frontiers in Medicine (Regulatory Science). 2015 International Peer-Reviewer for the Austrian Ludwig Boltzman Gesellschaft of Ludwig

Boltzmann Institute applications. 2015- Editorial Board, Cell and Gene Therapy Insights (Prof. Chris Mason, Imperial College,

London, Senior Editor; BioInsights) 2012 - 2015 International Mouse Phenotyping Consortium (IMPC) Line Exchange and MTA

Committee March 2011 - Advisory Board for Science Translational Medicine

PEER REVIEW (AD HOC GRANT REVIEW IN BOLD) 2019 Reviewer for BMC Medicine 2018 Reviewer for Science 2018 Editor for Frontiers in Medicine 2017 Reviewer for Journal of Law and the Biosciences 2017 Reviewer for PLoS Biology 2016 Reviewer for Regenerative Medicine 2016 Reviewer for Journal of the American College of Cardiology 2009-2016 Reviewer for all Training Related Grants for the Stem Cell Network 2015 Reviewer for Journal of Science Communication 2015 Reviewer for Expert Opinion on Therapeutic Patents 2015 Reviewer for Vaccine 2014 Reviewer for Nature Biotechnology 2014 Reviewer for Nature 2013 Reviewer for BMC Medical Ethics 2013 Reviewer for Medical Law International 2013 Reviewer for Progress in Neurobiology 2012-2013 Reviewer for American Journal of Bioethics – Primary Research 2013 Reviewer for Public Understanding of Science 2012-2013 Reviewer for Progress in Neurobiology 2013 Reviewer for SSHRC - Insights Grant 2012 Reviewer for American Journal of Human Genetics 2012 Reviewer for Journalism Practice

of 74 2011 Reviewer for Global Policy 2011 Reviewer for Science Translational Medicine 2011 Reviewer for Cell Stem Cell 2010 Reviewer for Regenerative Medicine 2010 Reviewer for Nature Biotechnology 2010 Reviewer for Public Understanding of Science 2010 External Reviewer for CIHR “Health Ethics, Law and Humanities” Grants 2009 Reviewer for Psychology, Health & Medicine 2009 Reviewer for Community Genetics 2009 Reviewer for Australian and New Zealand Journal of Public Health 2008 Wellcome Trust, UK, Enhancement Award 2008 Reviewer for BMC Medical Ethics 2008 Reviewer for BMC Genomics 2006-2008 Reviewer for CIHR “Health Ethics, Law and Humanities” Grants Committee for Operating Grants

and RFAs. 2007- Reviewer of Abstracts submitted for the Stem Cell Network AGM. 2007 Reviewer for Public Understanding of Science 2007 Reviewer for Social Science and Humanities Research Council (SSHRC) Operating Grants. 2007 Reviewer for Medical Decision Making, Journal of the Society for Medical Decision Making. 2005 Reviewer for Social Science and Medicine. 2005 Reviewer for Social Science and Humanities Research Council (SSHRC) Operating Grants.

SERVICE ACTIVITIES AND LEADERSHIP POSITIONS AT THE UNIVERSITY OF ALBERTA 2003-2017

SCHOOL OF PUBLIC HEALTH 2014 – 2016: Associate Dean for Research in the School of Public Health. 2013-2014: Lead Drafter – School of Public Health Guidelines for Merit Increments, End of First

Probationary Appointments, Tenure and Application for Promotion to the Rank of Professor and Developer of online FEC Report Form. • Assistance to the Dean for her presentation to the Minister's Advisory Committee

on Health 19 Oct 2009 • School of Public Health Strategic Planning 2009

2015-2016 Chair, Tier 2 Canada Research Chair in Health Economics/Health Services Research Advisory Selection Committee

2013 - 2015 PhD Curriculum Review Subcommittee 2014 Health Policy Advisory Selection Committee 2013 - 2016 Elected to the School of Public Health Faculty Evaluation Committee (FEC) 2012 - 2013 School of Public Health Dean Selection Committee 2012 - 2013 Working Group Qualitative Methods Education in the School of Public Health 2009 - 2013 Research Advisory Committee 2009 - 2010 Alberta policy coalition for cancer prevention 2009 - 2010 Space Planning Committee for Edmonton Clinic 2009 - 2010 Health Policy and Management Re-Design Committee (curriculum development)

UNIVERSITY OF ALBERTA 2016-2017 Advisory Search Committee, Vice President Research (Member; Chair David Turpin,

President, University of Alberta) 2016 Strategic Planning Committee – Research, Faculty of Medicine and Dentistry. 2015-2016 Appointed as one of two Vice President Research Fellows to undertake a consultation

to improve the policies and procedures of the University of Alberta Research Services

of 74 Office. Consultation will be with internal and external stakeholders and will involve the interface between the Research Services Office and other administrative units that manage research at the University of Alberta, such as TEC Edmonton (technology transfer and commercialization), NACTRC (clinical trials unit) and University of Alberta International. The goal will be to identify constraints and enablers for efficient research services and provide input from the perspective of active researchers on campus.

REPORT Bubela T and McCaffrey W (June 2016) Research Services at the University of Alberta: A Shared Responsibility. Consultation on Policies, Procedures and Practices of the Research Services Office. University of Alberta. 49pp.

2016 University of Alberta Precision Medicine Planning Working Group (Member) 2016 Adjudication Committee, J Gordin Kaplan Awards for Excellence in Research (Social

Science and Humanities; Science), University of Alberta 2016 Killam and Notley Postdoctoral Awards Committee (3 year appointment) 2016 Reviewer for Panel 2: Canadian Foundation for Innovation (CFI) Institutional Awards

Preliminary Applications for University of Alberta (42 applications) and Faculty of Medicine and Dentistry (23 applications)

2015 Review Committee, Department of Pediatrics Graduate Studies Program. Lead drafter of report to the Associate Dean Graduate Studies, Faculty of Medicine and Dentistry.

REPORT Bubela T, Jones N, Tyrrell G (December 2015) Graduate Studies Program Review: Department of Pediatrics. Report (29 pp.) commissioned by the Associate Dean Graduate Studies, Faculty of Medicine and Dentistry.

2015 Health Science Research Council Selection Committee on allocation of research space (Discovery Malls) in the Edmonton Clinic Health Academy (review of proposals)

2015, 2016 University of Alberta CIHR subcommittee for the selection of Banting Postdoctoral Fellow nominations

2015 Adjudication Committee – Vitamin Fund, Faculty of Agriculture, Life and Environmental Sciences, University of Alberta

2014 - 2016 University Research Policy Committee – representing the School of Public Health as Associate Dean for Research

2014 - Health Research Ethics Board (HREB) – Health Panel, University of Alberta (ethics review for The University of Alberta, Alberta Health Services (Capital Region) and Covenant Health Group)

2014 - 2015 Adjudication committee for McCalla Professorship Award 2014, 2015 Adjudication and planning committee for Campus Alberta Health Outcomes and Public

Health (HOPH) – Introductions on behalf of SPH, Session Chair, Discussion Leader 2013 - 2014 University of Alberta Biosafety Committee 2012 Northern Council (Dean’s representative) 2013-2014 Member of Advisory Committee to the Dean of Faculty of Medicine and Dentistry,

University of Alberta – Alberta Centre for Translational Science (ACTS) Initiative 2012 Data Summit – Organisation Committee, University of Alberta 2012

EXTRA-CURRICULAR ACTIVITIES 2000-2003 2001-2003 Book Review Editor and editorial board, Alberta Law Review 2000 Chair, Women’s Law Forum 2000-2003 Student Member, Canadian Bar Association

UNIVERSITY OF TORONTO PRE-2000 1998 Erindale College Teaching Excellence Award for Faculty Committee 1997-1998 Erindale Biology Executive Committee 1997-1998 Erindale Biology Curriculum Committee

of 74

RESEARCH

CURRENT RESEARCH PROGRAM

My program of research examines the ethical, legal and social implications of novel health biotechnologies. It takes a pluralist, systems approach, considering legal rules, institutions and community practices to understand global innovation ecosystems, including actors and networks for research and development, clinical translation, commercialization and adoption by health systems. I employ a mixed-methods approach to conduct empirical analyses of complex societal or technical problems. Given the interdisciplinary nature of my research, the audiences are diverse, including legal academics and bioethicists, scientific research communities, economists, university and funding decision makers, government policy makers, international organizations, industry, and civil society. To meet the needs of this diverse audience, I have published in both the academic literature in medical, ethics, policy, social science and law journals, and also in non-academic forms of dissemination for governments, non-state actors and the lay public.

My research program has three main foci, all related to my training and experience as a life sciences researcher, my subsequent training in intellectual property, health and biotechnology law and policy, and my present setting as an interdisciplinary researcher in health law and policy within a health sciences faculty.

A. Understanding Innovation Systems for Health Biotechnology: Commercialisation/ open science and intellectual property policies impact scientific culture as well as global knowledge and technology flows in health biotechnology. My research group has developed and deployed a range of novel bibliometric and scientometric methods to analyse the impacts, and we use these novel methods in conjunction with more traditional methods such as survey instruments, key informant interviews, social network analysis, and statistical modelling. With Dr. Richard Gold at the Faculty of Law, McGill University, we developed a transdisciplinary framework to understand the role of law and its relationship with institutions and practices in health biotechnology innovation systems. While interdisciplinarity leads to much insight, this component of my research moves further to integrate learnings from fields of law, economics, management, ethics, sociology, philosophy and science and technology studies to develop a comprehensive understanding of innovation systems in biotechnology. As part of a $3 million SSHRC Initiatives for the New Economy grant in 2008, led by Dr. Gold, we developed transdisciplinary methods to enhance mutual education and exchange, construct common analytical frameworks, a common vocabulary and a common set of research tools. This research resulted in an influential and well-publicized report on intellectual property systems in biotechnology. The report made the top-ten downloaded papers on the SSRN database (Sept-Oct 2008) in the categories Health Law Journals and LSN Science, Technology & Innovation Research Papers.

1. Gold ER, Adams W, Bernier L, Bubela, T, et al. (2008) Toward a New Era for Intellectual Property: From Confrontation to Negotiation. A Report by The International Expert Group on Biotechnology, Innovation and Intellectual Property. (The Innovation Partnership, 2008).

This work also led to continuing collaborations with two members of the SSHRC team, Drs Gold and David Castle (University of Victoria). We continue to develop novel methodologies for understanding the role of intellectual property within innovation systems:

2. Bubela T, et al. (2013) Nature Biotechnology 31(3): 202-206. [IF 23.268]

With further funding support from Genome Canada, the work also lead to a monograph (I co-authored 3 chapters) on intellectual property systems as they relate to access and benefit sharing for genetic resources and research collaborations between North and South research partners.

of 74 3. Bubela T, Gold ER (eds) Genetic Resources and Traditional Knowledge: Case Studies and Conflicting

Interests. (Williston, VT: Edward Elgar, 2012).

We have deployed these methods to empirically address policy issues with respect to the impact of commercialization activities on collaborative networks that advance health biotechnologies:

4. Bubela T, Strotmann A, Noble R, Morrison S (2010) Cell Stem Cell 7: 21-30. [IF 26.967]

further analysed the role of institutionalised technology transfer offices:

5. Bubela T, Caulfield T (2010) Trends in Biotechnology 28: 447-451. [IF 9.660]

and analysed emerging practices to minimize the negative impact of intellectual property on health innovation systems:

6. Bubela T, Cook-Deegan R (2015) Nature Biotechnology 33(2): 143-147. [IF 39.1] 7. Bubela T, et al. (2015) PLoS Biology 13(2): e1002060. [IF 12.690] 8. Bubela T, FitzGerald GA, Gold ER (2012) Science Translational Medicine 4(119): 11-16. [IF 10.575]

B. Understanding research commons. This research builds upon the work of Nobel Laureate and political economist, Elinor Ostrom to build a systems understanding of research commons and their governance. Research commons support pre-competitive research environments through data and materials sharing and supportive infrastructure such as databases and biorepositories. Our empirical research advances theory on the role of legal rules within knowledge commons and forms the basis of policy development for the governance of research commons.

9. Bubela T, et al. (2017) [book chapter] in Governing Medical Research Commons Cambridge University Press.

10. Bubela T, et al. (2012) Journal of Law, Information and Science 20(2): 98-121. 11. Schofield PN, Bubela T, et al. (2009) Nature 461: 171-173. [IF 36.104]

C. Knowledge translation in health, biotechnology and new technologies in biomedicine. This research explores how health and biotechnology research is represented by the research community, industry, politicians and policy makers, advocacy organisations, publics, and the popular media on multiple platforms, including traditional media and media 2.0. The research compares the translational layers between these stakeholder groups using a combination of qualitative (key informant interviews and focus groups) and quantitative research tools (lexicographic analysis, text coding, and statistical modelling). This work builds on earlier work with one of my mentors, Prof. Timothy Caulfield, Faculty of Law, University of Alberta.

12. Bubela T, Caulfield T (2004) CMAJ 170(9): 1399-1407. [IF 9.015].

I have since deployed novel text analytical methods and bibliometrics to examine translational fields of biomedicine.

13. Fung M, Atkins, HL, Yuan Y, Shi Q, Bubela T (2017) Stem Cell Reports 14. Li MD, Atkins, HL, Bubela T (2014) Regenerative Medicine 9 Epub ahead of print. DOI:

19.2217/RME.13.80 [IF 3.873] 15. Bubela T, Li MD, Hafez M, Bieber M, Atkins H (2012) BMC Medicine DOI: 10.1186/1741-7015-10-133. [IF

6.035]

We developed policy recommendations for science communication by media:

16. Bubela T, Nisbet MC, …, Caulfield T (2009] Nature Biotechnology 27: 514-518. [IF 31.090]

and recommendations for ethical risk communication amongst clinicians/researchers, patients/families and patient advocacy organizations in the context of early stage clinical trials of novel biotechnologies:

17. Benjamini S, Kowal SP, MacDonald I, Bubela T (2015) American Journal of Ophthalmology. 160:408-415. [IF 4.021; PMID 26032192]

of 74

PRIOR RESEARCH FOCI 1988-1999

Decade of field research experience in alpine environments in Australia and North America, integrating ecology and behaviour for the management of problem wildlife and the conservation of endangered mammal species.

• PDF research: Behavioural and genetic studies of collared pikas in the Yukon Territory, developed familiarity with DNA profiling.

• Doctoral research: Experimental studies on effects of sterilising introduced European red foxes by simulating immuno-contraceptive methods being developed by the Co-operative Research Centre for Biological Control of Vertebrate Pest Populations. Fox control is critical for the conservation of endangered Australian vertebrates.

• Honours research: Mastacomys fuscus is a vulnerable native rodent, endemic to subalpine regions of south-eastern Australia. Prior to my research, the ecology of this species was poorly understood.

RESEARCH GRANTS

RESEARCH GRANTS APPLIED FOR

2019-2022 Source Michael Smith Foundation for Health Research – Implementation Science Development Grant Title Breaking the cycle of recurrent fracture: Scaling up a fracture prevention program in British

Columbia Role Researcher Co-Lead (PI: Dr. Sonia Singh, Fraser Health Authority) Amount 499,999 $ RESEARCH GRANTS HELD CURRENTLY 2019-2021 Source The Connaught Foundation, University of Toronto Title mitoNET: The Power of Mitochondrial to Transform Human Health Role External Member (PI: Dr. Ana Andreazza, Pharmaceutical Sciences, University of Toronto) Amount 244,100 $

2018-2019 Source Michael Smith Foundation for Health Research – Implementation Science Development Grant Title Breaking the cycle of recurrent fracture: Scaling up a fracture prevention program in British

Columbia Role Co-Applicant (PI: Dr. Sonia Singh, Fraser Health Authority) Amount 10,000 $ To develop a full application for 500,000 $

2017-2018 Source Alberta Precision Health Initiative - Alberta Innovates Title Alberta Laboratory for Precision Health Role Principal Investigator Amount 300,000 $

2016-2019 Source BioCanRx NCE: Clinical, Social and Economic Impact Program Title Towards Rational Design of Policies and Practices to Enable Clinical Translation of Novel Cancer

Biotherapeutics in Canada. Role Principal Investigator Amount 346,386 $

of 74 2016-2018 Source Genome Canada Title Genomics and Personalized Health Ge3ls Network Role Theme Leader (Network Leaders: Francois Rouseau (Laval) and Christopher McCabe (Alberta)) Amount 1,000,000 $ (plus 1,000,000 $ Co-funding)

2015-2016 Source Advanced Education and Innovation (Alberta) Title ALMDx Role Principal Investigator (Lead PI: Michael Mengel, Department of Laboratory Medicine and

Pathology, University of Alberta) Amount 700,000 $

2015-2020 Source 2015 Networks of Centres of Excellence Title Biotherapeutics for Cancer Treatment / Biotherapies pour le Traitement du Cancer Network

(BioCanRx) Role Principal Investigator and Theme Co-Leader (Scientific Director: John Bell (OHRI)) Amount 54,378,500 $ (with 25,000 $ development fund 2013-2014)

2015 – Source The James and Jeanie Brown ALS Research Fund Goal Further research that will “prolong and/or improve the lives of people living with ALS” Role Researcher (Donation to Dr. Wendy Johnston, Faculty of Medicine and Dentistry, University of

Alberta to support the research and training). Amount 1,000,000 $

2013-2019 Source Alberta Innovates Health Solutions – CRIO Team Grant Title Alberta Ocular Gene Therapy Team Role Co-Lead (Collaborative Lead: Ian MacDonald) Amount 5,000,000 $ PRIOR RESEARCH GRANTS

2013-2018 Source Alberta Innovates Health Solutions – CRIO Team Grant Title Leading Clinical Trials in Islet and Stem Cell Transplantation, Restoration of Self-tolerance and

Beta Cell Regeneration - Solving the Supply and Survival Problem in Type 1 Diabetes Role Collaborative Member (Collaborative Lead: James Shapiro) Amount 5,000,000 $

2013-2018 Source Genome Canada 2012 Large-Scale Applied Research Project Competition Title PACE-'Omics: Personalized, Accessible, Cost-Effective applications of 'Omics technologies Role Co-Project Leader (Project Leader: Christopher McCabe) Amount 4,502,080 $

2012-2017 Source: CIHR: Emerging Team Grant, Rare Diseases Title: Choroideremia: expanding our understanding, exploring treatments Role: Co-Investigator (PI: Ian MacDonald) Amount: 930,305 $

of 74 2013-2016 Source Social Sciences and Humanities Research Council of Canada Title An Intellectual Property Index: Creating a firm foundation for transdisciplinary study, policy-

making and business strategy Role Co-Applicant (PI: E. Richard Gold) Amount 139,980 $

2014-2017 Source Genome Canada / Genome Quebec Subgrant/Contract from the Hôpital Maisonneuve Rosement Title Developing Cost Effective Immunotherapies Role Principal Investigator (with Dr. Christopher McCabe) Amount 92,700 $

2014-2015 Source Stem Cell Network: Public Policy Impact Grant Title Value-Engineered Translation – Cell Therapies (VET-CT) Role Principal Investigator (Lead PI: Christopher McCabe) Amount 50,000 $

2012-2014 Source Foundation Fighting Blindness Title Choroideremia: expanding our understanding, exploring treatments Role Co-Investigator (PI: Ian MacDonald) Amount 300,000 $

2012-2015 Source Choroideremia Research Foundation, Canada Title Choroideremia: expanding our understanding, exploring treatments Role Co-Investigator (PI: Ian MacDonald) Amount 125,000 $

2011-2015 Source Stem Cell Network Strategic Core Grant: Public Policy & ELSI Research in the Stem Cell Field Title Enhancing Translational Stem Cell Research: Innovative Models for Multi-Sectoral Collaboration. Role Principal Investigator Amount 350,000 $

2011-2015 Source Ontario Genomics Institute/Genome Canada Title NorCOMM2 - In vivo models for human disease & drug discovery Role Co-Applicant - GE3LS (PIs: Colin McKerlie and Steve Brown) Amount 5,242,298 $ with GE3LS component of 194,970 $

2010-2014 Source Ontario Genomics Institute/Genome Canada Title International Barcode of Life Project (iBOL) Role Co-Investigator (Project Leader: Paul Hebert with David Castle as GE3LS Project Leader) Amount 25,208,220 $ with 292,956 $ of total GE3LS component of 999,259 $

2009-2014 Source Genome Canada/Genome Alberta Title Biosystems for the Production of High-Value Plant Metabolites Role Co-Investigator (Project Leaders: Peter Facchini and Vincent Martin) Amount 13 471 000 $: GE3LS component of 647 819.04 $ (with Edna Einsiedel & Greg Hagen, UCalgary)

of 74 2011-2013 Source CIHR Operating Grant: Knowledge to Action Title Putting research to work: Understanding and improving knowledge translation in population

health Role Co-Applicant (PI: Maria Mayan) Amount 200,000 $

2010-2011 Source CIHR (Operating Grant: Health Systems, Ethics and Knowledge Translation Research on the

Implications of H1N1) Title H1N1 Knowledge Translation for Pregnant Women and Seniors Role Co-Principal Applicant (Cynthia Jardine – Nominated Principal App) Amount 99,989 $

2009-2011 Source The Stem Cell Network Strategic Core Grant Title Assessing health system barriers to the commercialization and utilization of stem cell therapies

in Canada Role Principal Investigator; Amount 150,000 $

2010 Source CIHR (Meeting, Planning and Development Grant) Title Assessing Canadian Knowledge Translation Approaches: Towards a Report Card on Research-to-

Action in Global Health Research. Role Principal Applicant on behalf of the Canadian Coalition for Global Health Research Amount 15,000 $

2008-2009 Source Stem Cell Network –Catalyst Grant Title Designing Metrics for Impacts and Social Benefits of the Stem Cell Network Role Principal Investigator Amount 50,000 $

2006-2010 Source Genome Prairie/Genome Canada Title Development of an Embryonic Stem Cell Library of Defined Mutations NorCOMM Project: Role Co-Applicant (PIs: Geoffrey Hicks and Janet Rossant)

Principal Investigator of GELS Component (with co-principal investigator, Edna Einsiedel, University of Calgary)

Amount 17,687,390 $ with GE3LS component of 230,761 $

2006-2007 Source Canadian Institutes of Health Research: Facing Our Future Title Impacts of Private Sector Representations of Genomics on Media: Coverage, Public Perceptions

and Health Policy Role Principal Investigator (Co-investigators: Tina Piper and Jennifer Argo) Amount: 61,021 $

2006-2008 Source Canadian Institutes of Health Research: Ethics Operating Title Intellectual property governance and non-state actors: The case of bill C-9 Role Co-investigator (PI: E. Richard Gold) Amount 175,042 $

of 74 2003-2007 Source Social Sciences and Humanities Research Council/New Economy Title Legal models of biotechnological intellectual property protection: A transdisciplinary approach Role Co-investigator (PI: E. Richard Gold) Amount 2,989,500 $

2007 Source International Polar Year Data Management Committee: DIAND/INA Title Review of law, practices and principles for data management and traditional knowledge in

Northern Canada Role Principal Investigator Amount $3,360

OTHER FUNDING

Other funding was provided through Advanced Food and Materials Network, Genome Canada and Stem Cell Network grants administered by the Health Law Institute, University of Alberta:

• Investigator: Genome Canada, $2,213,510: Translating Science: Genomics and Health Systems (PI: T. Caulfield, Health Law Institute, University of Alberta)

• Non-SCN Investigator: Stem Cell Network, $600,500: Towards the Clinic? Ethical, Legal and Social Issues (ELSI) Relevant to Emerging Stem Cell Therapies (PI: T. Caulfield, Health Law Institute, University of Alberta)

• Collaborator: Stem Cell Network, The Stem Cell Research Environment: Drawing the Evidence and Experience Together (PI: T. Caulfield, Health Law Institute, University of Alberta)

• Key Researcher: Advanced Food and Materials Network, $650,000: Social Issues In Nutritional Genomics: The Design of Appropriate Regulatory Systems and Issues of Public Representations and Understanding (PI: David Castle (U Ottawa) and Timothy Caulfield)

• Key Researcher: Advanced Food and Materials Network, (funding to U of A for one Research Assistant annually) Natural Health Product Regulations: Perceptions and Impact (PI Heather Boon (Pharmacy, University of Toronto))

2007 Following a peer-reviewed application, I was made an Investigator on the Stem Cell Network, a Networks of Centres of Excellence. My CV was selected as one of the CVs to put forward for the funding renewal for the Stem Cell Network. Membership of the network provides funding for trainees to attend the Annual General Meeting of the Stem Cell Network and other events and to apply for funding such as Catalyst grants from the network.

SCHOLARLY AND PROFESSIONAL WORK - PUBLICATIONS

REFEREED PUBLICATIONS (TRAINEES UNDERLINED) [ISI IMPACT FACTOR (IF) WHERE AVAILABLE; PUBMED ID]

2019 1. Brooks S, Bubela T (submitted, 2019) Application of protection motivation theory to clinical trial enrolment

for pediatric chronic conditions. BMC Pediatrics. 2. Bubela T, Kleiderman E, Master Z, McCabe C, Ogbogu U, Ravitsky V, Zarseczny A, Knoppers BM (submitted,

2019) Canada’s Assisted Human Reproduction Act: Pragmatic Reforms in Support of Research. Frontiers in Medicine.

3. Maximova K, Czoli C, O’Loughlin J, Minkley J, Raine K, Bubela T (submitted, 2019) Missed opportunities to promote tobacco cessation, physical activity and health eating? A systematic assessment of Canadian laws. CMAJ Open.

4. Mahjoub R, Bubela T, MacDonald IM, McCabe C (submitted, 2019) A novel model of value-based reimbursement: applications for gene therapy? Pharmacoeconomics.

of 74 5. Geary J, Reay T, Bubela T (in press, 2019) The impact of heterogeneity in a global knowledge commons:

Implications for governance of the DNA barcode commons. International Journal of the Commons. 6. Brooks S, Bubela T (in press, 2019) Participant perspectives on improving ocular gene therapy clinical trial

communications and conduct. Ophthalmic Genetics. [IF: 1.57; PMID: ] 7. Geary J, Bubela T (2019) Governance of a global genetic resource commons for non-commercial research: A

case-study of the DNA barcode commons. International Journal of the Commons 13(1). https://www.thecommonsjournal.org/articles/859/ [E-ISSN: 1875-0281]

8. Bubela T, Genuis SK, Junjua NZ, Krajden M, Mittmann N, Podolak K, Svenson LW (2019, in press) Medical Information Commons in Support of Learning Healthcare Systems: A View from Canada. Journal of Law, Medicine and Ethics 47(1), 97–105. [IF: 1.52; PMID: ] https://doi.org/10.1177/1073110519840488

9. McGuire AL, Majumber MA, Villanueva AG, Bardill J, Bollinger JM, Boerwinkls E, Bubela T, Deverka PA, Evans BJ, Garrison NA, Glazer D, Goldstein MM, Greely HT, Kahn SD, Knoppers BM, Koenig BA, Lambright M, Mattison JE, O’Donnell C, Rai AK, Rodriquez LL, Simoncelli T, Terry SF, Thorogood AM, Watson MS, Wilbanks JT, Cook-Deegan R (2019, in press) Importance of participant-centricity and trust for a sustainable medical information commons. Journal of Law, Medicine and Ethics. [IF: 152; PMID: ]

10. Viswanathan S, Boch R, Bubela T (28 March 2019, ePub) Recommendations for regulating the theoretical environmental risk of shedding for gene therapy and oncolytic viruses in Canada. Frontiers in Medicine 6: Article 58, 8 pp. doi: 10.3389/fmed.2019.00058.

2018 11. Nielsen J, Bubela T, Chalmers D, Johns A, Kahl L, Kamens J, Lawson C, Liddicoat J, McWhirter R, Monotti

A, Scheibner J, Whitton T, Nicol D (2018) Provenance and Risk in Transfer of Biological Materials. PLoS Biology 16(8): e2006031. https://doi.org/10.1371/journal.pbio.2006031 [IF: 9.797]

2017 12. Breden F, Luning Prak ET, Peters B, Rubelt F, Schramm CA, Busse C, Vander Heiden JA, hristley S, Chan

Bukhari SA, Thorogood A, Matsen F, Wine Y, Laserson U, Klatzmann D, Douek D, Lefranc MP, Collins AM, Bubela T, Kleinstein S, Watson CT, Cowell LG, Scott JK, Kepler TB (1 November 2017, epub) Reproducibility and Reuse of Adaptive Immune Receptor Repertoire Data. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2017.01418

13. Knowles L, Luth W, Bubela T (1 November 2017, epub) Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges. Journal of Law and the Biosciences. https://doi.org/10.1093/jlb/lsx030.

14. Deverka PA, Majumder MA, Villanueva AG, Anderson M, Bakker AC, Bardill J, Boerwinkle E, Bubela T, Evans BJ, Garrison NA, Gibbs RA, Gentleman R, Glazer D, Goldstein MM, Greely H, Harris C, Knoppers BM, Koenig BA, Kohane IS, La Rosa S, Mattison J, O'Donnell CJ, Rai AK, Rehm HL, Rodriguez LL, Shelton R, Simoncelli T, Terry SF, Watson MS, Wilbanks J, Cook-Deegan R, McGuire AL (2017) Creating a data resource: what will it take to build a medical information commons? Genome Medicine 9:84 Online: https://doi.org/10.1186/s13073-017-0476-3 [IF: 7.071; PMID: 28938910]

15. Nicol D, Eckstein L, Morrison M, Sherkow JS, Otlowski M, Whitten T, Bubela T, Burdon KP, Chalmers D, Chan S, Charlesworth J, Critchley C, Crossley M, de Lacey S, Dickinson JL, Hewitt AW, Kamens J, Kleiderman E, Kodama S, Liddicoat J, Mackey DA, Newsome AJ, Wagner JK, McWhirter RE (2017) Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. Genome Medicine 9:85 Online: https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0475-4 [IF: 7.071; PMID: 28946923]

16. Jasny BR, Wigginton N, McNutt M, Bubela T, Buck S, Cook-Deegan R, Gardner T, Hanson B, Hustad C, Kermer V, Lazer D, Lupia A, Manrai A, McConnell L, Noonan K, Phimster E, Simon B, Strandburg K, Summers Z, Watts D (2017) Fostering reproducibility in industry-academia partnerships. Science. 357:759-761. [IF: 37.205; PMID: 28839064]

17. Bubela T, Bonter K, Lachance S, Delisle J-S, Gold ER (2017) More Haste, Less Speed: Could Public Private Partnerships Advance Cellular Immunotherapies? Frontiers in Medicine. 16:134. Online: https://doi.org/10.3389/fmed.2017.00134 [PMID 28861415]

of 74 18. Bonter K, Breckenridge Z, Delisle J-S, Bubela T (e-pub ahead of print, 2017) Global Landscape of Cellular

Immunotherapy Clinical Trials: What Role for Industry? Regenerative Medicine. [IF 3.873; PMID 28850001] 19. Kowal S, Bubela T, Jardine C (2017) Experiences in broker-facilitated participatory cross-cultural research:

Overcoming practical and ethical challenges. International Journal Qualitative Methods 16:1-9. Online: http://journals.sagepub.com/doi/full/10.1177/1609406917706883. [IF 0.769]

20. Fung M, Yuan Y, Atkins H, Shi Q, Bubela T (2017) Responsible translation of stem cell research: an assessment of clinical trial registration and publications. Stem Cell Reports. Published online April 13, 2017: http://www.cell.com/stem-cell-reports/pdf/S2213-6711(17)30119-4.pdf [Official journal of the International Society for Stem Cell Research (ISSCR), Cell Press; IF 7.027; PMID 28416287]

21. Mansour Y, Nicols D, Bubela T (2017) The Ethics of Genome Editing in the Clinic: Considerations for Healthcare Leaders. Healthcare Management Forum. Published online April 7, 2017: http://journals.sagepub.com/doi/full/10.1177/0840470416689313.

22. Murdoch B, Ravitsky V, Ogbogu U, Ali-Khan S, Bertier G, Birko S, Bubela T, DeBeer J, Dupras C, Ellis M, Granados Moreno P, Joly Y, Kamenova K, Marcon A, Master Z, Paulden M, Rousseau F, Caulfield T. (2017) Non-Invasive Prenatal Testing and the Unveiling of an Impaired Translation Process. Journal of Obstetrics and Gynaecology Canada. 39(1):10-17 [IF 1.39; PMID 28062017].

2016 23. McGetrick JA, Bubela T, Hik DS (published online, Oct 2016) Natural Resource Development in Northern

Canada: Aboriginal Community Health and Socio-economic Perspectives in the Northwest Territories. Impact Assessment and Project Appraisal. [Journal of the International Association for Impact Assessment] http://www.tandfonline.com/doi/full/10.1080/14615517.2016.1239496

24. Geary J, Camicioli E, Bubela T (2016) DNA Barcoding in the Media: Does coverage of cool science reflect its social context? Genome. 59(9): 738-750 . DOI: 10.1139/gen-2015-0210 [IF 1.669; PMID 27463361]

25. Cook-Deegan R, Vishnubhakat S, Bubela T (2016) The Mouse that Trolled (Again). Journal of Law and the Biosciences 3(1): 185-191. DOI: 722 doi:10.1093/jlb/lsv035. [PMID 27774240]

26. Bubela T, Gold R (2016) Cell therapy licensing: a web for the unwary in Kimble v. Marvel Entertainment? Regenerative Medicine 11(2): 125-127. [IF 3.873; PMID 26876790]

27. Chan S, Bubela T, Dimopoulos IS, Freund P, Varkouhi AK, MacDonald I (2016) Choroideremia Research – Report and Perspectives on the Second International Scientific Symposium for Choroideremia. Ophthalmic Genetics 8:1-9 epub ahead of print: DOI:10.3109/13816810.2015.1088958 [Official journal of International Society for Genetic Eye Diseases and Retinblastomas - IF 1.866; PMID 26855058]

28. Nicol D, Bubela T, Chalmers D, Charbonneau J, Critchley C, Dickinson J, Fleming J, Hewitt AW, Kaye J, Liddicoat J, McWhirter R, Otlowski M, Ries NM, Skene L, Stewart C, Wagner J, Zeps N (In Press, 2016) Precision medicine: drowning in a regulatory soup? Journal of Law and the Biosciences Advance Access: 10.1093/jlb/lsw018

29. Weinryb N, Bubela T (2016) Stepping Into and Out of the Void: Funding Dynamics of Human Embryonic Stem Cell Research in California, Sweden, and South Korea. Stem Cell Reviews & Reports. 12(1): 8-14 DOI 10.1007/s12015-015-9626-4 Published online 02 October 2015 [IF 3.595; PMID 26432702]

2015 30. Mishra A, Schofield PN, Bubela T (2015) Sustaining large-scale infrastructure to promote pre-competitive

biomedical research: Lessons from mouse genomics. New Biotechnology. 33(2):280-294. [IF 3.199; PMID 26563511]

31. Kowal S, Jardine C, Bubela T (2015) “If they tell me to get it, I’ll get it. If they don’t….”: Immunization Decision-Making Processes of Immigrant Mothers. Canadian Journal of Public Health. 106(4):e230-e235 [IF 1.325; PMID 26285195]

32. Bubela T, McCabe C, Archibald P, Bradshaw S, Kefalas P, Mujoomdar M, Packer C, Piret J, Raxworthy M (2015) Bringing Regenerative Medicines to the Clinic: The Future for Regulation and Reimbursement. Regenerative Medicine 10:897-911. [IF 3.873; PMID 26565607]

33. Benjaminy S, Kowal SP, MacDonald I, Bubela T (2015) Communicating the Promise for Ocular Gene Therapy. American Journal of Ophthalmology 160:408-415. [IF 4.021; PMID 26032192]

of 74 34. Schindel DE, Bubela T, Rosenthal J, Castle D, du Plessis P, Bye R (2015) The New Age of the Nagoya Protocol.

Nature Conservation 12:43-56. [New Journal] 35. McGetrick JA, Bubela T, Hik DS (2015) Circumpolar stakeholder perspectives on Geographic Information

Systems for communicating the health impacts of development. Environmental Science & Policy 54: 176-184. [IF 3.514]

36. Oye K, Bubela T, Lawson C (2015) Regulate ‘home-brew’ opiates. Nature 521: 281-283. [IF 42.35; PMID 25993942]

37. Viswanathan S, Bubela T (2015) Current Practices and Reform Proposals for the Regulation of Advanced Medicinal Products in Canada. Regenerative Medicine 10(5):647-663. [IF 3.873; PMID 26237706]

38. Bubela T, Vishnubhakat S, Cook-Deegan R (2015) The Mouse that Trolled: The Long and Tortuous History of a Gene Mutation Patent that Became an Expensive Impediment to Alzheimer’s Research. Journal of Law and the Biosciences. April 23, 2015: 1-50. ePUB Ahead of Print: http://jlb.oxfordjournals.org/content/early/2015/04/23/jlb.lsv011.short?rss=1; doi:10.1093/jlb/lsv011 [New Law Journal from the Law Schools of Duke, Harvard and Stanford Universities; PMID 26594384]

39. Bubela T, Cook-Deegan R (2015) Keeping score, strengthening policy and fighting bad actors over access to research tools. Nature Biotechnology 33(2): 143-147. [IF 39.1; PMID 25658278]

40. Bubela T, Guebert J, Mishra A (2015) Use and Misuse of Material Transfer Agreements: Lessons from Research, Repositories, and Litigation. PLoS Biology 13(2): e1002060. [IF 12.690; PMID 25646804]

2014 41. Guebert J, Bubela T (2014) Implementing Socially Responsible Licensing for Global Health: Beyond Neglected

Diseases. Science Translational Medicine 6: 260Cm11 [IF 15.83; PMID 25355695] 42. Bubela T, McCabe C (2014) Value-Engineered Translation: Developing Biotherapeutics that align with health-

system needs. American Journal of Managed Care 20 (Special Issue 10): SP307-SP312 [PMID 25830190]. 43. Benjaminy S, Bubela T (2014) Ocular Gene Transfer in the Spotlight: Implications of Newspaper Content for

Clinical Communications. BMC Medical Ethics 15(1):58. doi: 10.1186/1472-6939-15-58 [IF 1.705; PMID 25027482]

44. Mishra A, Bubela T (2014) Legal Agreements and the Governance of Research Commons: Lessons from Materials Sharing in Mouse Genomics. Omics A Journal of Integrative Biology 18(4): 254-273. [IF 2.730; PMID 24552652]

45. Li MD, Atkins, HL, Bubela T (2014) The Global Landscape of Stem Cell Clinical Trials. Regenerative Medicine 9(1): 27-39. [IF 3.873; PMID 24236476]

2013 46. Bubela T, McCabe C (2013) Value-Engineered Translation for Regenerative Medicine: Meeting the Needs of

Health Systems. Stem Cells and Development 22: 89-93. [IF 4.670; PMID 24304083] 47. Caulfield T, Evans J, McGuire A, McCabe C, Bubela T, Cook-Deegan R, Fishman J, Hogarth S, Miller FA,

Ravitsky V, et al. (2013) Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate. PLoS Biology 11:e1001699 (6 pages). [IF 12.690; PMID: 24223516]

48. Benjaminy S, MacDonald I, Bubela T (2013) “Is a Cure in My Sight?” Multi-Stakeholder Perspectives on Phase-I Choroideremia Gene Transfer Clinical Trials. Genetics in Medicine 16: 379-385 doi:10.1038/gim.2013.148. [IF 5.560; PMID: 24071795]

49. Geary J, Jardine C, Guebert J, Bubela T (2013) Access and Benefits Sharing of Genetic Resources and Associated Traditional Knowledge in Northern Canada: Understanding the Legal Environment and Creating Effective Research Agreements. International Journal of Circumpolar Health 72: 21351 (9 pages). [IF 1.060; PMID: 23986896]

50. Gold ER, Cook Deegan R, Bubela T (2013) AMP v Myriad: A Surgical Strike Against Blockbuster Genetic Diagnostic Business Models. Science Translational Medicine 5(192): 5-6. [IF 15.83; PMID: 23825298]

51. Mathews DH, Cook-Deegan R, Bubela T (2013) Patents and Misplaced Angst: Lessons for Translational Stem Cell Research from Genomics. Cell Stem Cell 12: 508-512. [IF 25.421; PMID: 23642360]

52. Luth W, Jardine C, Bubela T (2013) When Pictures Waste a Thousand Words: Analysis of the 2009 H1N1 Pandemic on Television News. PLoS One 8(5): e64070. [IF 4.092; PMID: 23691150]

of 74 53. Bubela T, Gold ER, Graff GD, Cahoy DR, Nicol D, Castle D (2013) Patent Landscaping for Life Sciences

Innovation: Toward Consistent and Transparent Practices. Nature Biotechnology 31(3): 202-206. [IF 23.268; PMID: 23471065]

54. Hyshka E, Bubela T, Wild C (2013) Prospects for Scaling-Up Supervised Injection Facilities in Canada: The Role of Evidence in Legal and Political Decision-Making. Addiction 108: 468-476. [IF 4.313; PMID: 23286831]

2012 55. Bubela T, Yanow S (2012) Molecular Typing: A Legal Perspective. Public Health Ethics 5: 317-320. 56. Bubela T, Schofield PN, Ryan C, Adams R, Einhorn D (2012) Managing Intellectual Property to Promote Pre-

Competitive Research: The Mouse as a Model for Constructing a Robust Research Commons. Journal of Law, Information and Science 20(2): 98-121.

57. Bubela T, Li MD, Hafez M, Bieber M, Atkins H (2012) Is Belief Larger than Fact: Expectations, Optimism and Reality for Translational Stem Cell Research. BMC Medicine DOI: 10.1186/1741-7015-10-133. [IF 6.035; PMID: 23131007]

58. Bubela T, Reshef, A, Li MD, Atkins A, Caulfield T, Culme-Seymour E, Gold R, Illes J, Isasi R, McCabe C, Ogbogu U, Piret J, Mason C (2012) Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation. Regenerative Medicine 7(6): 735-740. [IF 3.873; PMID: 23020169]

59. Bubela T, FitzGerald GA, Gold ER (2012) Recalibrating Intellectual Property Rights to Enhance Translational Research Collaborations. Science Translational Medicine 4(119): 11-16. [IF 15.83]

60. Bubela T, Hagen G, Einsiedel E (2012) Synthetic Biology Confronts Publics and Policy Makers: Challenges for Communication, Regulation and Commercialization. Trends in Biotechnology 30 (3): 132-137. [IF 9.660; PMID: 22119159]

2011 61. Jardine C, Lechelt L, Wenger I, Bubela T, Given L (2011) H1N1 Knowledge Translation for Pregnant Women

and Seniors. International Journal of Qualitative Methods 10(4): 477. 62. Prado M, Cristina D, Bubela T (2011) Aligning the Activities of a Technology Transfer Office with the Social

Mission of a Life Sciences Research Institute in Portugal: Opportunities and Challenges for a New Office. AUTM Technology Transfer Practice Manual 3(4) Online: http://www.autm.net/Volume_4_TOC.htm.

63. Bubela T, Gold, ER, Morin, JF (2011) Wicked Issues at the Intersection of Intellectual Property and Public Health: Mechanisms for Policy Coherence. McGill Journal of Law and Health 4: 3-42.

2010 64. Bubela T, Morin JF (2010) Lost in Translation: The Canadian Access to Medicines Regime from Transnational

Activism to Domestic Implementation. Health Law Journal 18: 113-158. [PMID: 22125973] 65. Rachul C, Zarzeczny A, Bubela T, Caulfield T (2010) Stem Cell Research in the News: More than a Moral

Status Debate? SCRIPTED - A Journal of Law, Technology & Society 7: 311-323. 66. Bubela T, Caulfield T (2010) Role and Reality: Technology Transfer at Canadian Universities. Trends in

Biotechnology 28: 447-451. [IF 9.660; PMID: 20598388] 67. Bubela T, Strotmann A, Noble R, Morrison S (2010) Commercialization and Collaboration: Competing

Policies in Publicly-Funded Stem Cell Research? Cell Stem Cell 7: 21-30. [IF 26.967; PMID: 20621046] 68. Castle D, Phillips PWB, Brown A, Culver K, Castrataro D, Bubela T, Harmon S, Dutfield G, Barclay P (2010)

Floating the Knowledge Management Boat in a Sea of Intellectual Property Rights. SCRIPTED - A Journal of Law, Technology & Society 7: 32-50.

69. Prado M, Cristina D, Bubela T (2010) The Challenges and Opportunities in Setting up a Technology Transfer Office in a Life Sciences Research Institute in Portugal. Tomorrow's Technology Transfer: The Journal of the Association of University Technology Transfer Managers 2: 38-45.

2009 70. Schofield PN, Bubela T, Weaver T, Brown SD, Hancock JM, Einhorn D, Tocchini-Valentini G, de Angelis MH,

Rosenthal, N (2009) Post-Publication Sharing of Data and Tools. Nature 461: 171-173. [IF 36.104; PMID: 19741686]

71. Bubela T, Nisbet MC, Borchelt R, Brunger F, Critchely C, Einsiedel E, Geller G, Gupta A, Hampel J, Hyde-Lay R, Jandciu EW, Jones SA, Kolopack P, Lane S, Lougheed T, Nerlich B, Ogbogu U, O’Riordan K, Ouellette C,

of 74 Spear M, Strauss S, Thavaratnam T, Willemse L, Caulfield T (2009) Science Communication Reconsidered: Challenges, Prospects, and Recommendations. Nature Biotechnology 27: 514-518. [IF 31.090; PMID: 19513051]

72. Strotmann A, Zhao D, Bubela T (2009) Author Name Disambiguation for Collaboration Network Analysis and Visualization. Proceedings of The American Society for Information Science and Technology 2009 Annual Meeting, November 6-11, 2009, Vancouver, British Columbia, Canada.

73. Strotmann A, Zhao D, Bubela T (2009) A Multi-Database Approach to Field Delineation. Proceedings of the International Society for Scientometrics and Informetrics, 2009 Conference, July 14-17, 2009, Rio de Janeiro, Brazil.

74. Heaney C, Carbone J, Gold R, Bubela T, Holman CM, Cliaianni A, Lewis T, Cook-Deegan R (2009) The Perils of Taking Property Too Far. Stanford Journal of Law, Science and Policy 1: 46-64. [PMID: 20628480]

75. Caulfield T, Zarzecsny A, McCormick J, Bubela T, Critchely C, Einsiedel, E, Galipeau J, Harmon S, Huynh M, Hyun I, Iles J, Isasi R, Joly Y, Laurie G, Lomax G, Longstaff H, McDonald M, Murdoch C, Ogbogu U, Owen-Smith J, Pattinson S, Prmji S, von Tigerstrom B, Winickoff ED (2009) International Stem Cell Environments: World of Difference. Nature Reports Stem Cells doi:10.1038/stemcells.2009.61. [PMID: 19521798]

76. Caulfield T, Zarzecsny A, McCormick J, Bubela T, Critchely C, Einsiedel, E, Galipeau J, Harmon S, Huynh M, Hyun I, Iles J, Isasi R, Joly Y, Laurie G, Lomax G, Longstaff H, McDonald M, Murdoch C, Ogbogu U, Owen-Smith J, Pattinson S, Prmji S, von Tigerstrom B, Winickoff ED (2009) The Stem Cell Research Environment: A Patchwork of Patchworks. Stem Cell Reviews and Reports 5: 82-88.

2008 77. Bubela T, Boon H, Caulfield T (2008) Herbal Remedy Clinical Trials in the Media: a Comparison with the

Coverage of Conventional Pharmaceuticals. BMC Medicine 6: 35 (14 pages). [IF 5.750; PMID: 19036123]. 78. Knowles L, Bubela T (2008) Challenges for Intellectual Property Management of HIV Vaccine-Related

Research and Development: Part 1, The Global Context. Health Law Journal 16: 55-96. [PMID: 19536978] 79. Patten S, Bubela T, Knowles L (2008) Challenges for Intellectual Property Management of HIV Vaccine-

Related Research and Development: Part 2, The Canadian Context. Health Law Journal 16: 97-142. [PMID: 19536979]

80. Caulfield T, Shelley J, Alfonso V, Bubela T (2008) Nutrigenomics and the Promise of Prevention: Representations and Realities. Health Law Journal Special Edition 41-65.

81. Bubela, T (2008) Public representations of nutrigenomic testing: Website content and media coverage. Journal of Nutrigenetics and Nutrigenomics 1(4) 183.

82. Bubela T, Patten S, Wellmeier T (2008) Overview of the Canadian patent landscape of HIV Vaccine-related technologies. AIDS Research and Human Retroviruses 24: 116.

2007 83. Caulfield T, Bubela T, Murdoch C (2007) Myriad and the Mass Media: The Covering of a Gene Patent

Controversy. Genetics in Medicine 9: 850-855. [IF 5.280; PMID: 18091435]. 84. Bubela T, Koper M, Boon H, Caulfield T (2007) Media Portrayal of Herbal Remedy Versus Pharmaceutical

Clinical Trials: Impacts on Decision-Makers. Medicine and Law 26(2): 363-373. [PMID: 17639857] 85. Caulfield T, Bubela T (2007) Why a Criminal Ban? Analyzing the Arguments Against Somatic Cell Nuclear

Transfer in the Canadian Parliamentary Debate. American Journal of Bioethics 7(2): 51-61. [IF 4.378; PMID: 17366198]

2004-2006 86. Bubela T (2006) Science Communication in Transition: Genomics Hype, Public Engagement, Education and

Commercialization Pressures. Clinical Genetics 70: 445-450. [IF 3.273]. [PMID: 17026631] 87. Bubela TM (2004) Expert Evidence: The Ethical Responsibility of the Legal Profession. Alberta Law Review

41(4): 853-870. 88. Bubela T, Caulfield T (2004) Do the Print Media Hype Genetic Research? A Comparison of Newspaper

Stories and Peer Reviewed Research Papers. 170(9) Canadian Medical Association Journal 170(9): 1399-1407. [IF 9.015; PMID: 15111473].

of 74 Pre-2000 89. Bubela TM, Dickman CR, Newsome AE (1999) Diet and Winter Foraging Behaviour of the Red Fox (Vulpes

vulpes) in Alpine and Subalpine New South Wales. Australian Journal of Mammalogy 20: 321-330. 90. Bubela TM, Bartell R,Müller W (1998) Factors Affecting The Trappability of Red Foxes in Kosciusko National

Park: How Not to be Outfoxed. Wildlife Research 25: 199-208. [IF 1.279]. 91. Barker J, Lunney D, Bubela T (1994) Mammal Surveys in the Forests of the Carrai Plateau and Richmond

Range in North-east New South Wales. Australian Mammalogy 17: 19-29. 92. Bubela TM, Happold DCD (1993) The Social Organisation and Mating System of an Australian Subalpine

Rodent, the Broad-toothed Rat, Mastacomys fuscus Thomas. Wildlife Research 20: 405-417. [IF 1.279]. 93. Bubela TM, Happold DCD, Broome LS (1991) Home Range and Activity of the Broad-toothed Rat,

Mastacomys fuscus in Subalpine Heathland. Wildlife Research 18: 39-48. [IF 1.279]. 94. Carron PL, Happold DCD, Bubela TM (1990) The Diet of Two Sympatric Australian Subalpine Rodents,

Mastacomys fuscus and Rattus fuscipes. Australian Wildlife Research 17: 479-489. [IF 1.279]

NON-PEER REVIEWED ARTICLES

1. Bonter K, Bubela T (2014) Translating molecular diagnostics into the clinic. Biotechnology Focus May 28, 2014 Feature. Available online: http://biotechnologyfocus.ca/translating-molecular-diagnostics-into-the-clinic.

2. Bubela T, Taylor B (2007) Nutrigenomics, Mass Media and Commercialization Pressures. Health Law Review 16(3): 39-47. [Special Issue on Nutrigenomics]

3. Koper M, Bubela T Caulfield T, Boon H (2007) Media portrayal of conflicts of interest in biomedical research. Health Law Review 15: 30. [PMID: 17153272]

4. Bubela T, Caulfield T, Boon H (2006) Trends in Evidence-Based Medicine for Herbal Remedies and Media Coverage. Health Law Review 15: 3.

5. DeBow S, Bubela T, Caulfield T (2006) Stem Cells, Politics and the Progress Paradigm. Health Law Review 15: 50. [PMID: 17153769]

6. Fernando K, Bubela T, Caulfield T (2006) Public Trust and Regulatory Governance as represented through the Media. 15 Health Law Review 15: 12.

7. Koper M, Bubela T, Caulfield T, Boon H (2006) Media Portrayal of Conflicts of Interest in Herbal Remedy Clinical Trials. Health Law Review 15: 9.

8. Caulfield T, Bubela TM (2004) Media Representations of Genetic Discoveries: Hype in the Headlines? 12(2) Health Law Review 12(2): 53-61.

LETTERS TO THE EDITOR

1. Paulden M, Akude P, Bubela T, McCabe C (November 1, 2013) A Canadian screening program for hepatitis C: Is now the time? CMAJ online: http://www.cmaj.ca/content/185/15/1325/reply

2. Bubela T, Gold R (December 8, 2008) Managing intellectual property for health research and delivery. Rapid Response to: McKee, M. Global Research for Health. BMJ 337: a2733 (online edition).

3. Gold ER, Bubela T, Miller FA, Nicol D, Piper T (2007) Gene patents—more evidence needed, but policymakers must act. Nature Biotechnology 25: 388 – 389. [PMID: 17420737]

EDITED BOOKS

1. Bubela T, Gold ER (eds) Genetic Resources and Traditional Knowledge: Case Studies and Conflicting Interests. (Williston, VT: Edward Elgar, 2012) 373 pp.

ENCYCLOPAEDIA ENTRIES

1. Kowal S, Bubela T (2016) Legal Issues in Public Health. Quah S (ed) In International Encyclopedia of Public Health 2nd Ed. (Philadelphia PA: Elsevier, 2016).

of 74

BOOK CHAPTERS - ** PEER-REVIEWED

1. Bubela T, Adams R, Chandrasekharan S, Mishra A, Liu S (2017) Governance of Biomedical Research Commons to Advance Clinical Translation: Lessons from the Mouse Model Community. In Strandburg K, Madison M and Frischmann B (eds) Governing Medical Research Commons pp. 222-258 (Cambridge UK: Cambridge University Press, 2017). Part of the Cambridge Series on Governing Knowledge Commons.**

2. McCabe C, Bubela T. The health economics for regenerative medicine: how payers think and what that means for developers. In Viswanathan S, Hematti P (eds) Mesenchymal Stromal Cells: Translational Pathways to Clinical Adoption pp. 389-307 (Amsterdam: Elsevier, 2016).

3. Bubela T, Mishra A, Mathews D. Policies and practices to enhance multi-sectorial collaborations and commercialization of regenerative medicine. In Hogle LF (ed) Regenerative Medicine Ethics: Governing Research and Knowledge Practices. (New York: Springer, 2013)**

4. Bubela T, Gold ER. Indigenous Rights and Traditional Knowledge. In Bubela T, Gold ER (eds) Genetic Resources and Traditional Knowledge: Case Studies and Conflicting Interests. pp. 1-30 (Williston, VT: Edward Elgar, 2012).

5. Metcalf C, Bubela T. Aboriginal Rights and Traditional Ecological Knowledge in Northern Canada. In Bubela T, Gold ER (eds) Genetic Resources and Traditional Knowledge: Case Studies and Conflicting Interests. pp 270-309 (Williston, VT: Edward Elgar, 2012).

6. Hik DS, Bubela T, Nickels S. Respecting and Aligning Knowledge Systems in Northern Canada: Beyond the International Polar Year. In Bubela T, Gold ER (eds) Genetic Resources and Traditional Knowledge: Case Studies and Conflicting Interests. pp 310-338 (Williston, VT: Edward Elgar, 2012).

7. Bubela T. Grand Challenges for Evidence and Health Policy: Metrics and Indicators in Complex Systems. In Kouri R, Regis C (eds) Les grandsdéfis en droit et politiques de la santé/Grand Challenges in Health Law & Policy. pp. 55-80 (Toronto: Thomson Reuters, 2010).**

8. Bubela T. Introduction: Innovation Governance. Castle D (ed) The Role of Intellectual Property Rights in Biotechnology Innovation. (Williston, VT: Edward Elgar Publishing, 2009).

9. Caulfield T, Shelley J, Bubela T, Mineker L. Framing Nutrigenomics for Individual and Public Health: Public Representations and Consequences for an Emerging Field. In Castle D, Ries N (eds) Nutrition and Genomics: Issues of Ethics, Law, Regulation & Communication. pp. 223-245 (Amsterdam: Elsevier, 2008).**

10. Bubela T, Caulfield T. When Human Dignity is Not Enough: Embryonic Stem Cell Research and Human Cloning in Canada. In Einsiedel E (ed) Emerging Technologies: Hindsight and foresight pp. 161-184 (Vancouver: UBC Press, 2008).

11. Caulfield T and Bubela T. Popular Representations of Science, Research and Technology. In Ries N, Shelley J (eds) Food, Health and Biotechnology: Consumer and Social Issues in Canada’s New Food and Health Products Industries. pp. 24-28 (Guelph: Advanced Food and Materials Network, 2007).

12. Caulfield T, Bubela T. The Popular Media, Public Perceptions and Biotechnology Policy. In Stranger M (ed) Human Biotechnology and Public Trust: Trends, Perceptions and Regulation pp. 88-101 (Hobart: Centre for Law and Genetics, 2007).**

13. Gold ER, Bubela T. Contracting to Manage Intellectual Property: Collaborative Research Agreements and other Contracts. In Krattiger A, et al (eds) IP Management in Health and Agricultural Innovation-A Handbook of Best Practices. pp. 725-738 (Oxford: MIHR, PIPRA, 2007). This project was funded by the Rockefeller Foundation. The Handbook is primarily aimed at public sector institutions in developing countries (senior policy makers, university presidents and other heads of R&D institutions, technology transfer and licensing officers, and scientists). It is an effort to produce a most complete and authoritative resource in health and agricultural IP management as a basis of elevating the awareness and expertise in licensing transactions related to health and agriculture, particularly vis-a-vis serving the closely tied objectives of economic development.

14. Bubela T, Durell KL. Intellectual Property and Biotechnology. In Gad, SC (ed) Handbook of Pharmaceutical Biotechnology. pp. 1391-1432 (Cary NC: John Wiley & Sons, 2007).**

15. Bubela T, Caulfield T. Media Representations of Genetic Research. Einsiedel EF, Timmermans F (eds) Crossing Over. Genomics in the Public Arena (Calgary AB: University of Calgary Press, 2005).

of 74

POLICY REPORTS / POSITION PAPERS

1. Bieber M, Luth W, Camicioli E, Clark R, Yuan Y, Bubela T (2017) Strategy for Patient-Oriented Research: Bibliometric Analysis Report. Commissioned by the Alberta Strategy for Patient-Oriented Research (SPOR) Support Unit and Alberta Innovates (115 pp.)

2. Council of Canadian Academies (2017) Building on Canada’s Strengths in Regenerative Medicine. Available at: www.scienceadvice.ca. Member of Steering Committee: Janet Rossant (Chair), Tania Bubela, Allen Eaves, Michael Rudnicki. It overviews the current strengths and weaknesses in regenerative medicine in Canada, and identifies key opportunities for success in the field. The Report was commissioned by The Honourable Kirsty Duncan (Minister of Science, Canada), The Honourable Jane Philpott (Minister of Health), and The Honourable Navdeep Bains (Minister of Innovation, Science, and Economic Development).

3. Bubela T, McCabe C, James D, Mengel M (2017) ALMDx/PACEMOMICS final report: Lessons learned on precision medicine R&D and implementation in Alberta. Economic Development and Trade, Government of Alberta.

4. Bubela T, McCabe C, James D, Mengel M, Hugh J (2017) ProSigna™ Breast Cancer Gene Signature Assay Evaluation Report. ALMDx/PACEOMICS for Alberta Health Services.

5. Bubela T, McCabe C, James D, Mengel M (2017) A Biomarker Model for Prediction of Risk for Deep Vein Thrombosis in Pediatric Oncology Patients ALMDX/PACEOMICS Report: Part One for University of Alberta Diagnostics developer.

6. Bubela T, McCabe C, James D, Mengel M (2017) Development of Next Generation Sequencing (NGS) Gene Panel for Diagnosis and Prognosis of Mitochondrial Disorders ALMDX/PACEOMICS REPORT Part One for University of Alberta Diagnostics developer.

7. Bubela T, McCabe C, James D, Mengel M (2017) Point of Care Diagnostic Test for Metastatic Thyroid Cancer: ALMDX/PACEOMICS Report: Part One for University of Alberta Diagnostics developer.

8. Bubela T (2016) Technology and the Illicit Drug Trade: Biotechnology (21pp.) Report commissioned by CENTRA Technology, Inc. Virginia, USA.

9. Ali-Khan S, Kowal S, Luth W, Gold R, Bubela T (2016) Evolving terminology: from Personalized to Precision Medicine. PACEOMICS Policy Brief No. 10. Available at http://paceomics.org/wp-content/uploads/2014/10/Policy-brief-10-Evolving-terminology-for-Personalized-Medicine.pdf

10. Castle D, Bell J, Bubela T, Culver K, Hanner R, Phillips P (2013) Receptor Capacity for Biotechnology Innovation in Canada. Genome Canada Policy Brief No. 8.

11. Bubela T, Geary J, Guebert J, Shelley J (2013) Workshop Report: Barcoding and Natural Health Products. Medicinal Plant Barcoding and Health Products Research: Moving the Debate Forward on Access and Benefit Sharing. Mexico City, February 12-13, 2013.

12. Li MD, Atkins H, Hafez M, Bieber M, Bubela T (2012) Landscape of international translational stem cell research. Report for the Stem Cell Network and the Canadian Centre for Regenerative Medicine.

13. Callan B, Bubela T, Slater B, Gagnon MA, Morin JF, Belanger M, Gold ER (2011) Impact of Intellectual Property Protection on Pharmaceutical Innovation. Submission of the Technical Proposal to Health Canada Strategis Policy Branch, Office of Pharmaceuticals Management Strategies. Response to RFP (1000121857). Prepared on behalf of The Innovation Partnership, 138 pp.

14. Alberta Forum for Global Health Research (June 2010) Global Health Research in Alberta: Global Reach, Local Impact. Submission to Alberta Innovates – Health Solutions for Strategic Planning Process. [lead drafter]

15. Bubela T, Gold ER, Morin, JF, Carbone J, Gagnon MA, Srulovicz T, Joly Y (2010) Evidence and Background Information to Inform Canada’s Approach to Public Health and Intellectual Property Issues in International Fora. Submission to Health Canada’s International Affairs Directorate (IAD), 94pp.

16. Gold ER, Bubela, T, Carbone J, Gagnon MA, Srulovicz T, Joly Y (2010) At the intersection of health and intellectual property: Issues, tools and directions for Health Canada. Submission to Health Canada: Bioethics, Innovation and Policy Integration Division, 71pp.

17. Gold ER, Adams W, Bernier L, Bubela, T, et al. (2008) Toward a New Era for Intellectual Property: From Confrontation to Negotiation. A Report by The International Expert Group on Biotechnology, Innovation

of 74 and Intellectual Property. (The Innovation Partnership, 2008). Online: http://www.theinnovationpartnership.org/en/ieg/report/

**This report made the top-ten downloaded papers on the SSRN database (Sept-Oct 2008) in the categories Health Law Journals and LSN Science, Technology & Innovation Research Papers.

18. Bubela T and Strotmann A (2008) Designing Metrics to Assess Impacts and Social Benefits of Publicly Funded Research in Health and Agricultural Biotechnology. A Report to the International Expert Group on Biotechnology, Innovation and Intellectual Property (Montreal: The Innovation Partnership, 2008). http://www.theinnovationpartnership.org/en/ieg/cases/

19. Bubela T, Beas Rodriguez E, Metcalf C, Nnadozie K, Rodriguez E, Carbone J (2008) Respecting, Promoting, and Protecting Traditional Knowledge: A Comparative Case Study of Brazil, Kenya and Northern Canada. (2008) A Report to The International Expert Group on Biotechnology, Innovation and Intellectual Property. (Montreal: The Innovation Partnership, 2008). http://www.theinnovationpartnership.org/en/ieg/cases/

20. Morin, JF, Gold R, Bubela T, Bensimon C (2008) Governance Issues in Intellectual Property: the Jean Chretien Pledge of Africa Act. A Report to The International Expert Group on Biotechnology, Innovation and Intellectual Property. (Montreal: The Innovation Partnership, 2008). http://www.theinnovationpartnership.org/en/ieg/cases

21. Prepared on behalf of the North American Conditional Mouse Mutagenesis Project (NorCOMM) and the Canadian Mutant Mouse Repository (CMMR) (with Dr. Lauryl Nutter) “Response to the proposed New Substances Notification Regulations (Organisms): Revisions to Research Exemption”, Submission to the Government of Canada on impact of proposed regulatory changes on biomedical research community using genetically modified rodents as model organisms. January 22, 2008.

22. Bubela TM (1996) Management Supplement: ‘Social Effects of Sterilising Free-Ranging Vixens (Vulpes vulpesL.) in Subalpine Australia’. Unpublished Report for the New South Wales National Parks and Wildlife Service.

23. Bubela TM (1995) An Experimental Design for Fertility Control of Wolves (Canis lupus) in the Aishihik Area, Southwest Yukon. Unpublished Report for Yukon Renewable Resources, Fish and Wildlife Branch.

24. Bubela TM, Wilson BC (1993) Population structure and habitat use of the broad-toothed rat Mastacomys fuscus Thomas at Crackenback Ridge, Thredbo, New South Wales. Fauna Impact Survey for Kosciusko Thredbo Pty. Ltd.

Google Scholar (H-Index = 23; i10 index = 41) – 1983 citations by 2019. Note that citation patterns in the social sciences and humanities (including law and ethics) are distinct from and lower than in the sciences. Most legal journals are not ISI listed because the citations are embedded within detailed footnotes.

Author(s) Journal Year Citations Knowles, et al. J. Law and the Biosciences 2017 3 Breden, et al. Frontiers in Immunology 2017 32 Nicol, et al. Genome Medicine 2017 4 Dverka, et al. Genome Medicine 2017 10 Bonter, et al. Regenerative Medicine 2017 4 Jasny, et al. Science 2017 11 Fung, et al. Stem Cell Reports 2017 15 Murdoch, et al. J. Obstetrics & Gynecology Canada 2017 9 Kowal, et al. International Journal of Qualitative Methods 2017 2 Bubela, et al. Frontiers in Medicine 2017 1 Bubela, et al. Healthcare Management Forum 2017 1 McGetrick, et al. Impact Assessment & Project Appraisal 2017 1 Nicol, et al. J. Law and the Biosciences 2016 19 Chan, et al. Ophthalmic Genetics 2016 6 Mishra, et al. New Biotechnology 2016 5

of 74 Author(s) Journal Year Citations Geary, et al. Genome 2016 3 Weinryb & Bubela Stem Cell Reviews & Reports 2016 2 Bubela, et al. J. Law and the Biosciences 2016 3 McGetrick, et al. Environmental Science & Policy 2016 2 Bubela, et al. Regenerative Medicine 2015 23 Bubela, et al. J. Law and the Biosciences 2015 5 Oye, et al. Nature 2015 24 Viswanathan & Bubela Regenerative Medicine 2015 9 Bubela, et al. PLoS Biology 2015 13 Kowal, et al. Canadian Journal of Public Health 2015 23 Benjamini, et al. American Journal of Ophthalmology 2015 12 Bubela & Cook-Deegan Nature Biotechnology 2015 1 Schindel, et al. Nature Conservation 2015 7 Benjamini, et al. BMC Medical Ethics 2014 6 Benjamini, et al. Genetics in Medicine 2014 12 Bubela, et al. Regenerative Medicine Ethics 2014 5 Li, et al. Regenerative Medicine 2014 113 Bubela & McCabe American Journal of Managed Care 2014 6 Caulfield, et al. PLoS Biology 2014 54 Mishra, et al. OMICS 2014 8 Guebert & Bubela Science Translational Medicine 2014 6 Taylor & Bubela Health Law Review 2014 6 Bubela, et al. Health Law Review 2014 6 Gold, et al. Science Translational Medicine 2013 8 Matthews, et al. Cell Stem Cell 2013 11 Bubela, et al. Nature Biotechnology 2013 38 Hyshka, et al. Addiction 2013 35 Bubela & McCabe Stem Cells and Development 2013 14 Geary, et al. International Journal of Circumpolar Health 2013 5 Luth, et al. PLoS ONE 2013 10 Bubela, et al. BMC Medicine 2012 47 Bubela, et al. Journal of Law, Information and Science 2012 8 Bubela & Yanow Public Health Ethics 2012 6 Bubela, et al. Trends in Biotechnology 2012 22 Bubela, et al. Science Translational Medicine 2012 25 Bubela, et al. Regenerative Medicine 2012 6 Hik, et al. Genetic Resources and Traditional Knowledge 2012 1 Bubela & Gold Genetic Resources and Traditional Knowledge 2012 26 Metcalf & Bubela Genetic Resources and Traditional Knowledge 2012 1 Strotmann, et al. Journal of Infometrics 2012 9 Bubela & Caulfield Trends in Biotechnology 2010 57 Bubela, et al. Cell Stem Cell 2010 29 Bubela & Morin Health Law Journal 2010 11 Castle, et al. SCRIPTed 2010 10 Bubela, et al. McGill Journal of Law and Health 2010 5 Rachul, et al. SCRIPTed 2010 2

of 74 Author(s) Journal Year Citations Schofield, Bubela , et al. Nature 2009 164 Bubela, Nisbet, et al. Nature Biotechnology 2009 271 Strotmann, et al. Proceedings of the ASIST Annual Meeting 2009 39 Caulfield, et al. Health Law Journal 2009 7 Caulfield, et al. Nutrition and Genomics 2009 3 Strotmann, et al. 12th ISSI 2009 7 Caulfield, et al. Nature Reports Stem Cells 2009 14 Heaney, et al. Stanford Journal of Law, Science & Policy 2009 7 Caulfield, et al. Stem Cell Reviews & Reports 2009 38 Gold, et al. Toward a New Era of Intellectual Property 2008 27 Patten, et al. Health Law Journal 2008 1 Knowles, et al. Health Law Journal 2008 2 Bubela, et al. BMC Medicine 2008 28 Caulfield, Bubela & Murdoch Genetics in Medicine 2007 62 Caulfield & Bubela American Journal of Bioethics 2007 38 Bubela, et al. Medicine and Law 2007 11 Gold, et al. Nature Biotechnology 2007 5 Bubela Clinical Genetics 2006 35 Koper, et al. Health Law Review 2006 3 Bubela, et al. Health Law Review 2006 12 Fernando, et al. Health Law Review 2006 3 Bubela & Caulfield Crossing Over: Genomics in the Public Arena 2005 4 Caulfield & Bubela Health Law Review 2004 23 Bubela & Caulfield Health Law Review 2004 309 Bubela Alberta Law Review 2003 6 Bubela & Caulfield American Journal Human Genetics (Suppl) 2002 1 Bubela, Bartell &Müller Wildlife Research 1998 15 Bubela & Happold Wildlife Research 1993 17 Bubela, Happold & Broome Wildlife Research 1991 26 Carron, Happold & Bubela Wildlife Research 1990 41

of 74

SCHOLARLY AND PROFESSIONAL WORK - PRESENTATIONS

PAPERS PRESENTED AT WORKSHOPS AND SYMPOSIA - “INVITED” INDICATES THAT ALL EXPENSES WERE COVERED BY ORGANIZERS.

2019 1. Bubela T, Navigating the 3 Rs for cellular immunotherapies: Rights, regulation and reimbursement.

Technological Platforms for Cell Therapies Workshop, Simon Fraser University, Burnaby BC, March 7, 2019. [invited speaker]

2. Bubela T, Towards interdisciplinarity in the Faculty of Health Sciences. Workshop on strategies to promote new innovative models for Indigenous research reconciliation. Musquem Cultural Centre, BC, January 22, 2019. [invited panel discussant]

2018 1. Bubela T, Ethical dilemmas in translational regenerative medicine. 2018 Diabetes Canada/ Canadian Society

of Endocrinology and Metabolism Professional Conference, Halifax, October 10-13, 2018. 2. Bubela T, Cellular Quirks: Regulatory and intellectual property interests for cell therapies and manufacture.

Joint Meeting of CCIC and ImmunoBC 2018, North Vancouver, June 19-21, 2018. 3. Bubela T, Implementation and de-implementation dilemmas for molecular cancer diagnostics: Lessons from

a publicly funded health system. 7th Annual Roundtable Workshop on Regulation and Reimbursement of Molecular Diagnostics. Arizona State University, Tempe, Arizona, April 20, 2018. [invited speaker]

4. Bubela T, Mansour, Y, Bieber M, Howard B, Are Universities Patent Trolls? Analyzing a Decade of University Patent Litigation. Lawpalooza, Faculty of Law, Stanford University, Palo Alto, March 22-23, 2018. [submitted presentation]

2017 5. Bubela T, Precision oncology for Alberta: Innovating health system readiness. American Association of

Clinical Chemists/Canadian Association of Clinical Chemists. Stanley Park Tea House, Vancouver, BC October 27, 2017. [invited, keynote speaker]

6. Bubela T, Open and responsible innovation – collaborative forms of research and product development. Gene Editing for advanced therapies. OECD Expert Meeting. Berlin, Germany July 6-7. [invited keynote speaker] which resulted in the following publication: Garden H, Winickoff D (2018) Gene Editing for Advanced Therapies: Governance, Policy and Society, OECD Science, Technology and Industry Working Papers 2018/12, OECD Publishing. (32pp) https://ideas.repec.org/p/oec/stiaaa/2018-12-en.html - contributed to the OECD Expert Meeting (see below) and the drafting of the report.

7. Bubela T, More Haste, Less Speed: Could Public Private Partnerships Advance Cellular Immunotherapies? Summit for Cancer Immunotherapy 2017. Gatineau, Quebec June 26, 2017. [invited plenary speaker]

8. Bubela T, Legal and ethical challenges for innovative ocular therapies: Stem Cells, Gene Therapies, Gene Editing. Alberta Vision Net Research Day, University of Alberta. Edmonton, Alberta May 5, 2017. [invited speaker and panelist]

9. Bubela T, Precision ONCOLOGY for Alberta: Innovating Health System Readiness. ARCC: Canadian Centre for Applied Research and Cancer Control. Toronto, Ontario. May 25-26, 2017. [plenary speaker and panelist]

10. Bubela T, Precision Public Health. Campus Alberta Health Outcomes and Public Health Annual Provincial Forum. Edmonton, Alberta. May 16, 2017. [invited speaker and panelist]

11. Bubela T, Precision Medicine for Alberta: Are we systems ready? Session: Precision Medicine: Applying Theory to Practice for Value with CDx. CADTH Symposium 2017. Ottawa, Ontario. April 24, 2017 [speaker and panelist]

12. Bubela T, McCabe C, James D, Mengel M, Hugh J. Priming Systems for Development, Implementation, and Evaluation of Precision Health Technologies: Lessons from Alberta. Respiratory Seminar Series, Center for Heart Lung Innovation, St. Paul’s Hospital, Vancouver, British Columbia. March 24, 2017. [invited speaker]

of 74 13. Bubela T. Making Cell and Gene Therapy Happen in Canada... who will pay and how much. CellCAN’s First

PanCanadian Strategic Forum on Cell and Gene Therapy. Montreal, Quebec. March 9-10, 2017. [invited keynote speaker]

14. Bubela T. Governance of Biomedical Research Commons: Lessons from Laboratory Mice and DNA Barcodes. Ecology and Evolution Seminar Series, Department of Biological Science, University of Alberta. February 17, 2017. [invited speaker]

15. Bubela T. Precision Medicine for Alberta: Are we systems ready? Integrated Health Records: Improving Patient Care for Albertans. COACH/ANHIX Conference. Calgary, Alberta. February 8, 2017. [invited keynote speaker]

16. Bubela T. Translating Translation: Non science challenges from bench to bedside for novel biotherapeutics. Department of Biological Sciences, MSC Seminar Series, University of Alberta. January 20, 1016. [invited speaker]

2016 17. Bubela T. Translating Translation: Non science challenges from bench to bedside for novel biotherapeutics.

Department of Pharmacology Seminar Series, University of Alberta. December 2, 1016. [invited speaker] 18. Bubela T. What to do about CRISPR? Views from the Bench. Centre for Law and Genetics Genome Editing

Workshop. University of Tasmania, Tasmania, Australia. November 12-13, 2016. [invited speaker] 19. Bubela T. Governance of Biomedical Research Commons: Lessons from the Humble Laboratory Mouse. MTA

Workshop. Centre for Law and Genetics Genome. University of Tasmania, Tasmania, Australia. November 9-10, 2016. [invited speaker]

20. Bubela T. Impact of intellectual property rights on reproducibility of science and academic-industry partnerships. IV Arnold Workshop “Reproducibility in Academia-Industry Partnerships. American Association for the Advancement of Science, Washington D.C. USA. October 24-25, 2016. [invited speaker, panelist and workshop participant]

21. Bubela T. Lessons in university intellectual property management: The secret to survivin’ or a train bound for nowhere? Sixth Beedie Innovation Conference. Simon Fraser University, Vancouver, BC, Canada. September 29, 2016. [invited keynote speaker]

22. Bubela T. Lessons in Governance of Biomedical Research Commons. AIRR 2016 Community Meeting: Progress in Standards, Tools and a Common Repository for Adaptive Immune-Receptor Repertoire Data. National Institutes of Health, Rockville, Maryland, USA. June 27-30, 2016. [invited keynote speaker]

23. Bubela T. Interdisciplinary Genomics Research. 2016 Congress of the Humanities and Social Sciences. Calgary Alberta, Canada. May 31, 2016. [invited speaker and panelist]

24. Bubela T. Intellectual Asset Management Challenges for Precision Medicine. 2016 CADTH Symposium, Ottawa, Ontario, Canada. April 11, 2016. [submitted abstract]

25. Bubela T. The Role of Universities in Innovation and Technology Transfer. Intellectual Property Rights and Innovation in the Fourth Industrial Revolution. Centre for International Governance Innovation (CIGI), Toronto, Ontario, Canada. March 22-23, 2016. [invited speaker]

26. Bubela T. Building the Medical Information Commons. Building the Medical Information Commons Advisory Committee Meeting. Baylor College of Medicine, Houston, Texas USA, March 2-3, 2016. [invited speaker]

27. Bubela T. Universities as patent litigants: the case of NIPT. Commercialization of Non-Invasive Prenatal Testing. Montreal, Quebec, Canada, February 10-11, 2016. [invited speaker]

2015 28. Bubela T. Governance of Biomedical Research Commons: Lessons from the humble laboratory mouse.

Department of Social Science of Medicine, McGill University, Montreal, Quebec Canada. October 28, 2016. [invited speaker]

29. Bubela T & McCabe C. Translation of Innovative Oncology Products: Engaging with Stakeholders. BioCanRx – Biotherapeutics for Cancer Treatment Workshop on Socio-economic Issues in Cancer Biotherapeutics Development. Ottawa, ON, Canada. Sep 24-25, 2015. [invited speaker]

of 74 30. Kowal S, Benjaminy S, MacDonald I & Bubela T. Gene Therapy Research Reporting Trends in the USA, UK,

and Canada and Implications for Clinical Communication. International Society for Genetic Eye Disease and Retinoblastoma 2015 Meeting. Halifax, NS. August 6-8, 2015

31. Bubela T & Cook-Deegan R. Mining Data Mountain: Data-sharing principles and practices. Community Meeting: Analysis, Management and Sharing of Antigen Receptor Repertoire Sequence Data. Vancouver, Canada. May 31, 2015. [invited speaker]

32. Bubela T. Headroom and Value in Biotherapeutics R&D. Canadian GE3LS and Health Services and Policy Research Conference. Vancouver, Canada. April 20, 2015. [invited speaker]

33. Bubela T & McCabe C. Translational Research for Reimbursement: The Value Engineered Translation Framework. BioCanRx Board Meeting. Toronto, Canada. January 5, 2015. [invited speaker]

2014 34. Bubela T & McCabe C. Translational Research for Reimbursement: The Value Engineered Translation

Framework. Regenerative Medicine Translation – a pathway into clinical practice. London, UK. December 10, 2014. [invited speaker and workshop co-organizer]

35. Bubela T. Technology Landscaping to Support Value Engineered Translation. Methods to Support Regenerative Medicine Translation. London UK. December 9, 2014. [invited speaker and workshop co-organizer]

36. Bubela T. Traversing the 3 Rs: Regeneration, Regulation, & Reimbursement. London Regenerative Medicine Network. London, UK. December 8, 2014. [invited keynote speaker]

37. Bubela T & McCabe C. Addressing Barriers to Clinical Translation of Regenerative Medicine. Driving Regenerative Medicine to the Market and Clinic: An Exploration of Enablers, Impediments and Ethical-Legal Challenges. Toronto, Canada. November 6-7, 2014.

38. Bubela T. Legal Agreements and the Governance of the Mouse Research Commons. 2nd Thematic Conference on Knowledge Commons, New York, USA. September 5-6, 2014. [Submitted abstract, peer reviewed]

39. Bubela T. Intellectual Property and the Mouse Commons. The Network for Bodies, Organs and Tissues (NBOT) Inaugural Annual Symposium, 2014. Faculty of Law, University of Sydney, Sydney, Australia. July 14-15, 2014. [Invited speaker]

40. Bubela T. Cost Effective Therapeutic Development of Regenerative Medicine. Leading or Limping?: Regulation in the Age of Personalised Medicine. Centre for Law & Genetics, Faculty of Law, University of Tasmania, Hobart, Australia. July 12-13, 2014. [Invited speaker]

41. Bubela T. Legal, regulatory and systems barriers for clinical translation of innovative bio-therapies for retinopathies. Second International Symposium for Choroideremia Research. Denver, Colorado. June 17-19, 2014. [Invited speaker]

42. Bubela T. Intellectual property issues and the mouse commons. Infrafrontier/IMPC Workshop – Promoting the International Exchange of Mouse Mutant Resources. Munich, Germany, May 8-9, 2014. [Invited speaker]

43. Bubela T. Using patent data to analyse policy issues in translational medicine: regenerative medicine and genomics. Analyzing Policy Impacts on Biotechnology Innovation Using Patent Data. Duke in Washington, Washington D.C., March 14, 2014. [invited speaker and workshop co-organizer]

44. Bubela T. The effects of the Myriad case on the regenerative medicine industry. The Future of Gene Patents – Making Sense of the Supreme Court’s Decision in the Myriad Case. Rayburn House Office Building, Washington D.C., March 13, 2014. [invited speaker and workshop co-organizer]

2013 45. Bubela T. International collaborative barcoding research: moving the debate forward on access and benefit

sharing of genetic resources to promote biodiversity. 5th International Barcode of Life Conference, Kunming, China, October 27-31, 2013. [invited plenary speaker]

46. Bubela T. Collaborative Mechanisms for the Clinical Translation of Stem Cell Therapies in a Global Environment. University of Wisconsin Law School, Madison, Wisconsin, October 14, 2013. [invited speaker]

of 74 47. Bubela T, Gold ER. Commercialization and Intellectual Property 101. Understanding Stem Cell Controversies:

An Intensive Couse on Regulatory and Socio-Ethical Issues. Stem Cell Network, Montreal, Quebec, April 23-25, 2013. [invited speaker, chair and panellist]

48. Bubela T. Matching Patients, Society and Health System Needs. Understanding Stem Cell Controversies: An Intensive Couse on Regulatory and Socio-Ethical Issues. Stem Cell Network, Montreal, Quebec, April 23-25, 2013 [invited speaker, chair and panellist]. Understanding Stem Cell Controversies: An Intensive Couse on Regulatory and Socio-Ethical Issues. Stem Cell Network, Montreal, Quebec, April 23-25, 2013. [invited speaker, chair and panellist]

49. Bubela T. Commercialization: Stakeholders’ Perspectives. Understanding Stem Cell Controversies: An Intensive Couse on Regulatory and Socio-Ethical Issues. Stem Cell Network, Montreal, Quebec, April 23-25, 2013. [invited speaker, chair and panellist]

50. Bubela T. Commercialization and Translational Challenges for Whole Genome Sequencing. Exploring the unique social/ethical and health system challenges of low cost whole genome sequencing. CIHR Institute of Genetics, Montreal, Quebec, April 19-20, 2013. [invited speaker]

51. Bubela T. Medicinal plant barcoding and health products research – Introduction to Workshop. Medicinal Plant Barcoding and Health Products Research: Moving the Debate Forward on Access and Benefit Sharing. Mexico City, Mexico, February 12-13, 2013. [oral presentation, workshop organiser]

52. Bubela T. Introduction to International Law on Access and Benefit Sharing: Barcoding and Natural Health Products. Medicinal Plant Barcoding and Health Products Research: Moving the Debate Forward on Access and Benefit Sharing. Mexico City, Mexico, February 12-13, 2013. [oral presentation, workshop organiser]

53. Bubela T. How Technology Transfer and Other IP Agreements can Spur Bench to Bedside Translation. Innovative Medicines (IMI) – Critical Path – Collaborating for Cures. Brussels, Belgium, February 8, 2013. [invited speaker and panellist]

54. Bubela T. NorCOMM 2 GE3LS Research, NorCOMM 2 Scientific Advisory Board Meeting, Toronto, Ontario, January 21, 2013.

55. Bubela T. Building Robust and Sustainable Bioresources: Lessons from the Mouse World on IP, MTAs and other Thorny Issues. California Institute for Regenerative Medicine (CIRM) January 18, 2013. [invited speaker]

56. Bubela T. Collaborative Mechanisms to Enhance the Clinical Translation of Stem Cell Therapies in a Global Environment ITRC Meeting, City of Hope, Passadena, California January 17, 2013. [invited speaker by the Canadian Consul General in California]

2012 57. Bubela T, Li M, Atkins H. Translating Stem Cell Research: Reality and Representations World Stem Cell

Summit West Palm Beach, Florida, December 4-6, 2012. [invited speaker] 58. Bubela T. UPDATE: Enhancing Translational Stem Cell Research: Innovative Models for Multi-Sectorial

Collaboration. Joint Meeting Stem Cell Network Board and Research Management Committee, Toronto, Ontario, October 26, 2012. [invited speaker]

59. Bubela T. Strategic uses of Landscaping for Business, Institutions and Policy. Patent Law: Reformed but Un-repented. Life Science INNOVATION Northwest Seattle, Washington, July 11-12, 2012. [invited speaker, panellist]

60. Bubela T. Novel methods for patent landscaping: incorporating statistical modeling. Managing Knowledge in Synthetic Biology: The Creation of Tools for Stronger Intellectual Property Analysis. Edinburgh, United Kingdom, June 20-21, 2012. [co-organiser, speaker, participant]

61. Bubela T. Translating Stem Cell Research: Reality and Representations. Using and Abusing Evidence in Science and Health Policy. Banff, Alberta, May 31-June 1, 2012. [invited speaker]

62. Bubela T. New Approaches to health law teaching and research. Curriculum Network Meeting: The Expanding Health Law Curriculum: New Questions, New Approaches, New Scholarship. University of Toronto, Ontario, May 3, 2012. [invited speaker]

63. Bubela T, Li MD, Bieber M, Atkins H. Translating Stem Cell Research: Reality and Representations. Till & McCullough Meetings, Montreal, Quebec, April 30-May 2, 2012. [invited plenary speaker]

of 74 64. Bubela T. Enhancing Translational Stem Cell Research: Innovative Models for Multi-Sectoral Collaboration.

Joint Meeting Stem Cell Network Board and Research Management Committee, Toronto, Ontario, March 7, 2012. [invited speaker]

65. Bubela T. Sustaining Equitable Research Partnerships: An Institutional Perspective. Annual Meeting on Drugs that Target Multiple Receptors for Anthelmintics, University of Botswana, Gabarone, Botswana, March 1-2, 2012. [invited speaker]

66. Bubela T, Jardine C, Driedger SJ. Building equitable research partnerships for HIV vaccine research. University of Nairobi Collaborative Meeting, University of Nairobi, Kenya, January 23-27, 2012. [unable to attend in person, presentation given by SJ Driedger]

2011 67. Bubela T. Clinical translation of stem cell research: Addressing the challenges. Workshop on the Innovation

Pool in Australian Biotechnology: Assessing Strategies for Fostering Innovation through Patenting and Patent Pooling, University of Tasmania, Hobart, Australia, December 15-16, 2011. [invited speaker, workshop participant]

68. Bubela T. NorCOMM 2: GE3LS Research. NorCOMM 2 Scientific Advisory Board Meeting. Toronto, Ontario, December 15, 2011. [invited speaker – presentation delivered via skype]

69. Bubela T. Synthetic biology and production of opiates: Overview of social, ethical & legal issues. Tasmanian Alkoloids, Launceston, Australia, December 12, 2011. [oral presentation and discussant]

70. Bubela T. Access to genetic resources and benefit sharing: Implications for barcoding. 4th International Barcode of Life Conference. University of Adelaide, Adelaide, Australia, November 28– December 3, 2011. [contributed oral presentation]

71. Bubela T. Clinical translation of stem cell research: Addressing the challenges. Innovation 2011, Montreal, Quebec, November 20-21, 2011. [invited speaker and panellist]

72. Bubela T. Managing IPRs in In Genomic Diagnostics: Lessons from the Mouse World. Workshop on Intellectual Property and Genomic Diagnostics. Duke University, Durham, North Carolina, November 4, 2011. [invited speaker, workshop participant]

73. Bubela T. Managing the pre-competitive research environment: Evidence and Outcomes. 6th Annual Conference of the EPIP Association: Fine-Tuning IPR Debates. Université libre de Bruxelles, Brussels, Belgium, September 8-9, 2011. [invited keynote speaker, panellist]

74. Bubela T. Science’s “Unobtanium”? – Building Robust Research Commons. VALGEN Workshop Intellectual Property in the ABC World, Banff, Alberta, January 21, 2011. [invited speaker]

2010 75. Bubela T. Building a Robust Research Commons: Enhancing the Precompetitive EnvironmenT 2010 ITMAT

International Symposium Interesting Times: The Academic Contribution to Development of novel Therapeutics in an Era of Reform, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, October 26-27, 2010. [invited speaker]

76. Bubela T. Models for Constructing a Robust Research Commons. Creative Commons, San Francisco, California, September 8, 2010. [invited speaker]

77. Bubela T. Managing Intellectual Property within a Precompetitive Space. QB3 University of California, San Francisco, California, September 7, 2010. [invited speaker]

78. Bubela T. Building a Robust Research Commons: Enhancing the precompetitive environment Banff Conference on Plant Metabolism, Banff, Alberta, June 24-28, 2010. [invited speaker]

79. Bubela T. Setting the Scene – Models for Dealing with IP. Session on Intellectual Property within a Precompetitive Space. Precompetitive Boundaries: Open Innovation in Drug Discovery and Development Meeting, The Wellcome Trust, London, United Kingdom, June 17-18, 2010. [invited speaker]

80. Bubela T. Intellectual Property and the “Mouse Commons”. Mouse Models for Human Disease, CASIMIR Consortium and the European Commission, the Royal Society, London, United Kingdom, May 19-20, 2010. [invited speaker]

81. Bubela T. Socially Responsible Management of Health Research. 2010 ICRH Young Investigators (YI) Forum, Vancouver, British Columbia, May 7, 2010. [invited speaker]

of 74 82. Bubela T. The Case for Socially Responsible Licensing in Alberta. Licensing Executives Society Edmonton

Chapter, Faculty Club, University of Alberta, Edmonton, Alberta, April 14, 2010. [invited speaker] 83. Bubela T. Exploring the bounds of the public domain: Who wins; who loses (A Contrarian Rant), UN-IP

Workshop, European University Institute, Florence, Italy, March, 2010. [invited speaker] 84. Bubela T. Intellectual Property and Commercialization Models, PhytoMetaSyn Scientific Advisory Board

Meeting, Montreal, Quebec, March 19-20, 2010. [oral presentation] 85. Bubela T. The Stem Cell Research Environment: Drawing the Evidence and Experience Together, Stanford

University, California, January 22, 2010. [invited speaker] 2009 86. Bubela T, Morin JF. Lost in Translation: The Canadian Access to Medicines Regime from Transnational

Activism to Domestic Implementation. Insights: A Focus on Public Health Research, School of Public Health, University of Alberta, Edmonton, Alberta November 12, 2009. [oral presentation]

87. Bubela T, Spear M. Health Communication 2.0: Hype or Reality. Public Health Seminar, School of Public Health, University of Alberta, Edmonton, Alberta, October 20, 2009. [invited speaker]

88. Bubela T. Grand Challenges for Evidence and Health Policy: Metrics and Indicators in Complex Systems. National Health Law Conference, Montreal, Quebec, October 2-3, 2009. [invited speaker]

89. Bubela T. Aligning Metrics with Mission for Biomedical Research. Faculty of Law, University of Cape Town, Cape Town, South Africa, May 12, 2009. [invited speaker]

90. Bubela T, Einsiedel E. GE3LS and Socio-Economic Research: NorCOMM. NorCOMM AGM, Banff, Alberta, April 24, 2009. [oral presentation]

91. Bubela T, Gold R. Toward a New Era in Intellectual Property: Implications and Opportunities for CIPO, Canadian Intellectual Property Office, Ottawa, Ontario, February 18, 2009. [invited speaker]

2008 92. Bubela T. Aligning Mission with Metrics for Publicly Funded Research Institutions: The case of the Canadian

Stem Cell Network. The UN-IP Workshop, Floating the Knowledge Management Boat in a Sea of Intellectual Property Rights, SCRIPT/AHRC Centre, Edinburgh University, Edinburgh, Scotland, December 10, 2008. [invited speaker]

93. Bubela T. Toward a New Era for Intellectual Property: Research Methods. Responsible Innovation, Wageningen University and Research Centre, Wageningen, Netherlands, December 8-9, 2008. [invited speaker]

94. Bubela T, Gold R. Toward a New Era for Intellectual Property: From Confrontation to Negotiation. Global Forum for Health Research Ministerial, Special Session on Intellectual Property Regimes, Bamako, Mali, November 15-19, 2008. [poster presentation]

95. Bubela T, Beas Rodriguez E, Metcalf C, Nnadozie K, Rodriguez E, Carbone J. Respecting, Promoting, and Protecting Traditional Knowledge: A Comparative Case Study of Brazil, Kenya and Northern Canada. Propriété intellectuelle, biotechnologies, et enjeux sociaux à l’heure de la globilisation, Science Po, Paris, France, November 13-14, 2008. [invited speaker]

96. Bubela T. Aligning Mission and Metrics for Biomedical Research. School of Public Health, University of Alberta, Edmonton, Alberta, September 30, 2008. [invited speaker]

97. Bubela T, Caulfield T. Industry perspectives: Genetic Research, CAM and Pharma Clinical Trials, and Conflicts of Interest. From Evidence to Policy: Popular Representations and Science Communication Workshop, Washington D.C. June 9-10, 2008. [invited speaker]

98. Ogbogu U, Bubela T, Caulfield T. The stem cell revolution: Claims, expectations and reactions in political, media and public discourse. From Evidence to Policy: Popular Representations and Science Communication Workshop, Washington D.C. June 9-10, 2008.

99. Bubela T, Einsiedel E. GE3LS and Socio-Economic Research: NorCOMM. NorCOMMAGM, Toronto, Ontario, May 14, 2008. [oral presentation]

100. Bubela T, Caulfield T, Shelley J. Public Representations of NutrigenomicTesting: Website Content and Media Coverage. Nutrigenomics 08, Melbourne Australia May 5-9, 2008. [invited speaker]

of 74 101. Morin JF, Bubela T, Wry T. Lost in Translation: NGOs and Patent Governance. International Studies

Association Conference, San Francisco, California, March 22-29, 2008. 2007 102. Caulfield T, Bubela T, et al. Nutrigenomics and the Promise of Prevention: Representations and Realities.

Visions, National Health Law Conference, Banff, Alberta, November 8-10, 2007. 103. Bubela T. “Managing Large Collaborative Research Project IP and Research Outputs for Innovation and

Access: NorCOMM, IPY”, National Graduate Institute for Policy Studies, Tokyo, Japan, October 26, 2007. [invited speaker]

104. Bubela T, Einsiedel E, Ashley C. North American Conditional Mouse Mutagenesis Project: GE3LS and Socio-Economic Research. Ontario Genomics Institute GE3LS Workshop, Toronto, Ontario, September 4, 2007. [oral presentation]

105. Ogbogu U, Bubela T, Fernando K. Paranoia. The Media’s Role in Shaping Public Confidence in Biotechnology Regulation. 30th International Academy of Law and Mental Health International Congress, Padua, Italy, June 25-30, 2007.

106. Caulfield T, Alfonso V, Shelly J, Bubela T. Nutrigenomics and the Promise of Prevention: Representations and Realities. Media, marketing, regulation and nutrigenomics: An International Workshop, Exeter, United Kingdom, June 22-23, 2007.

107. Bubela T. Canadian Perspectives on Traditional Knowledge. Unpacking Access: Towards the Practical Implementation of Biotechnology European University Institute, Florence, Italy, June 4-5, 2007. [invited speaker]

108. Bubela T, Einsiedel E. GE3LS and Socio-Economic Research: NorCOMM AGM, Toronto, Ontario, May 24-25, 2007. [oral presentation]

109. Bubela T, Strotmann A. IP Structures and Knowledge Flows in Genomics: Developing Better Measures. Genomics and Intellectual Property: Considering Alternatives to Traditional Patenting Workshop, Genome BC and The W. Maurice Young Centre for Applied Ethics, Vancouver, British Columbia, March 9, 2007. [invited speaker]

110. Caulfield T, Bubela T, Murdoch CE. Myriad in the Media: An Analysis of Newspaper Reports. Genomics and Intellectual Property: Considering Alternatives to Traditional Patenting Workshop, Genome BC and The W. Maurice Young Centre for Applied Ethics, Vancouver, British Columbia, March 9, 2007. [invited speaker]

111. Bubela T Einsiedel E. Activity 24: GE3LS & Socio-economic Research. NorCOMM Quarterly Meeting, Mount Sinai Hospital, Toronto, Ontario, March 4, 2007. [oral presentation]

2006 112. Gold ER, Bubela T. Of Mice and Women. Genomics Institute, Duke University, Durham, North Carolina,

December 5, 2006. [invited speaker] 113. Hicks G, Bubela T, Ding H, Einsiedel EF, Jefferies W, Lefevbre L, McKerlie C, Nagy A, Stanford WL, Rancourt

D, Ding, Rossant J. Pre-Clinical Mouse Models for Arthritis. Canadian Arthritis Network Annual Scientific Conference, Winnipeg, Manitoba, December 2006.

114. Hicks G, Bubela T, Ding H, Einsiedel EF, Jefferies W, Lefevbre L, McKerlie C, Nagy A, Stanford WL, Rancourt D, Ding, Rossant J. NorCOMM: High Throughput Mammalian Functional Analysis for the Discovery of Novel Determinants of Human Disease. World Congress of Psychiatric Genetics, Cagliari, Italy, October 2006.

115. Bubela T. Canadian Science and Technology Policy. Intellectual Property Modelling Group, Centre for Intellectual Property Policy, McGill University. Intellectual Property, Biotechnology Capacity and Development Buenos Aires, Argentina, September 25-26, 2006. [oral presentation]

116. Bubela T and Einsiedel E. Testing New Governance Models for Genomic Innovation: GE3LS Research and NorCOMM. NORCOMM Workshop and Team Research Meeting, Toronto, Ontario, June 14, 2006. [oral presentation]

117. Bubela T, Koper M, Boon H, Caulfield T. Media Portrayal of Herbal Remedy Versus Pharmaceutical Clinical Trials: Impacts on Decision-Makers. World Association for Medical Law 16th World Congress on Medical Law, Toulouse, France August 7-11, 2006. [oral presentation]

of 74 118. Bubela T, Caulfield T. Commercialisation and Converging Social Concerns – a need for new governance?

Human Genetics Licensing Symposium, Health Canada and Genome BC, Vancouver, British Columbia, March 20, 2006. [invited speaker]

2005 119. Caulfield T, Bubela T. Stem Cell Patents: Converging Social Concerns? Patenting Lives, Queen Mary

Intellectual Property Research Institute, London, United Kingdom, December 1-2, 2005. [invited speaker] 120. Bubela T, DeBow S, Caulfield T. Stem Cells, Politics and the Progress Paradigm. Stem Cell Network Annual

General Meeting, Calgary, Alberta, November 23-25, 2005. [oral presentation] 121. Caulfield T, Bubela T, Kurata CV, Ogbogu U. Unpacking the Justifications for the Canadian Ban on

Therapeutic Cloning. Challenges in Regenerative Medicine (ChaRM) Conference, Toronto, Ontario, October 20-21, 2005.

122. Bubela T, Caulfield T, Koper M, Moran T. Media Portrayal of Herbal Remedy Clinical Trials. Functional Foods, Nutraceuticals& Natural Health Products: From Research and Innovation to Policy and Regulation, AFMNet, Montreal, Quebec, October 3-4, 2005. [oral presentation]

123. Bubela T. What’s Hot in Canadian IP Law. Biotechnology and Intellectual Property: Reinventing the Commons, Montreal, Quebec, September 25-27, 2005. [invited speaker]

124. Bubela T, Caulfield T, Kurata V. Parliament, Politics and Science Policy: Case Study of Stem Cells & SCNT. Bioethics and Governments: Comparing French and American Responses to New Human Technologies Stanford Law School, Stanford University, Stanford, California, September 22-24, 2005. [invited speaker]

125. Caulfield T, Bubela T. Stem Cell: Politics, Publics and the Press. Looking Back, Looking Forward: Lessons for Governing Emerging Technologies, Canadian Biotechnology Secretariat and Genome Canada, Ottawa, Ontario, September 22, 2005.

126. Caulfield T, Bubela T. Parliamentary Politics and Science Policy: The Case of Stem Cell Research. Sheffield Institute of Biotechnology Law and Ethics, University of Sheffield, Sheffield, United Kingdom, September 14, 2005.

127. Metcalf C, Bubela T. Traditional Ecological Knowledge, Indigenous Rights and the Constitution. Law and Society Summer Institute, Oxford University, Oxford, United Kingdom, June 2005.

128. Cloutier LM, Bubela T. The Management of Technology at the Source: An Institutional Economics Analysis of the Commercialization of Intellectual Property by Universities. Science for Sale? Public Communication of Science in a Corporate World, Cornell University, Ithaca, New York, April 15-17, 2005.

Pre-2004 129. Caulfield T, Bubela T. Media, Marketing and Genetic Research: The Policy Implications of 'Genohype’.

American Society of Human Genetics Annual Meeting, Toronto, Ontario, October 27, 2004. 130. Caulfield T, Bubela T. Media Portrayals of Genetic Discoveries: What Does the Evidence Tell Us?

HGM2004, Human Genome Meeting, HUGO, Berlin, Germany, April 4-7, 2004. [oral presentation] 131. Bubela TM, Caulfield T. Media Portrayal of Genetic Discoveries: A Comparison of Newspaper Stories and

Peer Reviewed Research Papers. GE3LS Winter Symposium, Montreal, Quebec, 2003. [oral presentation] 132. Caulfield T, Bubela T. Headlines and hype?; Media portrayals of genetic discoveries. Crossing Over:

Genomics in the Public Arena1, Genome Prairie, Kananaskis, Alberta, 2003. [invited presentation] 133. Caulfield T, Bubela T. Media Portrayal of Genetic Discoveries: A Comparison of Newspaper Stories and

Peer Reviewed Publications (with Tania Bubela) (abstract #1266), The American Society of Human Genetics, Baltimore, Maryland October 15-19, 2002.

134. Newsome A, Hinds L, Bubela, T (1995) Social systems, compensatory breeding and prospects for immuno-sterility in foxes. Proceedings of the 10th Australian Vertebrate Pest Control Conference, Hobart, Tasmania, p 377.

135. Bubela, TM. Home range and social organisation of the broad-toothed rat Mstacomys fuscus. Australian Mammal Society Meeting, Canberra, Australia, 1990.

of 74

POSTERS PRESENTED AT WORKSHOPS AND SYMPOSIA

1. Kowal S, Camicioli E, Dennett E, Bubela T “Conducting ethically robust pediatric clinical trials for chronic manageable diseases: Lessons from a Scoping Review” Women and Children’s Health Research Institute Research Day 2016, Edmonton, Alberta, Nov 16, 2016.

2. Bubela T, Luth W, Kowal S “Treatment research reporting trends for genetic eye diseases and patient sharing on Twitter: implications for clinical communication” American Society of Human Genetics Annual Meeting, Vancouver, BC, Oct 18-22, 2016.

3. Kowal S, Dennett L, Camicioli E, Bubela T “Conducting ethically robust pediatric diabetes clinical trials: Lessons from a Scoping Review” Canadian Diabetes Association/CSEM Professional Conference, Ottawa, Ontario, Oct 26-29, 2016.

4. Caulfield T, Bubela T, Kurata V “Unpacking the Justifications for the Canadian Ban on Therapeutic Cloning” Stem Cell Network Annual General Meeting, Calgary, Alberta, November 23-25, 2005.

5. SSHRC Showcase of Strategic Research Clusters and INEs. “Legal Models Of Biotechnological Intellectual Property Protection: A Transdisciplinary Approach” Ottawa, Ontario, February 16-18, 2005 at the Château Laurier.

6. Caulfield T, Bubela T "Media, Marketing and Genetic Research: The Policy Implications of 'Genohype,'" American Society of Human Genetics Annual Meeting, Toronto, Ontario, October 27, 2004.

7. Bubela TM, Outerbridge T, Washenfelder C “Genetics in the News: Is the Public Listening?” Poster presentation at “Precedent and Innovation: Health Law in the 21st Century”, Health Law Institute, Edmonton, Alberta, 2002.

8. Caulfield T, Bubela T “Public Education through the Media’s Portrayal of Genetics.” Poster presented at the “American Society of Human Genetics Conference” Baltimore, Maryland (abstract #1266) 2002.

9. Bubela TM The effects of surgical sterilisation on the social behaviour of the red fox. VIth International Theriological Congress, Sydney, Australia, 1993.

10. Bubela TM Home range and social behaviour of the broad-toothed rat, Mastacomysfuscus Thomas. The Scientific Significance of the Australian Alps, First Fenner Conference, Australian Academy of Science, Canberra, Australia, 1988.

INVITED LECTURES (2000 & EARLIER) 2000 Department of Biological Science, University of Alberta 1997 Yukon College, Whitehorse Yukon Science Institute, Whitehorse 1996 Division of Life Sciences, University of Toronto at Scarborough Department of Zoology, University of Toronto Department of Biology, Trent University 1995 Yukon Renewable Resources, Fish and Wildlife Branch, Whitehorse Alaska Department of Fish and Game, Fairbanks Alaska 1994 School of Biological Sciences, University of Sydney CSIRO Division of Wildlife and Ecology School of Natural Resources, Utah State University Department of Zoology, University of British Columbia, Vancouver. 1993 Research School of Biological Sciences, Australian National University. Vertebrate Biocontrol Centre Annual Meeting, Braidwood. Kosciusko National Park Advisory Committee. 1992 School of Biological Sciences, University of Sydney. Vertebrate Biocontrol Centre Annual Meeting, Long Beach. Australian Alps Liaison Committee, Howmans Gap, Vic. 1991 CSIRO Division Of Wildlife and Ecology, Canberra. 1990 Fox Control Workshop, Canberra.

of 74

PARTICIPATION IN AND ORGANISATION OF WORKSHOPS

1. Panel Chair and Participant Round Table on Integrative Medicine, Canada India Networking Initiative (CINI 2018), Surrey, British Columbia, June 9-11, 2018.

2. Steering Committee Member and Participant, Innovate: New Approaches to Canadian International Cooperation Symposium, Vancouver, British Columbia, June 6-7, 2018.

3. Session chair, panellist and participant, Designing Indicators for Open Science Performance. Wellcome Trust, London, May 31-June 1, 2018. Funded by the Wellcome Trust, Bill & Meilinda Gates Foundation, Jisc, Deaprtment for Business, Energy and Industrial Strategy, UK, and Research England. Working meeting to develop qualitative and quantitative indicators for open life sciences projects.

4. Session chair, Genome BC Annual Forum. Vancouver, British Columbia, May 24, 2018. 5. Scientific Advisory Council Member, Medical Information Commons Advisory Council Meeting. Baylor

College of Medicine, Houston, Texas, March 21-22, 2018. 6. Participant, Vancouver Health Economics Methodology (VanHEM) Meeting, May 11, 2018. 7. Session chair and participant, Value of Information/Implementation International Workshop. Banff,

Alberta, February 7-8, 2018. This workshop brought together international experts, funders and health system decision-makers to discuss Value of Information economic modeling methods for precision medicine technology assessment and implementation. The workshop was led by Drs Christopher McCabe and Brenda Wilson of the Canadian Precision Medicine Policy Network.

8. Session chair and participant, AIRR 2017 Community Meeting. National Institutes of Health, Rockville, Maryland, USA. December 3-5, 2017. This workshop brought together the AIRR community to agree to policies and practices for data and materials sharing and standard and governance structures to join the Antibody Society as an AIRR community section. I have been working closely with the AIRR community, as a member of a core working group, in the development of its governance proposal and associated data and materials sharing policies.

9. Workshop Organiser and Session Chair, Data Access/Data Integration for Precision Health. Calgary, Alberta, October 25-26, 2017. This workshop brought together 37 multi-sector, mutli-disciplinary, inter-provincial group of participants to consider enablers and barriers to the use of big data by Canadian health systems to support the real-time evaluation of precision health technologies, including the use of life-cycle health technology assessment. It based its discussion on 2 case studies- Hepatitis C screening, diagnosis and treatment and genomic medicine in cancer and rare diseases. A publication and health system report are in preparation.

10. Workshop Organiser and Session Chair, Adaptive Licensing Frameworks for Regulation and Reimbursement of Precision Medicines: Balancing Access and Value. Banff, Alberta June 28-29, 2017. This workshop brought together 40 international experts in development of innovative therapies, health and safety regulation, reimbursement, industry risk-sharing models, post-market evidence development, and patient advocacy to advance development of reimbursement models that balance access and value. A publication is in preparation.

11. Participant, Preimplantation Genetic Diagnosis (PGD) and Screening (PGS) Workshop. Ottawa, Ontario. August 25, 2017. The workshop was one of a series funded by the Stem Cell Network that culminated in a report and series of recommendations to reform the Canadian Assisted Human Reproduction Act. The overall recommendations were presented by Prof. Barth Knoppers at the 2017 Till and McCulloch Meeting in Mt. Tremblant, Quebec on November 7, 2017.

12. Participant and member of the Steering Committee for a Council of Canadian Academies workshop that lead to the Report: Building on Canada’s Strengths in Regenerative Medicine. Toronto, Ontario. October 13-14, 2016. As a member of the Steering Committee, I helped CCA staff identify workshop participants, provided expert guidance for research and writing, reviews and comments on drafts of the report, responded to external peer review comments, and as authors provided final sign-off on the report. In addition, I conducted the bibliometric analyses that supported the report findings. The Report contributes to:

of 74 a. Minister of Innovation, Science, and Economic Development is currently seeking input on

Canada’s Innovation Agenda. b. Minister of Science has a particular interest in regenerative medicine and is looking to

understand how the government should invest in this field. 13. Participant in multi-stakeholder workshop: Regulatory and Reimbursement Obstacles and Drivers for

Clinical Uptake of Molecular Diagnostics. Center for Law, Science and Innovation, Sandra Day O’Connor College of Law, Arizona State University, Scottsdale Arizona, USA. April 8, 2016.

14. Co-organiser and Chair: Session 6 – Innovating molecular diagnostic technologies for the clinic. Canadian GE3LS and Health Services and Policy Research Conference. Vancouver, Canada. April 21, 2015.

15. Co-organiser, speaker, and panel chair at two linked workshops in London UK December 9-10, 2014. The workshop was co-organised by the UK Cell Therapy Catapult, NICE (UK HTA Agency) and brought together representatives from Canadian and European health regulatory and HTA agencies to discuss barriers to the clinical translation of regenerative medicine.

16. Co-organiser, speaker, and session responder: Driving Regenerative Medicine to the Market and Clinic: An Exploration of Enablers, Impediments and Ethical-Legal Challenges. Toronto, Canada. November 6-7, 2014.

17. Invited Scientific expert CADTH Exchange Retreat. Toronto, October 9-10, 2014. Discussion of integration of ELSI (ethical, legal, social issues) into health technology assessment practices in Canada.

18. Chair of Panel Discussion on Resource Sharing and Ways Forward. Infrafrontier/IMPC Workshop – Promoting the International Exchange of Mouse Mutant Resources. Munich, Germany, May 8-9, 2014.

19. Mock panel review of BioCanRx NCE application, May 1, 2014, Ottawa, ON, Canada. 20. National Forum on Genomics and Personalized Health, April 15-16, 2014, Montreal QC, Canada for lead

representatives of all teams funded by Genome Canada in the Personalized Medicine Competition 2012. Drs Bubela and McCabe represented the PACEOMICS Team and additionally participated in the Third Modality GE3LS Consultation.

21. Organisation and participation in the Research Oversight Committee (ROC) meeting, ECHA, Edmonton, Alberta with the PACEOMICS theme leaders. April 10, 2014 commenced with a mini-symposium which showcased the research of three PACEOMICS ROC members: David Lea (Health Canada); Lou Garrison (University of Washington); and Kathryn Phillips (University of California, San Francisco). April 11, 2014 comprised the ROC review of progress against milestones and deliverables of the PACEOMICS grant. Also in attendance were representatives from funding agencies: Genome Canada, Genome Quebec, Genome Alberta, CIHR, Alberta Innovates – Health Solutions and Alberta Health Services.

22. Co-organiser of two linked workshops in Washington D.C., March 13-14, 2014. The first was held at Rayburn House Office Building (Congressional Offices, Capitol Hill) and comprised a Congressional Briefing hosted by Duke Sanford School of Public Policy and the Office of Congresswoman Debbie Wasserman Schultz, followed by sessions on the impact of the AMP v Myriad Supreme Court Decision on gene patents on industry (I presented on impacts on regenerative medicine), global perceptions of the ruling, and the use of evidence in jurisprudence that has significant impacts on scientific fields of endeavour and innovation. I organised, with Dr. Gregory Graff (Colorado State University) a second day workshop on Analyzing Policy Impacts on Biotechnology Innovation Using Patent Data.

23. Invited participant and discussant: INFRAFRONTIER, IMPC & IKMC Rome Meeting 2013, Rome Italy, December 2-3, 2013.

24. Panellist and draft report co-author for Genome Canada. Receptor Capacity for Biotechnology Innovation in Canada. Ontario September 24, 2013.

25. Lead Organizer of Medicinal Plant Barcoding and Natural Health Products Research: Moving the Debate Forward on Access and Benefit Sharing. Multi-stakeholder, international policy workshop. Mexico City, Mexico February 12-13, 2013.

26. Co-organizer of Managing Knowledge in Synthetic Biology conference held on June 20-21, 2012 in Edinburgh, Scotland. Academic partners: E. Richard Gold, McGill University; Gregory Graff, Colorado State University; Daniel Cahoy, Pennsylvania State University; Dianne Nicol, University of Tasmania; David

of 74 Castle, University of Edinburgh; Jeremy de Beer, Faculty of Law, University of Ottawa; Vincent Martin, Concordia University; Peter W.B. Phillips, Johnson-Shoyama Graduate School of Public Policy, University of Saskatchewan.

27. iBOP Asia—Science and Technology Innovations for the Base of the Pyramid in Southeast Asia, Ateneo School of Government, Manila, Philippines. April 29, 2011.

28. SAGE Congress and Arch2POCM Workshop, San Francisco, April 15-17, 2011. 29. Workshop on Stem Cell Therapy Funding, Banff. March 25, 2011. 30. Nature Redesigned: GE3LS Phytometasyn and Synthetic Biology Workshop, Banff. March 24, 2011 31. Forum on Public Private Partnerships: Institutional Analysis of the Reward Structures for Precompetitive

Drug Discovery through Proof of Concept, Toronto February 16, 2011. 32. Planning workshop: Assessing health system barriers to the commercialization and utilization of stem cell

therapies in Canada, Edmonton. January 27, 2011. 33. Stem Cell Therapy Workshop – Joint workshop organized by the Stem Cell Network and Health Canada,

Ottawa. December 13-14, 2010. Workshop to discuss commercialization and regulatory barriers to the introduction of stem cell therapies to the clinic.

34. Hinxton Group 2010: Proprietary Challenges in Stem Cell Research, Manchester, United Kingdom October 31- November 2, 2010.

35. International BarCode of Life (iBOL) Scientific Steering Committee Second Meeting, Guelph, Ontario, Canada September 23-25, 2010.

36. McLaughlin-Rotman Centre for Global Health, Fostering the Global Bioeconomy: Canada’s Health Biotechnology Collaboration with Emerging Economies, Ottawa Ontario, June 14, 2010 [Participant].

37. Canadian Coalition for Global Health Research, Assessing Canadian Knowledge Translation Approaches In Global Health Research, Workshop Mount Royal University, Calgary Alberta, May 27-28, 2010 [Planning Team].

38. European Commission, Are Mice Relevant Models for Human Disease Royal Society, London, May 21, 2010. [Panel member: What are the Clinical and Industry Requirements for Mouse Models – with representatives from Institut de Researches Servier, France; Genentech; CXR Biosciences Ltd.; GlaxoSmithKline, UK; Astra-Zeneca; Imperial College, London; and Regeneron]

39. Alberta Forum, Canadian Coalition for Global Health Research, University of Calgary, Alberta, April 19-20, 2010. [Planning Team]

40. VALGEN, Genome Canada ABC Integration Workshop, Banff Alberta, January 28-29, 2010. [Participant] 41. Media, Public Engagement & Health Policy Workshop, Montreal, November 20, 2009 (Department of

Journalism, Concordia University). [Participant] 42. 8th Interphenome Meeting, Principles for Phenotype Data Dissemination, La Jolla, November 3, 2009.

[Participant] 43. Canadian Coalition for Global Health Research. Integration Day. Ottawa, October 24, 2009. [Participant] 44. Canadian Coalition for Global Health Research. Learning Day. Ottawa, October 25, 2009. [Participant] 45. Ontario Genomics Institute. Synthetic Biology – Engineering the Future. Toronto, October 27, 2009. Public

Forum followed [Participant] 46. CASIMIR - Coordination and Sustainability of International Mouse Informatics Resources, Data Sharing in

Mouse Functional Genomics, Rome, Italy May, 20-22, 2009. [Organising committee and session chair] 47. Canada’s Access to Medicines Regime: Hindrance or Hope? Workshop sponsored by The Initiative for Drug

Equity and Access at the Leslie Dan Faculty of Pharmacy, University of Toronto and the Centre for Intellectual Property Policy at McGill University, Ottawa, May 7, 2009. [Participant]

48. Health Canada, Implementation of Gene Licensing Guidelines for Genetic Testing Facilities, Edmonton, October 20, 2008. [Participant]

49. Planning meeting and committee for CASIMIR WP6 Workshop on Data Sharing in Functional Genomics, Rome, Italy, Oct 7, 2008. [Participant]

50. Launch, Ottawa, September 9, 2008: Gold ER, Adams W, Bernier L, Bubela, T, et al. (2008) Toward a New Era for Intellectual Property: From Confrontation to Negotiation. A Report by The International Expert

of 74 Group on Biotechnology, Innovation and Intellectual Property. [Participant]

51. Advisor: Duke Institute for Genome Science and Policy, Center for Public Genomics 4th Annual Retreat, April 18, 2008, Duke University, Raleigh, North Carolina. [Participant]

52. PI and Trainee Talks, Session 2. Stem Cell Network Annual General Meeting, Toronto, Ontario, November 7-9. 2007. [Chair]

53. Roundtable on Innovation Systems: How Can Innovation Systems Help Improve Equitable Access to Products and Services? Global Forum for Health Research, “Mobilizing Support for Global Health Research”, 29 October-3 November 2007, Jihua Convention Centre, Beijing, China. [Chair]

54. NCIC Media & Policy Research in Cancer Prevention Workshop, September 21, 2007, Ottawa hosted by the National Cancer Institute of Canada. [Participant]

55. Bridging the Invention-Innovation Gap in the Commercialization of Publicly Funded Research, September 10, 2007, Chateau Laurier, Ottawa. Hosted by the University of Ottawa and the Centre for Intellectual Property Policy, McGill University. [Rapporteur].

56. National Workshop on Genome Canada’s Strategic Research Theme: GE3LS - Policy and Knowledge Transfer (GE3LS = genomics and ethics, environment, economics, law and society) Monday, May 28, Ottawa. [Participant]

57. Dr Bubela became an official consultant on the National Human Genome Research Institute grant, Duke Center for Public Genomics headed by Dr. Robert Cooke-Deegan. Dr Bubela participated in the Center’s retreat held at Duke University on March 23, 2007.

58. Health Canada, Licensing Guidelines for Genomics Technologies, Ottawa December 2006. [Participant] 59. Health Law Institute, University of Alberta and Centre for Intellectual Property Policy, McGill University,

Myriad Genetics: Caught in the Eye of a Policy Storm, Edmonton, November 27-29, 2006. [Participant] 60. Intellectual Property Modelling Group, Centre for Intellectual Property Policy, McGill University.

Intellectual Property, Biotechnology Capacity and Development Buenos Aires, Argentina, September 25-26, 2006. [Workshop co-organiser]

61. Centre for Modelling Human Diseases. Attacking the Mouse Genome Mount Sinai Hospital, Toronto 13 June 2006. [Participant]

62. CIHR Institute of Genetics. Genetic Diversity and Science Communication, Toronto, April 2006. [Participant] 63. Genome Alberta, Biotechnology Patents and Policy: What’s the Evidence? Banff, AB, 25-27 May 2006.

[Participant] 64. Intellectual Property Modelling Group, Centre for Intellectual Property Policy, McGill University. The Role

of Intellectual Property Rights in Biotechnology Innovation, Florence Italy, October 24-25, 2005. [Chair: panel on Innovation Governance]

65. Intellectual Property Modelling Group, Centre for Intellectual Property Policy, McGill University. Biotechnology and Intellectual Property: Reinventing the Commons, Montreal, Canada, September 25-27, 2005. [Participant]

66. T. Bubela and T. Caulfield. GE3LS : Where to Now? Genome Prairie GE3LS Team Meeting, Banff, AB, 15-17 June 2005. [Participant]

67. Intellectual Property Modelling Group, Centre for Intellectual Property Policy, McGill University. Health Biotechnology and Intellectual Property: A New Approach. Hosted at the European University Institute, Florence, Italy, 27-28 October 2004. [Participant]

68. Intellectual Property Modelling Group, Centre for Intellectual Property Policy, McGill University. Agricultural Biotechnology and Intellectual Property: A New Framework. Institute of Forest Biotechnology, Raleigh, NC, 3-4 June 2004. [Participant]

of 74

ENGAGED SCHOLARSHIP

KNOWLEDGE TRANSLATION WITH POLICY MAKERS, INDUSTRY AND RESEARCH STAKEHOLDERS

Note that many of the workshops attended and presented at (see above for details) involved a multi-stakeholder audience, including policy makers, funders, university administrators, technology transfer offices, non-governmental organizations, patient advocacy groups, and industry. This section outlines only meetings and consultation sessions that were not in the form of workshops. March 9, 2019 Panelist, speaker, and round-table expert: Career Pathways in Pharmaceutical Sciences. Faculty of Pharmacy, University of British Columbia. April 13,2018 Panelist on Science Communication Ethics, taking questions from the audience of

science writers and communicators at the Science Writers and Communicators of Canada Annual Conference, Vancouver, British Columbia.

March 1, 2018 Biotechnology Industry and Government Working Group (BIGWG) to formulate recommendations for reform of the New Substances Notification Regulations (Organisms) with Public Health Agency of Canada, Health Canada, and Environment and Climate Change Canada. Goal is to address regulation of viral therapies and viral vectors for clinical trials in Canada. Note that work and consultations with clinical research community, industry and Environment and Climate Change Canada and Health Canada was ongoing through 2017.

January 27, 2017 Biotechnology Industry and Government Working Group (BIGWG) to formulate recommendations for reform of the New Substances Notification Regulations (Organisms) with Public Health Agency of Canada, Health Canada, and Environment and Climate Change Canada. Goal is to address regulation of viral therapies and viral vectors for clinical trials in Canada.

June 2, 2016 Bieber M, Bubela T (June 2016) Presented methods and tools for bibliometric analysis approaches to Alberta Innovates-Health Solutions.

February 23, 2016 Presented to Health Canada- Health Products and Food Branch Bilateral Meeting

Program – prepared a brief on New Substances Notification Regulations (Organisms) and their impact for the import and manufacture of viral vectors (gene and oncolytic viral therapies) for use in clinical trials in Canada on behalf of CellCan.

February-March 2016 Delegate from the University of Alberta to an expert stakeholder group to map the outcomes for the science enterprise and basic research system in Alberta leading to a Strategy Roadmap to inform the development of science policy for Alberta, develop a shared understanding among stakeholders of the expectations of the science and basic research system, and inform the development of system functions and basic research programming. Initiative lead by the Government of Alberta: Advanced Education.

October 2013 Attended the CIHR OOGT Reforms Bootcamp hosted by the Institute of Health Services and Policy Research, Institute of Gender and Institute of Population and Public Health, Montreal, October 10-11, 2013.

July 2013 Benjaminy S, Bubela T (July 2013) Understanding the landscape of stem cell clinical trials for retinopathies: A technical guide. Report for Choroideremia Research Foundation (US).

July 2013 Benjaminy S, Bubela T (July 2013) Understanding the landscape of stem cell clinical trials for retinopathies: A lay summary. Report for Choroideremia Research Foundation (US).

June 27, 2013 Consultation with Jonathan Gitlin, Science Policy Analyst, Policy & Program Analysis Branch, Office of the Director, National Human Genome Research Institute, National Institutes of Health on broader impacts for NIH funded research of SCOTUS decision in AMP v. Myriad.

of 74 February 26, 2013 Genome Canada Competition in Genomics and Personalized Medicine Debrief. Alberta

Innovates – Health Solutions, Edmonton. Consultation meeting with key stakeholders in health genomics to better understand challenges and barriers for Alberta researchers to be competitive in national funding calls.

November 8, 2012 Publishing for Impact. Panel for SPH and Nursing students and faculty at the University of Alberta on academic publishing.

September 14, 2012 Member advisory board- Dialogue on Intellectual Property (IP) related to the Biopharmaceutical Industry. Pfizer Canada, Montreal.

March 23, 2012 Open Data: Legal and Conceptual Issues. Data event at the University of Alberta for researchers and administrators to raise awareness about data and publications sharing.

October 17, 2011 Bubela T, Bieber M. Key Performance Indicators for the Innovative Medicines Initiative (IMI). Consultation Report.

December 2012 AMICUS CURIAE BRIEF on genetic diagnostics for Breast Cancer (BRCA1 patents) with E. Richard Gold (Professor, Faculty of Law, McGill University), James P. Evans (Professor, Medical Genetics and Internal Medicine, University of North Carolina and Chair, Federal task force on impact of patents on genetic testing for the Secretary’s Advisory Committee on Genetics, Health and Society), and Dianne Nicol (Vice-Dean of Law, University of Tasmania) submitted to the United States Supreme Court to support an application for certiori in the case of The Association for Molecular Pathology, et al.v. United States Patent and Trademark Office and Myriad Genetics.

December 2010 AMICUS CURIAE BRIEF on genetic diagnostics for Breast Cancer (BRCA1 patents) with E. Richard Gold (Professor, Faculty of Law, McGill University) and James P. Evans (Professor, Medical Genetics and Internal Medicine, University of North Carolina and Chair, Federal task force on impact of patents on genetic testing for the Secretary’s Advisory Committee on Genetics, Health and Society) submitted to the United States Courts of Appeals for the Federal Circuit in the case of The Association for Molecular Pathology, et al.v. United States Patent and Trademark Office and Myriad Genetics.

November 2010 Invited to join the Cell Therapy Alliance, Edmonton Advisory Group. Partners are ABCtech, patient representatives, former DM Health, clinicians, bioengineers and researchers. The Alliance is a multi-stakeholder group of individuals in Edmonton and Calgary whose aim is to raise the profile of cell therapies in Alberta. The Advisory’s goal is to promote cell therapies and regenerative medicine with the hope that through educational initiatives and discussion we can speed their process to commercialization and ultimately to the bedside.

October 31, 2010 Hinxton Group 2010: Proprietary Challenges in Stem Cell Research, Manchester, United Kingdom with The Hinxton Group and Expert Stakeholders. This meeting resulted in a consensus statement: Statement on Policies and Practices Governing Data and Materials Sharing and Intellectual Property in Stem Cell Science initially to be posted on the Hinxton Group website. The Hinxton Group is an international consortium on stem cells, ethics and law: www.hinxtongroup.org/

October 1, 2010 Research Fellow with Science at Creative Commons. In collaboration with John Willbanks, Creative Commons (CC) Vice President, Science, I will (1) Evaluate and inform the world of CC tools for materials transfer in mailing lists, interest groups, meetings, workshops and conferences; (2) Brainstorm on technology transfer efficacy in universities and research agencies; (3) Interface with public agencies, non-profit commons efforts, and funding officials educating them on the value and mechanisms for open materials transfer; and (4) Provide briefings for CC staff on open materials commons and systems.

July 2010 Invited to join: Health and Healthcare Common Pooled Resources Working Group, Indiana University, Bloomington, IN, USA with Nobel Laureate, Prof. Elinor Ostrom and

of 74 multi-stakeholder working group. Monthly teleconferences to discuss health and healthcare common as a common pool resource.

June 8, 2010 Alberta Innovates– Health Solutions Strategic Consultation with Industry, government and technology transfer representatives. To discuss the new corporation’s strategies and programs for supporting health research and innovations, led by the Health Research Strategy, which is being developed by Alberta Health and Wellness and Advanced Education and Technology. The Health Research Strategy will describe in broad strokes the areas of research priority for the Government of Alberta.

February 2010 Meetings on the development of technology transfer policies and infrastructure with the Director General and staff of the Tanzania Commission for Science and Technology following a 2 day intensive, multi-stakeholder training session (see section on Capacity Building in Developing Countries below).

October 26, 2007 Meeting and Discussion on IPR policy in Canada and Japan and IPR strategy for biotechnology at the Secretariat of Intellectual Property Strategy Headquarters, Cabinet Secretariat, DIET, Tokyo Japan (Japanese Parliament).

October 27, 2007 Meeting and discussion with policy officials at the Japanese Patent Office on international post-genomic patent trends.

October 29, 2007 Satellite Session: Global Forum for Health Research, “Mobilizing Support for Global Health Research”, Canadian Coalition for Global Health Research, Jihua Convention Centre, Beijing, China

November 22, 2005 Health Canada consultation on uptake of OECD guidelines for licensing of genetic inventions, Edmonton.

POLICY/LEGAL CONSULTING

2017 Alberta SPOR Support Unit (Strategy for Patient-Oriented Research) - $50,000 contract from Alberta Innovates to conduct bibliometric/research outcomes analysis for Canadian Patient Oriented Research with report due May 2017.

2013 Genome Canada Policy Brief No. 8– Case study and co-author (above) 2011 The Innovation Partnership (Chapter Lead)—Health Canada contract Callan et al. 2011

(above) 2010 The Innovation Partnership (Lead Author: Bubela, T) (2010) Evidence and Background

Information to Inform Canada’s Approach to Public Health and Intellectual Property Issues in International Fora. Health Canada Global Health Studies. Report for Health Canada’s International Affairs Directorate (IAD) The Innovation Partnership (Co-author: Bubela, T) (2010). Intellectual Property and Health, A Report to Health Canada: Bioethics, Innovation and Policy Integration Division

2007 The Health Sciences Policy Division of Health Canada Tania Bubela for San Patten and Associates, Inc. for the project titled: “Overview of the Canadian Patent Landscape of HIV Vaccine-Related Technologies.” Contract Reference Number: 4500160376

2005 Field Law LLP, Legal Research on Constitutional Issues of Freedom of Expression and Equality for Factum on Appeal at the Alberta Court of Appeal.

ENVIRONMENTAL CONSULTING

Aug-Sep 1995 Fertility Control of Wolves (Canis lupus) in the Aishihik Area of Yukon Territory for Yukon Renewable Resources, Fish and Wildlife Branch.

Aug 1995 Fertility Control of Wolves (Canis lupus) in the calving grounds of the Forty Mile Caribou Herd for the Alaska Department of Fish and Game.

Nov 1993 Fauna Impact Survey for Kosciuszko Thredbo Pty. Ltd.

of 74

ENGAGEMENT WITH LAY STAKEHOLDERS

February 27, 2018 Bubela T [Invited Panelist] Patient and Community Engagement Event, Simon Fraser University, Surrey BC organized in partnership with the BC Strategy for Patient Oriented Research (SPOR) Support Unit and the Fraser Health Authority.

September 17, 2016 Bubela T Vision Quest. Edmonton. [invited panelist - plenary panel on clinical trial participation].

August 27, 2015 Career paths in bio-science: Health Law. Heritage Youth Researcher Summer Program, Alberta Innovates – Health Solutions, Edmonton.

October 2015 Bubela T Vision Quest. Toronto. [invited panelist - plenary panel on clinical trial participation].

July 14, 2015 Bubela T (2014) Is home-brew heroin really just a beer away? Reflections on regulation of yeast-based production of opiates. Impact Ethics in Health Research, Law & Policy, Public Health, Research Ethics. Available at: http://impactethics.ca/2015/07/14/is-home-brew-heroin-really-just-a-beer-away-reflections-on-regulation-of-yeast-based-production-of-opiates/ [Blog designed to communicate about ethics issues with lay audiences – Invited submission].

November 2, 2013 Benjaminy S. Clinical Trials: Participation Pros & Cons. Vision Quest. Vancouver, [invited presentation based on material prepared by Bubela T for Vision Quest in 2012].

July 2013 Benjaminy S, Bubela T (July 2013) Understanding the landscape of stem cell clinical trials for retinopathies: A guide for lay audiences. Report for Choroideremia Research Foundation (US).

August 2013 Career Panel Alberta Innovates – Health Solutions, Edmonton. [Speaker and Panellist on careers in biomedicine].

July 2013 Bubela T, Benjaminy S. Career paths in bio-science: Bioethics. Heritage Youth Researcher Summer Program, Alberta Innovates – Health Solutions, Edmonton.

April 4, 2013 Bubela T. What’s a biologist like you doing in a courtroom like this? Invited luncheon talk to the Women’s Law Forum, Canadian Bar Association, Edmonton.

November 2012 Bubela T, Benjaminy S. Translational medicine: Moving research from the lab bench into the clinic – ocular gene and stem cell therapies. Ross Sheppard Composite High School, Edmonton.

May 15, 2013 CIHR Café Scientifique: Genetic Testing and You! Edmonton Alberta. April 18, 2013 CIHR Café Scientifique: Genetic Testing and You! Montreal Alberta- cast member: “It’s

Not That Simple,” Karen’ Rothenberg. Oct 13, 2012 Being Part of a Clinical Trial- Vision Quest – Edmonton, Sponsored by the Foundation

Fighting Blindness. <http://www.youtube.com/watch?v=wscpGN7ibHE&feature=relmfu>

May 4, 2011 Science Café: Synthetic Biology - Engineering the Building Blocks of Life. For the public. Billiard Club, Edmonton.

April 30, 2011 Cell Therapies: Are they for me in my lifetime? Public Forum for patients and other interested members of the public at the Lyon’s Senior Centre, Edmonton Alberta organized by the Cell Therapy Alliance and in part supported by the Stem Cell Network. Lead by patient advocates for Parkinson’s Disease.

November 23, 2010 Speaker: Science Café- Reinventing Nature Using Synthetic Biology- Are there limits to how far we should go. Sponsored by the University of Calgary and the TELUS World of Science: This successful debate format on issues related to synthetic biology for the general public (held in a pub for 2 hours) will be repeated in the New Year in Edmonton: http://www.ucalgary.ca/community/sciencecafe.

November 16, 2006 Expert discussant following “A Number” by Caryl Churchill Presented by Trunk Theatre, Trans Alta Arts Barn, Edmonton in Partnership with Genome Alberta.

of 74

MEDIA COVERAGE

GENERAL:

1. Interview with and quoted by: Beloz, J (January 23, 2019) A new study shows stem cells can reverse MS in some patients. But researchers have questions. Vox online: https://www.vox.com/2019/1/15/18182095/ms-multiple-sclerosis-stem-cell-transplant

2. The Promise of Precision Medicine. Podcast with Michael Joyce: Guests: Tania Bubela, Timothy Caulfield, Michaeld Joyner, and Eric Topol. Healthnewsreview.org

3. Interview with and quoted by: Dolgin, E (August 10, 2017) Profile: Michael Sporn: A legacy of greater knowledge. Nature 548: S16-S18 (http://www.nature.com/nature/journal/v548/n7666_supp/full/548S16a.html?foxtrotcallback=true)

4. Interview with and quoted by: Ledford, H (March 15, 2017) ‘Zombie’ patent fights over mutant mice return. Nature News (http://www.nature.com/news/zombie-patent-fights-over-mutant-mice-return-1.21620).

5. Radio Interview (aired March 11, 2017) with Peter Watts on Corus Talk Radio Stations (Edmonton and Calgary) on Canadian Council of Academies Report: Building on Canada’s Strengths in Regenerative Medicine, released on March 9, 2017. It overviews the current strengths and weaknesses in regenerative medicine in Canada, and identifies key opportunities for success in the field. Bubela T was a member of the four-person Steering Committee and conducted the supporting bibliometric analyses of the field of regenerative medicine in Canada.

6. Interview with Ledford H (March 9, 2017) for Nature News item on University of South Florida law suit against the NIH over Alzheimer’s disease mouse models.

7. Cheung A (2015) Apple's newest courtroom foe is a patent-savvy university. Reuters New York (October 16, 2015) http://www.reuters.com/article/2015/10/16/us-apple-patent-wisconsin-idUSKCN0SA09G20151016

8. Ledford H (2015) Congress seeks to quash patent trolls. Nature News May 20, 2015. http://www.nature.com/news/congress-seeks-to-quash-patent-trolls-1.17578 (Quotes T. Bubela on two patent troll papers with Dr. Cook Deegan in Nature Biotechnology and Journal of Law and the Biosciences).

9. Ledford H (2015) Why predatory ‘patent trolls’ could soon find it harder to operate in the United States. Scientific American May 22, 2015. As above.

10. Aharonian G (2015) Nature magazine’s patent stupidity. PATNEWS May 28, 2015. [Influencial patent policy blog approving of and re-quoting T. Bubela while criticising Ledford (2015)].

11. Brown M (2014) Taking health discoveries from cutting edge to clinic. University of Alberta Latest News, December 19, 2014. http://uofa.ualberta.ca/news-and-events/newsarticles/2014/december/taking-health-discoveries-from-cutting-edge-to-clinic

12. Caution urged as doctors push ahead with DNA-tailored treatments. ABC News, Sunday July 13, 2014. http://www.abc.net.au/news/2014-07-12/caution-urged-over-dna-tailored-treatments/5592252 [Website, ABC Television News and ABC Radio].

13. Interview with Elie Dolgin, Staff writer Nature – about the Structural Genomic Consortium contract with the CHDI Foundation for drug discovery research for Huntington’s Disease that expands the pre-competitive research environment (IP free) to the Proof of Clinical Mechanism. Cited in E. Dolgin. Patent-free pact pushes the boundaries of precompetitive research. Nature Medicine 20: 564-565 (2014).

14. Interview with Heidi Ledford, Staff writer Nature – About impact of gene patenting decisions on regenerative medicine following Washington Workshop, March 2014 (20 March 2014).

15. Andrea, Congressional Briefing on DNA Patents (A.K.A The Post About my Right to Interpret my Genome Sequence into Poetry). Brave Bosoms – Life from a Previvor’s Perspective (March 20, 2014): http://www.bravebosom.com/congressional-briefing-on-dna-patents-a-k-a-the-post-about-my-right-to-interpret-genome-sequence-into-poetry/.

16. Bubela T 23andMe’s Legal Woes Continue. Genevalues – A blog about the ethics and economics of personalised medicine. Guest blog for Stuart Hogarth (December 3, 2013). (222 visits in first day online) Online: http://genevalues.wordpress.com/2013/12/03/23andmes-legal-woes-continue/.

17. PodCast on Synthetic Biology. Cell Press (2012) online: http://www.cell.com.

of 74 18. Hayden EC (2011) License rules hinder work on rare disease: Animal model off-limits to Rett-syndrome

researchers. Nature 470: 318-319. 19. Technology Transfer at Canadian Universities. The Cross-Border Biotech Blog: Biotechnology, Health and

Business in Canada, the United States and Worldwide. (October 28, 2010) online: http://crossborderbiotech.ca/2010/10/28/technology-transfer-at-canadian-universities/#more-5022. Reporting on Bubela & Caulfield (2010) Trends in Biotechnology.

20. Munster C. Feds should have learned lessons on H1N1 rollout from listeriosis crisis. Hill Times (November 16, 2009).

COVERAGE OF OYE, BUBELA & LAWSON (2015) NATURE.

Global coverage in 483 sources in Factiva. Highlights include the New York Times, The New Yorker, New Scientist, Scientific American, Nature News, The Economist, The Globe and Mail, front page of the Edmonton Journal, CBC National News (Radio) and TV coverage on PBS, CTV, Global and Dinner TC (City TV). Cites to coverage include:

1. Ehrenberg R. (2015) Engineered yeast paves way .for home-brew heroin. Nature 521: 267-268. 2. Just a sip could get you high. New Scientist, 23 May 2015, 1539 words. 3. Pratt S. Homemade heroin a public health threat, U of A professor says. Edmonton Journal, 21 May

2015, 585 words. 4. Pratt S. U of A professor fears rise of 'home-brewed' heroin. Calgary Herald, 21 May 2015, 616 words. 5. Leung W. Brewing drugs: The next step in medical science? The Globe and Mail, 19 May 2015. 6. Guttenfelder D. Home-Brewed Morphine Is Around The Corner. National Public Radio, 04:10 PM, 19

May 2015, 730 words. 7. Wilton K. Scientists put yeast to test in bid to make painkillers. Montreal Gazette, 19 May 2015, 327

words. 8. Hadlington S. Opiate-Making Yeast Could Lead to "Home-Brewed Heroin". Scientific American, 09:00

AM, 19 May 2015, 948 words 9. Stix G. Prospect of Home-Brew Opiates Demonstrates the Wild and Woolies of Synthetic Biology.

Scientific American, 06:55 AM, 19 May 2015, 1038 words. 10. Rajan N. Home-Brewed Morphine Now Possible With Beer-Making Kit. The Huffington Post, 05:21 AM,

19 May 2015, 390 words. 11. Chang A. Breakthrough may lead to synthetic morphine; Scientists find a way to make painkillers

without opium, but abuse remains a concern The Toronto Star, 19 May 2015, 406 words. 12. Theobald C. Brewing morphine Researchers bio-engineering yeast to produce the opiate. The Edmonton

Sun, 19 May 2015, 467 words. 13. McNeil DG. Makings of a New Heroin. The New York Times, 19 May 2015, 1262 words. 14. Home-made heroin 'within two years' The Daily Telegraph, 19 May 2015, 224 words. 15. Blakely R. Genetic engineers create 'homebrew heroin'. The Times, 19 May 2015, 150 words. 16. Discovery opens door for homemade morphine, painkillers. The Economic Times, 09:36 PM, 18 May

2015, 482 words. 17. McNeil DG Jr. ‘Brewed’ morphine raises concerns about regulation. International New York Times, 19

May 2015, 1129 words. 18. Gallagher J. 'Home-brewed morphine' made possible. BBC, 06:24 PM, 18 May 2015, 467 words. 19. Ross J. Gangs to have a shot at home-brew heroin. The Australian, 19 May 2015, 216 words. 20. 'Home-brewed morphine' made possible. Radio New Zealand, 06:00 AM, 18 May 2015, 465 words. 21. Turning Yeast Into Morphine At Home Could Be A Brewing Controversy. Science 2.0, 09:30 AM, 18 May

2015, 952 words. 22. Feltman R. Home-brewed heroin could be a thing, thanks to genetically engineered yeast. Washington

Post.com, 18 May 2015, 629 words. 23. Whoops! Scientists unlock key to making morphine at home. New York Post, 11:05 AM, 18 May 2015,

495 words.

of 74 24. Devin H. Home-brewed heroin? Scientists create yeast that can make sugar into opiates. The Guardian,

11:48 AM, 18 May 2015, 868 words 25. “Home Brew Heroin” Is Almost Here, Scientists Warn. BuzzFeed, 18 May 2015, 883 words. 26. Fox M. Home-Brew: Scientists Tweak Yeast to Grow Morphine. NBC News, 10:04 AM, 18 May 2015, 519

words. 27. Discovery opens door for homemade morphine, painkillers. FOX 5 KVVU-TV, 09:05 AM, 18 May 2015. 28. Rehle M. 'Home-brew' morphine from brewer's yeast now possible. Canadian Broadcasting Corp., 09:53

AM, 18 May 2015, 453 words (followed by evening news and interview with Greg Razmussen). 29. Genetically Modified Yeast Will Make It Possible to Home-Brew Opiates. Wired, 09:00 AM, 18 May 2015,

1177 words. 30. Discovery Opens Door for Homemade Morphine, Painkillers. ABC News, 09:00 AM, 18 May 2015, 142

words. 31. Gene breakthrough sparks 'home-brewed morphine' fears. Agence France Presse, 09:00 AM, 18 May

2015, 601 words. 32. Leake J. GM yeast can turn sugar to morphine. The Sunday Times, 17 May 2015, 376 words. 33. Home-brewed heroin may soon be in the works. The Economist, 23 May 2015:

http://www.economist.com/news/science-and-technology/21651571-home-brewed-heroin-may-soon-be-works-only-connect.

34. Twilley N. Home-Brewed Heroin. The New Yorker. 18 May 2015: http://www.newyorker.com/tech/elements/home-brewed-heroin.

Follow on coverage after the e-pub ahead of print of another link in the morphine synthesis pathway in Winzer et al. Science on 25 June 2015: 35. Brown E. Science inches closer to ‘home brew’ heroin. Los Angeles Times, 25 June 2015. Available at:

http://lat.ms/1TRUBHf. 36. Feltman R. Home-brewer herion is near after scientists nail down poppy morphine gene. The

Washington Post, 25 June 2015.

COVERAGE OF ALBERTA OCULAR GENE THERAPY - AI-HS CRIO TEAM GRANT

October 17, 2013 1. St. Albert Leader.com, U of A researchers tackling genetic eye disorder, reprint of article by Cathrine

Griwkowsky, photo by Perry Mah. http://www.stalbertleader.com/2013/10/17/u-of-a-researchers-tackle-eye-disease/

October 16, 2013 2. Eye Disease Foundation.com, Researchers offer hope for patients with rare eye disorder, includes caption

from article by Keith Gerein, and photo and embedded video by Greg Southam, Edmonton Journal. http://eyediseasefoundation.com/rare-eye-diseases/researchers-offer-hope-for-patients-with-rare-eye-disorder

October 11, 2013 3. City TV, Edmonton, Breakfast Television, live interview with Mark Huyser-Wierenga by host Ryan Jespersen

aired at 8:05 am. http://www.btedmonton.ca/videos/2736314703001/: Publicity Value: $759.50 4. Global TV, Regina, rebroadcast of report by Su-Ling Goh aired at 8:09 am: Publicity Value: $1,016.67 5. Global TV, Regina, rebroadcast of report by Su-Ling Goh aired at 8:32 am.: Publicity Value: $108.33 October 10, 2013 6. City TV, Edmonton, Breakfast Television, News, report aired at 6:05 am and 8:05 am.: Publicity Value:

$1506.75 7. Edmonton City and Press.com, University of Alberta Team Awarded $5M for Experimental Eye Treatment,

reprint of portion of article by Keith Gerien, Edmonton Journal. Includes link to article at Edmonton Journal.com. http://edmonton.cityandpress.com/node/6908800

8. Edmonton Journal, New hope for sufferers of rare vision disorder – U of A team gets $5M grant for experimental eye treatment, article by Keith Gerein, photo by Greg Southam, page A3.

of 74 9. EdmontonJournal.com, University of Alberta team awarded $5M for experimental eye treatment, article by

Keith Gerein, photo by Greg Southam. Includes video supplied by AIHS. http://www.edmontonjournal.com/health/University+Alberta+team+awarded+experimental+treatment+with+video/9018193/story.html

10. Edmonton Sun, U of A researchers tackling genetic eye disorder, article by Cathrine Griwkowsky, photo by Perry Mah, page 7.

11. Ramsay C. Experimental trial at U of A could restore vision loss. Global News (October 10, 2013). 12. Global TV, Calgary, report by Su-Ling Goh aired at 6:25 pm.: Publicity Value: $775.00 13. Global TV, Edmonton, report by Su-Ling Goh aired at 6:25 pm.: Publicity Value: $1,083.36 14. Global News.ca, Experimental trial at U of A could restore vision loss, article by Caley Ramsay, includes

embedded video of newscast “Health Matters” segment with Su-Ling Goh. http://globalnews.ca/news/896316/experimental-trial-at-u-of-a-could-restore-vision-loss/

15. Montreal Gazette.com, Dr. Ian MacDonald checks Mark Huyser-Wierenga’s eye on Oct. 9, 2013, reprint of photo and caption by Greg Southam, Edmonton Journal. http://www.montrealgazette.com/MacDonald+checks+Mark+Huyser+Wierenga+2013+Huyser+Wierenga+Crown+prosecutor+choroideremia+slowly+losing+vision/9018194/story.html

16. Multibriefs.com, Ophthalmologists Executive Briefing, includes headline and link to article in Edmonton Journal. http://www.multibriefs.com/briefs/Mv-opthameb/101013.html

October 9, 2013 17. Griwkowsky C. University of Alberta looks forward to $5M grant for eye research. Edmonton Sun (October 9,

2013) http://www.edmontonsun.com/2013/10/09/university-of-alberta-looks-forward-to-5m-grant-for-eye-research.

18. I4U News.com, University of Alberta looks forward to $5M grant for eye research, reprint of headline and link to article by Catherine Griwkowsky, Edmonton Sun. http://www.i4u.com/2013/10/ian-macdonald/research-forward-alberta-looks-university-grant-eye-5m

19. TV Balla.com, University of Alberta looks forward to $5M grant for eye research, reprint of headline and link to article by Catherine Griwkowsky, Edmonton Sun. http://www.tvballa.com/2013/10/ian-macdonald/alberta-eye-university-grant-5m-research-looks-forward.

20. Calgary Herald, Seeing the Impact of Collaborative Research, paid ad by AIHS B7. 21. Edmonton Journal, Seeing the Impact of Collaborative Research, paid ad by AIHS A11. 22. Globe and Mail, Seeing the Impact of Collaborative Research, paid ad by AIHS A9. 23. National Post, Seeing the Impact of Collaborative Research, paid ad by AIHS FP3. 24. CTV Edmonton,News at 6, report aired a 6:16 pm. Publicity value: $1,136.67. 25. AIHS.ca. New gene therapy trial set to help people with genetic eye diseases, AIHS news release.

http://www.aihealthsolutions.ca/news/2013-10-09.php. 26. Mouallem O. A Vision for the Future: A new chapter in Choroideremia research. Health Solutions (Fall 2013)

COVERAGE OF PACEOMICS - GENOME CANADA GRANT

1. Alary B. Making personalized medicine a health-care winner. University of Alberta Express News (March 26, 2013) online: http://news.ualberta.ca/newsarticles/2013/march/making-personalized-medicine-a-health-care-winner.

2. Radio Interview: AM – 630 CHED Edmonton, Alberta (March 27, 2013). Alberta about personalized medicine and Genome Canada funding announcement.

3. Radio Interview: News Talk 770 (CHQR) Calgary, Alberta (March 27, 2013). Alberta about personalized medicine and Genome Canada funding announcement.

COVERAGE OF STEM CELL RESEARCH:

1. Sornberger J. Keep calm and carry on searching for cures (02 December 2013). Canadian Stem Cell Foundation Blog. [Coverage of Li et al. Regen Med, 2013] Online: http://stemcellfoundation.ca/en/blog/categories/listings/newsdesk

of 74 2. Aldhous P. Stem cell crusaders. New Scientist (10 August 2013) 42-45. [Provided significant background

content, but not quoted] 3. Bersenev A. Public Expectations and reality of stem cell therapies in translation. Cell Trials - Current Trends

in Cell Therapy (December 7, 2012) online: http://celltrials.info/2012/12/07/public-expectations-reality-stem-cell-therapies-translation/. [Coverage of BMC Medicine paper]

4. Silversides A. Stem Cell Hype Risks “Backlash”. CMAJ (October 8, 2009) DOI:10.1503/cmaj.109-3074. Online: http://www.cmaj.ca/earlyreleases/8oct09_stem_cell.dtl.

5. Lang M. Canada losing ground in stem cell research” Calgary Herald (November 25, 2005). [Coverage of Bubela’s presentation on politics and stem cell research at the Stem Cell Network AGM held in Calgary]

COVERAGE OF BUBELA ET AL. NATURE BIOTECHNOLOGY (2009):

1. Lane B. “Closed minds stifle science”. The Australian (July 8, 2009) online: http://www.theaustralian.news.com.au/story/0,25197,25747761-30417,00.html.

2. Salleh A. Scientists risk becoming ‘PR hacks’. ABC Science (July 3, 2009) online: http://www.abc.net.au/science/articles/2009/07/03/2613817.htm.

3. Lauder A. New media and science communication standards needed: experts. Express News (June 19, 2009) online: http://www.expressnews.ualberta.ca/article.cfm?id=10274.

4. Timed with the World Federation of Science Journalists meeting in London, Nature magazine put together a selection of recent articles focusing on journalism and science communication. The selection included the Bubela et al. (2011) Nature Biotechnology article. online: http://www.nature.com/news/specials/sciencejournalism/index.html.

5. MIT Knight Science Journalism Tracker posted a PDF version of the Nature Biotechnology article. Previously, the article had only been available to readers with an institutional subscription.

6. Knight Science Journalism Tracker. Nature Biotechnology: A lot of people who are not science journalists explain the problems facing those who are. (June 11, 2009). Also see responses. Online: http://ksjtracker.mit.edu/?p=9540.

7. Nisbet MC. At Nature Biotech, Science Communication Re-Considered. Framing Science Blog (June 10, 2009) online: http://scienceblogs.com/framing-science/2009/06/at_nature_biotech_science_comm.php.

COVERAGE OF BUBELA ET AL. BMC MEDICINE (2008):

1. Misleading Media Coverage Of Medicine. Medical New Today (November 28, 2008) online: http://www.medicalnewstoday.com/articles/131099.php.

2. Misleading Media Coverage Of Medicine. Science Daily (November 26, 2008) online: http://www.sciencedaily.com/releases/2008/11/081126075613.htm.

3. Media Often Err in Reporting Health News: Study. MedIndia, General Health News (November 30, 2008) online: http://www.medindia.net/news/Media-Often-Err-in-Reporting-Health-News-Study-44618-1.htm.

4. Misleading Media Coverage Of Medicine. BreastCancer.Net News (November 27, 2008). 5. Do Herbs Get a Bad Press? Neuroskeptic Blogspot (November 28, 2008) online:

http://neuroskeptic.blogspot.com/2008/11/do-herbs-get-bad-press.html.

SEPT-DEC 2008: PRESS COVERAGE OF REPORT BY THE INTERNATIONAL EXPERT GROUP ON BIOTECHNOLOGY, INNOVATION AND INTELLECTUAL PROPERTY AND ASSOCIATED CASE STUDIES:

1. Waltz E. (2008) FDA launches priority vouchers for neglected-disease drugs. Nature Biotechnology 26: 1315-1316.

2. Beardsley TM (2008) Editorial: Preventing Patent Purgatory. Bioscience 58:907. 3. Saez C. Parole d’experts: la propriété intellectuelle sur les biotechnologies a besoin d’un nouveau depart. IP

Watch (December 1, 2008). 4. Una partnership per i brevetti. Il Sole (December 1, 2008). 5. Laws to protect native knowledge 'are failing'. SciDev Net (November 28, 2008).

of 74 6. Mara K. Ministers, Stakeholders Meet in Mali to Strategise on Health Research Systems. IP Watch

(November 20, 2008). 7. Tests du cancer du sein: contestation des brevets, dernier round. AFP (November 19, 2008). 8. Wemgehört das traditionelle Wissen? Telepolis (November 17, 2008). 9. IP laws not helping indigenous people protect traditional knowledge. Mongabay.com (November 17, 2008). 10. Keenan T. Something’s rotten in the state of patents. Business Edge 4(20) (October 3, 2008). 11. Singh S. Report faults US patent system on biotechnology, calls for change. The Wall Street Journal’s

LiveMint.com (India) (October 15, 2008). 12. Young D. Broader IP Flexibility Urged for Drugmakers. BioWorld (October 15, 2008). 13. Butkus B. Experts Brief US Lawmakers on ‘Broken’ IP System Believed to Curb Biotech Innovation. BioTech

Transfer Week (October 15, 2008). 14. Yang T. CAMPUS: McGill prof urges patent reform. The McGill Tribune (September 30, 2008). 15. Morgan J. Patent system ‘stifling science’. BBC News (September 28, 2008). 16. “Patent system 'stifling science'” Tehran Time (Iran’s Leading International Daily) (September 25, 2008). 17. Cookson C. Patent wars hurting life sciences. Financial Times, FT.com World (September 23, 2008). 18. Vongdouangchanh B. Time to fix, modernize innovation gap, say biotechnology industry stakeholders. The

Hill Times (September 22, 2008). 19. Cherry B. Intellectual property can work for developing nations. Sunday Monitor, Monitor Online Business &

Technology (September 21, 2008). 20. Alphonso C. Patent system seen stifling medical breakthroughs. The Globe and Mail A4 (September 20,

2008). 21. New W. New IP Model Proposed To Facilitate Technology Access in Developing Countries. IP Watch

(September 19, 2008). 22. Sawahel W. New IP Model Proposed To Facilitate Technology Access in Developing Countries. Intellectual

Property Watch Biotechnology (September 19, 2008). 23. Cherry B. Intellectual property ‘needs revamp’ for developing nations. Science and Development Network

News (September 17, 2008). 24. Intellectual property 'needs revamp' for developing nations. SciDev Net (September 16, 2008). 25. Girardi G. Sistema de patente tem falhas. O Estado de s. Paulo (Brazil) (September 11, 2008). 26. Research says copyright system has collapsed. Business Daily Africa (September 11, 2008). 27. Mbogo S. Research says copyright system has collapsed. Business Daily (Kenya) (September 11, 2008). 28. Mamou Y. Un grouped experts recommande de repenser les règles du droit de brevets. Le Monde

(September 10, 2008). 29. Martino M. Stuy: Biotech patent system broken. Fierce Biotech, the Biotech Industry’s Daily Monitor

(September 10, 2008). 30. Gold R. ‘Old IP’ System Stifles Biotech Innovation, Hinders Third-World Rx Access, Report Says. Biotech

Transfer Week (September 10, 2008). 31. Research reveals biotech patent system breakdown. Asian News International (September 10, 2008). 32. Cooper D. IP law creating ‘bare medicine chest’. ABC News online (September 10, 2008). 33. ‘Old IP’ System Stifles Biotech Innovation, Hinders Third-World Rx Access, Report. Biotech Transfer Week

(September 10, 2008). 34. Study: Biotech patent system broken. FierceBiotech, The Biotech Industry's Daily Monitor (September 10,

2008). 35. Patent system seen stifling medical breakthroughs: A more collaborative approach is needed to bring

research to market, McGill professor says in report. Globe and Mail (September 10, 2008). 36. IP laws creating 'bare medicine chest'. ABC Science (September 10, 2008). 37. Research reveals biotech patent system breakdown. North Korea Times (September 10, 2008). 38. ECO. Un grouped experts appelle à une “nouvelle ère do propriété intellectuelle. Agence France Presse,

New York (September 9, 2008).

of 74 39. Especialist aspedema abertura de uma 'nova era do direito autoral’. Agence France Presse – Portuguese

(September 9, 2008). 40. Un grupo de expertos llama a una "nueva era de la propiedad intelectual". Agence France Presse – Spanish

(September 9, 2008). 41. Ungrouped, experts recommande de repenser les règles du droit des brevets. Le Monde (September 9,

2008). 42. Ungrouped, experts appelle à une "nouvelle ère de propriété intellectuelle”. Agence France Presse

(September 9, 2008).

TEACHING

TEACHING PHILOSOPHY

The role of an institution of higher education is to attract the next generation of creative thinkers and leaders, and to foster an environment where both practical and academically-focused learning can occur.1 Learning and knowing are communal acts, guided through mentorship and facilitated by collegial and respectful interactions.2 Within research-intensive universities, learning and knowledge are advanced through a culture of discovery research, integrative and applied scholarship, and dynamic teaching that promote critical thinking, a thirst for life-long learning, concern with social issues, and civic engagement.3 As a university instructor, I have embraced my role to assist students in their development of knowledge and skills to work in interdisciplinary and collaborative settings, and to consider seemingly intractable global problems. Within this role, I have found that theory and practice vitally interact and “new intellectual understandings can arise out of the very act of application”.4 It has been my privilege to be a guide, mentor and teacher for undergraduate and graduate students across diverse faculties. I have taught large undergraduate biology classes at both Universities of Toronto and Alberta. At the University of Alberta I have led cross-faculty undergraduate classes in business law; graduate courses in the MBA and MPH programs in intellectual property law/technology commercialization and health law, respectively; PhD courses in communication in public health, and a range of workshops and seminars on legal and ethical issues for students and practitioners across disciplines; as well as active engagement, translating complex legal, ethical and social issues in the development of novel biotechnologies for lay audiences through workshops and cafés scientifiques. Teaching such diverse subject-matter and audiences requires flexibility in course development and delivery, combined with an interdisciplinary focus that links theory to social and political realities. Interdisciplinary teaching prepares students for work environments, including within academia, that are moving “from routine processes within narrowly defined functions and towards teamwork which crosses functional boundaries”.5

In my experience, students learn most effectively when instructors not only have content expertise, but are passionate about their subject matter. My passion comes from bringing diverse research interests to the classroom and expanding these to real-world applications. My research is focused on ethical, legal and social implications of the development of novel health biotechnologies within global innovation ecosystems to meet societal needs. It spans research and development, clinical translation, commercialization and adoption by health systems; it integrates disciplinary methods, concepts and theories to address complex societal or

1 University of Alberta. Dare to Deliver: Academic Plan 2011-2015. Online: http://www.president.ualberta.ca/ 2 Palmer, P.J. To know as We are Known. (New York: Harper and Row, 1983). 3 Boyer, E.L. Scholarship Reconsidered: Priorities of the Professoriate. ( The Carnegie Foundation, 1990). 4 Ibid. 5 National Committee of Inquiry into Higher Education (1997) Report of the National Committee. (Chairman: Sir Ron Dearing). Online: www.leeds.ac.uk/educol/ncihe/.

of 74 technical problems6 in the tradition of Mode-2 knowledge production7 that combines theoretical and practical perspectives, an orientation to applied problems, with societal engagement and accountability in line with the mission and values of the School of Public Health8.

Regardless of course level, fostering an environment for learning requires simultaneously focusing on the needs of individual students and the collective. I find that students learn best when they are actively engaged with material and the process of learning. My role is to provide both the knowledge base and to facilitate participation and group activities so that students can also learn from each other. While the latter is more challenging in larger class settings, it is not impossible but requires greater moderator skills. In smaller professional program settings, students bring a wealth of practical skills and knowledge that only enhances the collective learning experience. Students learn from each other.

It is also my role to limit the stress of the university environment through being responsive to student needs, clearly articulating objectives and assessment criteria, and providing a high level of feedback designed to develop communication skills and content expertise as well as improving performance on future assessment. I provide a variety of instructional methods from purely didactic to case-based group projects, where students can turn their knowledge base and experience to address real-world problems at the intersection of health, innovation and law. Because law and technology develops rapidly, my goal is to help students develop skills and techniques to identify legal and ethical issues, find relevant sources of law and policy, critically apply these to the issues, but also reflect on future developments and applications from a normative perspective. It is this ability to respond to problems as they emerge that will create the innovative leaders of the future.

MCCALLA PROFESSORSHIP In 2014, I was awarded a McCalla Professorship by the University of Alberta to integrate Research and

Teaching. My application responded to public perception that Universities are unresponsive to societal needs and interests. The 2001Kellogg Commission identified that “society has problems” but “institutions have “disciplines”. “In the end, what [public] complaints add up to is a perception that, despite the resources and expertise available on our campuses, our institutions are not well organized to bring them to bear on local problems in a coherent way.’ (Kellogg Commission on the Future of State and Land-Grant Universities. New York: NASULGC, 2001). I proposed an approach that cuts across disciplines to address a priority issue for the Government of Alberta and the University of Alberta: the translation and commercialization of the innovative research conducted by faculty and students. Interdisciplinary training modules in intellectual property and regulatory law support commercialization and translational research activities and help to develop a culture of entrepreneurship amongst graduate students, postdoctoral fellows, faculty and other research staff. However, in discussion with faculties and programs across campus, skills and knowledge in these areas are lacking, and graduate students, in particular, have minimal opportunities for exposure.

The School of Public Health is oriented towards addressing applied problems and is also concerned with issues of social justice and equity, including the adoption of novel technologies by health systems. My research and engagement activities integrate these issues through considerations of cost and access to biomedical innovations, the development of socially responsible licensing practices to ensure access to innovation in developing countries, and the development of equitable research partnerships with developing country institutions and technology developers. The objectives of my McCalla Professorship are therefore to:

1. develop case-based training modules accompanied by instructor resources on the commercialization and translation of research for use in diverse faculties, including the health faculties, science, and engineering;

2. integrate my research on the legal, ethical and social considerations for commercialization and translation of primarily publicly funded biomedical research into the training modules; and

3. develop dissemination strategies for the modules, including the development of online resources. 6 Klein, J. T. Interdisciplinarity: History, theory, and practice. (Detroit, MI: Wayne State University Press, 1990). 7 Gibbons, M., Limoges, C., Nowotny, H., Schwartzman, S., Scott, P. & Trow, M. The new production of knowledge. The dynamics of science and research in contemporary societies. (London: Sage, 1994). 8 School of Public Health. Mission and Values. Online: www.publichealth.ualberta.ca.

of 74 The expected outcomes are four training modules for commercialization and translation of university

research that integrate legal, ethical and societal considerations for the management of research outputs created using public funds. Each of the training modules will be based on an exemplar case of innovation at the University of Alberta in the fields of genomics, diagnostics, drug/vaccine development, and biomedical engineering and developed with expert input from technology developers. These case studies will provide a template for the future development of case studies. During the course of the Professorship, I will pilot two of the training modules for graduate students in health faculties, life sciences and biomedical engineering at the University of Alberta. One module will pilot an online delivery platform.

COURSES TAUGHT

CLASSES – SIMON FRASER UNIVERSITY

• Bubela T, The Challenges of Regulating Genomic Technologies. 1 hour Guest Lecture: Third Year Undergraduate Course, Plant Physiology, Faculty of Science, March 29, 2019.

• Bubela T, The Challenges of Health Communication in the Internet Age. 3-hour Guest Lecture: PhD Course, Faculty of Health Sciences, Simon Fraser University, April 4, 2018; March 28, 2019.

• Bubela T, Precision Oncology in Canada: Innovating Health System Readiness. 3-hour Guest Lecture: Graduate Course Department of Biology, Physiology and Kinesiology, Simon Fraser University, March 6, 2018.

COURSES – UNIVERSITY OF ALBERTA

2014- Development and teaching of case-based ethics workshops to meet Faculty of Graduate Studies requirements for ethics instruction. Modules developed and delivered in seven 4 hour sessions for research graduate students (MSc and PhD) and course-based graduate students. Separate case-based modules developed for each area of specialization: Global Health, Biostatistics, Epidemiology, Health Policy and Management, and Health Promotion.

2011- PHS 603, Scientific Communication in Public Health (PhD Course Coordinator), Enrolment 16 in 2014

2010- PHS 606 Health Law and Administration, Enrolment: 12 in 2014 2008-2010 BLAW 658 Intellectual Property Law and Technology Transfer, MBA Specialization in Technology

Transfer and Commercialization, Enrolment 14 in 2010 2005-2009 BLAW 301 Legal Foundations of the Canadian Economy: 2 sections annually, Enrolment: 77-83. 2000 Pollution Biology (BIO381), Enrolment: 184 (Sessional Lecturer, Dept. Biological Sciences,

University of Alberta.

TEACHING EVALUATIONS

SCHOOL OF PUBLIC HEALTH

Selected Questions 2017 PHS 606: Health Law and Administration

Class Size (n=12/12) Strongly Disagree = 1 to Strongly Agree = 5

Overall, this instructor was excellent The instructor was well prepared for each class Overall, the quality of the course content was excellent I deepened my interest in the subject matter of this course

4.8 4.8 4.7 4.8

Selected Questions 2014 PHS 603: Science Communication in Public Health


Overall, this instructor was excellent The instructor was well prepared for each class Overall, the quality of the course content was excellent I increased my knowledge of the subject matter in this course

4.4 4.6 4.2 4.6

of 74 Selected Questions 2014 PHS 606: Health Law and Administration



4.5 4.8 4.3 4.9


Class Size (n=1) Strongly Disagree = 1 to Strongly Agree = 5


5 5 5 5




4.8 4.9 4.6 4.6




4.8 4.8 4.9 4.9




4.9 4.8 4.9 5




4.8 4.8 4.7 4.5




4.9 4.9 5 5

SCHOOL OF BUSINESS

Questions summarized from courses taught in the School of Business: • Overall, this instructor was excellent (0 = strongly disagree to 5 = strongly agree) • I increased my knowledge of the subject areas in this course (0 = strongly disagree to 5 = strongly agree) • The instructor was well prepared (0 = strongly disagree to 5 = strongly agree) • Overall, the quality of the course content was excellent (0 = strongly disagree to 5 = strongly agree)

of 74 Note that the policy in the School of Business is not to distribute teaching evaluations in classes with fewer than 6 students. Until 2010, the MBA class, BLAW 658 had fewer than 6 students.

2015

Course number and section

Number of Students Enrolled

Student Evaluation (Summary Questions—median out of 5) Instructor

Subject Knowledge

Preparation

Quality of course

BLAW 658 25 4.8 4.9 4.9 4.8

2011




Subject Knowledge

Preparation

Quality of course

BLAW 658 16 4.8 4.8 4.8 4.6

2010




Subject Knowledge

Preparation

No. of Observations

BLAW 658 14 4.6 4.6 4.8 13

2009




Subject Knowledge

Preparation

No. of Observations

BLAW 301, LEC B2 79 4.2 4.8 4.6 43 BLAW 301, LEC B3 77 4.5 4.7 4.8 48

2008




Subject Knowledge

Preparation

No. of Observations


2007




Subject Knowledge

Preparation

No. of Observations


of 74 2006




Subject Knowledge

Preparation

No. of observations

B LAW 301, LEC B1 B LAW 301, LEC B2

77 81

4.7 4.6

4.8 4.8

4.7 4.8

56 49

2005

MAJOR PROJECTS/DIRECTED READINGS COURSES SUPERVISED

2012: Shelly Benjaminy (Public Health) Janis Geary (Public Health) Fall 2011: Kent Gislason (Law)

Westerly Luth (Public Health) Janis Geary (Public Health)

Summer 2005: Joe Patton “Valuing the Social Enterprise” Directed studies paper supervised, MBA/LL.B

FACULTY ADVISING: MASTERS OF PUBLIC HEALTH (MPH) – HEALTH POLICY AND MANAGEMENT

Note that Faculty advising involves program planning and faculty supervision and grading of the mandatory practicum placement and capstone project. C indicated convocated. PT = Part-time; FT = Full-time Admitted 2016 Wesley Vuong FT Tahmid Kashem FT Admitted 2015: Rachel Erdman FT Christina Valesco PT Admitted 2014: Alison Drake C Anna Brown C Admitted 2013: Meighan Maguire C

Admitted 2012: Mallory Nault C Sandra Rees C Jennifer Pougnet C Derek Clark C Admitted 2011: Mayank Singal C Husaifa Faisal C Admitted 2010: Amber Wolfe PT

ADDITIONAL TEACHING ACTIVIES

INVITED STUDENT LECTURES:

• Bubela T, Governance of Genetic Resource Commons. Guest Lecture: Biology 335, Department of Biological Sciences, University of Alberta, March 30, 2017.

• Bubela T, Governance of Biomedical Research Commons. Guest Lecture: Biotechnology Law, Faculty of Law, University of Alberta, March 15, 2017.

• Bubela T, What Graduate Students Need to Know About Patenting and Commercialization. Faculty of Graduate Studies. August 27, 2015.

• Bubela T, Communicating with Multiple Audiences. Capping Event, School of Public Health, University of Alberta, Edmonton, November 15, 2013.

• Bubela T, Intellectual Property and Commercialization 101. Faculty of Engineering Fireside Chat. University of Alberta, Edmonton, November 5, 2013



Student Evaluation (Summary Questions—median out of 5) Instructor Subject

Knowledge Preparation No. of

observations BLAW 301, B1 BLAW 301, B2

81 80

4.4 4.7

4.6 4.8

4.6 4.8

49 42

of 74 • Bubela T, End of Life Decision Making. Guest Lecture: Law and Medicine, Faculty of Law, University of

Alberta • Bubela T, Health Care System: Regulations of Health Professionals - Academic Half Day for Community

Medicine Residents at the University of Alberta, Faculty of Medicine and Dentistry. 2012 • Bubela T, Social, Legal and Ethical Issues Associated with the Synthetic Biology Production of Opiates.

Chemical Engineering, University of Alberta, 15 November 2011. • Bubela T, What Graduate Students Need to Know About Intellectual Property. Faculty of Graduate Studies.

19 May 2011. • Bubela T, Full-day workshop presenting case study: CellBio Therapeutics: Commercializing Stem Cell

Research, Understanding Stem Cell Controversies, Hyatt Regency, Calgary, 2-4 March 2011. • Bubela T, The Challenges of Health Communication in the Internet Age. HPS 508 Psychosocial Perspectives in

Health, May, 2011. • Bubela T, Challenges of Health Communication in the Internet Age. Politics of Technology and Economic

Development, 300 Level Political Science April7, 2010. • Bubela T, The Challenges of Health Communication in the Internet Age. PHS 603, Scientific Communication

in Public Health: Guest Lecture, March 25, 2010. • Bubela T, “Managing Collaborative Research and Research Licensing” Lecture for Graduate Students in the

Department of Laboratory Medicine and Pathology, University of Alberta. February 11, 2009 • Bubela T ,“Regulating Stem Cell Research and Commercialisation” Lecture given to students registered in

Regenerative Medicine, May 2008, Faculty of Medicine, University of Toronto. • Bubela T ,“Managing Collaborative Research and Research Licensing” Lecture for Graduate Students in the

Department of Laboratory Medicine and Pathology, University of Alberta. March 11, 2008

TEACHING – UNIVERSITY OF TORONTO 1997-1999 Introductory Genetics (BIO203S), Enrolment: 182 First year biology (BIO151Y), Enrolment: 438 1996 Fundamentals of Ecology (BIOB12Y), Enrolment: 96 Environmental Biology (BIOB14F), Enrolment: 110 Field Course in Ecology (BIOC02F), Enrolment: 6

• designed and coordinated laboratory courses and supervised >20 graduate teaching assistants • redesigned teaching and laboratory manuals in genetics and evolutionary biology with an emphasis on

clarity of objectives, in-lab assessment, and problem based learning. • worked closely with Academic Skills Centre to implement innovational teaching methods. We

developed a highly successful Bioethics assignment for Introductory Genetics, based on the Problem Based Learning Model of the Faculty of Medicine, University of Toronto.

• coordinated exam grading and student records. • developed course web pages and multi-media lectures. • faculty advisor and counsellor for over 1000 biology students.

of 74

GRADUATE STUDENTS/HIGHLY QUALIFIED PERSONNEL Note: I did not have graduate students in the School of Business (2004-2008) because there was no graduate program in my area of specialisation (business law). This was one of my primary motivations for moving my appointment from the School of Business to the School of Public Health.

POSTDOCTORAL FELLOWS – PRIMARY SUPERVISOR AT UNIVERSITY OF ALBERTA Name Years Project Funding Next Position Amrita Mishra 2011 - 2014 Genome Canada – NORCOMM II Project Director, Indo-Canadian

Women's Association, Edmonton, AB Ashok Kumbamu 2010 - 2011 Genome Canada –

PhytoMetaSyn, iBOL Researcher, Biomedical Ethics, Mayo Clinic, Rochester, Minn

Andreas Strotmann 2005 - 2010 Genome Canada – NORCOMM Stem Cell Network – Catalyst Grant

Senior Researcher and Team Lead, GESIS, Leibniz Institute for the Social Sciences, Germany

POSTDOCTORAL FELLOWS – CO-SUPERVISED AT OTHER INSTITUTIONS Name Years University Next Position Jean-Frederic Morin 2010-2011 McGill University Associate Professor, Department of Political

Science, l’ Université Libre de Bruxelles Camille Ryan 2008-2010 University of Calgary Professional Research Associate, Total Utilization

of Flax Genomics project, College of Agriculture and Bioresources, University of Saskatchewan

Subhashini Chandrasekharan

2008-2010 Duke University Research Assistant Professor, Institute for Genome Sciences & Policy, Duke University

PHD STUDENTS Name Years Project Funding Project/Thesis Title Co-supervisor Janis Geary

2011 – Candidacy 2013 Defended April 13, 2017

Genome Canada - iBOL, PhytoMetaSyn

Governance structures for global research commons for genetic resources: Expanding the Institutional Analysis and Development (IAD) Framework using institutional logics and relational contract theory

Dr. Cynthia Jardine, School of Public Health, U Alberta

Rebecca Foley

2016- BioCanRx The right to try versus the right to die: Comparing the roles of support groups and social media in the decisions of cancer and ALS patients.

Dr. Elaine Hyshka, School of Public Health, U Alberta

MSC STUDENTS Name Years Project/Thesis Title Co-Supervisor Mackenzie Moir 2015 - 2018

Convocated Communication and Decision Making: An Examination of Communication Needs of ALS Patients and Caregivers

Dr Wendy Johnston, Faculty of Medicine and Dentistry, U Alberta

Caroline O’Keefe-Markman

2014 – 2018 Convocated

Resource Allocation Decision-Making for Screening, Diagnosis and Treatment of Hepatitis C in Canada

Dr. Christopher McCabe, Faculty of Medicine and Dentistry, U Alberta

of 74 Name Years Project/Thesis Title Co-Supervisor Stephanie Kowal 2011 – 2014

Convocated Risk Communication and Vaccination Uptake by Recent Immigrant Mothers of Edmonton

Dr. Cynthia Jardine, School of Public Health, U Alberta

Westerly Luth 2011 – 2014 Convocated

Video games for obesity interventions: A new generation of health messaging for adolescents

Jennifer Ann McGetrick


Geographic Information Systems as a Communication Tool for Aboriginal Community Stakeholders in Environmental Assessment of Natural Resource Development in the Canadian Sub-arctic

Dr. David Hik, Department of Biology, U Alberta

Shelly Benjaminy


Ocular gene transfer communications: developing ethical frameworks for phase I choroideremia clinical trials. MSc thesis. University of Alberta, Department of Public Health Sciences; 2013.

Dr. Ian MacDonald, Chair, Department of Ophthalmology, Faculty of Medicine and Dentistry, U Alberta

GRADUATE STUDENT - AWARDS Name Years Scholarship/Award AmoAmount Janis Geary 2014-2015

2011 - 2014 2011-2014 2014-2015

University of Alberta Izaak Walton Killam Memorial Scholarship Canadian Institutes for Health Research Frederick Banting and Charles Best Doctoral Award Alberta Innovates – Health Solutions Incentive PhD Studentship Alberta Innovates – Health Solutions \ PhD Studentship

$35,000

$30,000 P/A

$8,500 P/A $35,000 P/A

Shelly Benjaminy 2011 – 2013 2012 2011 2011 2010-2011 2010

Queen Elisabeth II Graduate Scholarship, UofA Alberta Advanced Education and Technology Graduate Scholarship, Government of Alberta Myer Horowitz Graduate Students’ Association Graduate Scholarship, University of Alberta Health Quality Council of Alberta Scholarship Department of Ophthalmology, University of Alberta Graduate Stipend Dean’s List, School of Public Health, University of Alberta

$10,800 P/A

$3,000

$1,200

$6,400 $7,500 P/A

Westerly Luth 2012-2013 2013-2014 2012

Canadian Institutes for Health Research Frederick Banting and Charles Best Graduate Scholarship Queen Elisabeth II Graduate Scholarship, University of Alberta (3 years) Walter H Johns Graduate Fellowship, University of Alberta

$17,500 $10,800 $5,523

of 74 Name Years Scholarship/Award Amount Jennifer Ann McGetrick

2011-2013 2013 2012-2013 2012-2013 2012-2013 2012

Queen Elisabeth II Graduate Scholarship, UofA (3 years) Alberta Advanced Education and Technology Graduate Scholarship, University of Alberta Northern Science Training Program, Aboriginal Affairs and Northern Development Canada Circumpolar/Boreal Alberta Research Grant, Canadian Circumpolar Institute Association for the Advancement of Science Program for Excellence in ScienceResearch International Arctic Science Committee Outstanding Poster Award, Association of Polar Early Career Scientists

$10,800 P/A $3,000P/A

$7,100

$4,000

Stephanie Kowal

2014 2014 2013 2013-2015 2013 2013 2013 2012-2013 2012-2013 2012-2013 2012 2012

National Collaborating Centres for Public Health – Knowledge Translation Graduate Student Award Health Science Inquiry – Best Journal Submission Bente Roed Graduate Student Award, Academic Women’s Association, University of Alberta Women and Children’s Health Research Institute: Graduate Studentship Women and Children’s Health Research Institute/Community-University Partnership Science Shop: CBR Summer Studentship Douglas R. Wilson Award for Best Master’s Poster Presentation, School of Public Health, UofA Alberta Ministry of Enterprise and Advanced Education: Alberta Graduate Scholarship Canadian Institutes for Health Research Frederick Banting and Charles Best Graduate Scholarship Walter H. Johns Fellowship, University of Alberta Nominated Member of the American Association for the Advancement of Science Program for Excellence in Science Research Health Quality Council of Alberta Studentship for Interdisciplinary Health Research Douglas R. Wilson Award for Best Master’s Oral Presentation, School of Public Health, UofA

$1,500

$500

$24,000 P/A

$5,200

$100

$3,000

$17,500

$6,000

$6,400

$100

Mackenzie Moir 2015 2015 2016-2018

Public Health Distinction Scholarship - MSc SPH, University of Alberta University of Alberta Thesis-based Master’s Recruitment Scholarship Strategy for Patient-Oriented Research (SPOR) Graduate Studentship in Patient Oriented Research: Alberta Innovates, Health Solutions

$15,000

$17,000 plus tuition and fees

$30,000 PA plus training in POR

Rebecca Foley 2016 University of Alberta PhD Recruitment Scholarship

$24,000 plus tuition and fees

2018 SSHRC Doctoral Award $35,000 2018 Faculty of Graduate Studies Graduate Award,

University of Alberta $5,000

of 74

GRADUATE STUDENTS – NEXT POSITIONS Name Year Next Position Location Stephanie Kowal 2014 Knowledge

Translation Coordinator/Research Associate

School of Public Health, University of Alberta (Dr. Tania Bubela)

Westerly Luth 2014 Research Associate/Project Manager

School of Public Health, University of Alberta (Drs Tania Bubela and Christopher McCabe)

Freja McGetrick 2014 PhD Student School of Public Health, University of Alberta (Dr. Candace Nykiforuk)

Shelly Benjaminy 2013 PhD Student Bioethicist

School of Public Health, University of Alberta Neuroethics Core, Faculty of Medicine, University of British Columbia (Dr. Judy Illes); Bioethicist, Donnelley Ethics Program, Shirley Ryan AbilityLab, Chicago ILL.

UNDERGRADUATE AWARDS: Name Years Scholarship/Award Amount Matthew D. Li

2011-2012 2012

Stem Cell Network Social Sciences Summer Studentship Alberta Innovates – Health Solutions Summer Studentship

$5,000 $5,200

Moses Fung 2013 Stem Cell Network Social Sciences Summer Studentship

$5,000

VISITING GRADUATE STUDENTS: • Noomi Weinryb: PhD Student, visiting with the School of Business and myself from the University of

Uppsala, Sweden – inter-jurisdictional funding structures for human embryonic stem cell research. • Harley Ferreira de Cerqueira: PhD Student, Law, Catholic University of San Paulo – 7 months visiting

student awarded an Emerging Leaders of the Americas Scholarship from the Government of Canada. January-October 2011

• Talya Ponchek: PhD Student, Law, University of Haifa, Israel, Canadian Studies Fellowship. October-November 2011

COMMITTEE FOR SJD CANDIDATE: • Li Du, supervised by Profs Linda Reif and Timothy Caulfield, Faculty of Law, University of Alberta

o Convocated Fall 2014

COMMITTEE FOR PHD CANDIDATES: • Heather Morris (School of Public Health) Elaine Hyshka - supervisor

o Enrolled September 2016 • Katherine Bonter (Department of Family Medicine, McGill University) Dr. Gillian Bartlett - supervisor • Elaine Hyshka (Centre for Health Promotion Studies) T Cameron Wild – supervisor

o Candidacy Examination passed 2013; PhD defended 2015 o Current position – Assistant Professor, School of Public Health, University of Alberta and

Research Director, Royal Alexandra Hospital • Michael Paulden (Department of Emergency Medicine, Faculty of Medicine and Dentistry) Christopher

McCabe – supervisor

of 74 o Candidacy Examination passed 2015; PhD defended 2016 o Current position – Assistant Professor, School od Public Health, University of Alberta

COMMITTEE FOR MSC CANDIDATES: • Hannah L. Brooks (School of Public Health) Elaine Hyshka – supervisor

o Convocated Fall 2018 • Jacqueline Noga (School of Public Health) Norman Neumann and Duncan Saunders – supervisors

o Convocated Spring 2017 • Leah Lechelt (Centre for Health Promotion Studies) Cynthia Jardine – supervisor

o Convocated Spring 2013

EXAMINATION COMMITTEE FOR PHD CANDIDATES: • Shabnam Massah (Faculty of Health Sciences, Simon Fraser University) Gratien Prefontaine – supervisor

(Fall 2017) o Chair, PhD Defence

• Nikki Kain (School of Public Health) Cynthia Jardine – supervisor (Fall, 2016) o Chair, Candidacy Examination

• Chris Michell-Viret (Faculty of Medicine and Dentistry) Jeremy Beach – supervisor (December 9, 2013) o Candidacy Examination - External

• Kathy Belton (Department of Public Health Sciences) Linda Carroll – supervisor (August 9, 2012) – o Candidacy Examination.

• Amanda Barratt, “The Battle for Policy Space: Strategic Advantages of a Human Rights Approach in International Intellectual Property Negotiations.” University of Cape Town, South Africa, October 2008.

• Laura Weeks, Department of Community Health Sciences, University of Calgary, February 13, 2009. • Mark Messih, “Clinical Translation of Neuro-Regenerative Medicine in India: A study on barriers and

strategies” Institute of Medical Sciences, University of Toronto, October 2010. • Kapil Andrew Kapoor, “Paving the Silk Road: sub-Saharan Africa’s Collaboration with China and India in

Health Biotechnology” Institute of Medical Science, University of Toronto, May 2011.

EXAMINATION COMMITTEE FOR LL.M. CANDIDATES: • Poku Adusei (Faculty of Law) 2004/05; • Cheryl Power (Faculty of Law) 2005/06 • Nduka Ahanonu (Faculty of Law) 2005/06 • Cathy Anne Pachnowsk (Faculty of Law) 2006/07 • Marina Ivanova (Faculty of Law) 2007 • Pook Phan (Faculty of Law) 2008 • Owen Kirkaldy (Faculty of Law) 2008

OTHER HIGHLY QUALIFIED PERSONNEL (HQP) SUPERVISED: I have supervised fulltime and part-time research assistants from a variety of faculties. These are either supported by studentships, or through my research funding. These trainees join my graduate students in being active members of my research group. They are instructed in qualitative and quantitative research methodology and the academic/legal/policy issues related to their respective projects. All research assistants meet with me and other research assistants and staff on a weekly basis to discuss progress on projects and learn about/discuss research more broadly.

of 74 Name Years Degree Funding Next Position

Juliana Garrone

2018- BA-MPH BioCANRx Occupational Therapy Student: Queen’s University

Alecia Tingling

2018- BSc BioCANRx Nursing Student: UBC

Daniela Di Francesco

2017- BSc BioCANRx Student: SFU

Mark Bieber 2013- BSc All Grants Core Staff: Computer analytics and database specialist

Stephanie Kowal

2014- MSc Alberta Ocular Gene Therapy Team-CRIO Core Staff: Knowledge Translation Coordinator/ Research Associate

Westerly Luth

2014- Core Staff PACEOMICS & The James and Jeanie Brown ALS Research Fund

Core Staff: Research Associate

Shelagh Genuis

2016- PhD Genome Canada: Precision Medicine Network

Core Staff: Network Coordinator

Yael Mansour

2016- JD/MBA PACEOMICS Student: Law/MBA

Monica Wang

2016 JD ALMDx and PACEOMICS Student: Law

John Minkley 2016 JD PACEOMICS Student: Law Bethany McCabe

2016 BA Alberta Ocular Gene Therapy Team-CRIO Student: History and German

Kiah Van der Loos

2016 LLB ALMDx and PACEOMICS Student: Law (University of Edinburgh)

Caitlin Vale 2016 B Eng Genome Canada: Precision Medicine Network & Alberta Ocular Gene Therapy Team-CRIO

Student: Civil Engineering

Jaclyn Hutchison

2016- BSc (Hons) BioCanRx Student: Occupational Therapy

Zackariah Breckenridge

2015-2018

BSc BioCanRx Stem Cell Network, Clinical Trial Coordinator: University of Alberta Faculty of Medicine and Dentistry

2015 2015 2016

Stem Cell Network Bursary: Introduction to Cost Effectiveness Modelling Course ($900) Till & McCulloch Meetings Travel Bursary ($1500) Women and Children’s Health Research Institute ($24,000

Kristina Lea 2014-2016

BSc PACEOMICS, Stem Cell Network Student: Medicine, University of Alberta

Katherine Fu 2015 - MSc ALMDx Student: Law Moses Fung 2013 -

2014 BSc (Hons) Stem Cell Network ELSI Summer

Studentship Student: Medicine, University of Alberta

of 74

Additional law students worked with me on collaborative projects with the Health Law Institute, University of Alberta: C. Vince Kurata (2005 – 2006); Suzanne DeBow (2005 – 2006); Kanchana Fernando (2005 – 2008); Jacob Shelly (2007 – 2008); Colin Ouelette (2008 – 2009). Julia Carbone was a law student at McGill University and Kent Nnadozie and Karen Durrell were SJD candidates at McGill University. Jacob Shelly continued to collaborate with me in 2011 – 2013 as an SJD candidate at the University of Toronto.

Name Years Degree Funding Next Position Jenilee Guebert

2011 - 2014

JD Genome Canada – PhytoMetaSyn Stem Cell Network

Department of Justice, Canada

Amir Reshef 2012 JD/MBA Stem Cell Network ELSI Summer Studentship

Lawyer, Dentons LLP. Edmonton

Benjamin Taylor

2007 - 2010

BA - JD CIHR – Catalyst Grant CIHR – Operating Grant

Lawyer, Barr Picard LLP, Edmonton

Emily Kraus 2007 - 2008

MSc Stem Cell Network Medical Student, University of Calgary

Maria Chau 2007 - 2009

JD SSHRC - INE Lawyer, Miller Thomson LLP, Edmonton

Megan Koper

2006 - 2008

BSc - JD SSHRC – INE CIHR – Catalyst Grant

Lawyer, Parlee McLaws LLP, Edmonton

Christopher Ali

2007 - 2008

BA CIHR – Catalyst Grant MSc Film and Media Studies, Concordia University, Montreal

Shawn Hagen

2007 - 2009

BSc - JD CIHR – Catalyst Grant Lawyer, Jackie, Handerek & Forester LLP, Leduc, Alberta

Jared Bachynski

2007 - 2008

BComm Stem Cell Network University of Columbia, Law School

Dipesh Mistry

2007 - 2009

Lawyer SSHRC - INE Lawyer, Edmonton

Liesel Knall 2007-2008

Anthropologist SSHRC - INE

Matthew D. Li

2007-2009

BSc (Hons) Stem Cell Network MD, Stanford Medical School

Emma Camicioli

2007 - BA Stem Cell Network, PACEOMICS, ALS Student, University of Calgary

Freya Hik 2007- B. Eng Stem Cell Network, PACEOMICS, BioCANRx

Engineering, University of Alberta

Mackenzie Martin

2007-2009

BA Stem Cell Network, PACEOMICS Rhodes Scholar, Oxford

Aimee Zylstra

2007-2009

BSc - JD PhytoMetaSyn

Thomas Moran

2006 - 2007

BComm/BSc SSHRC - INE Lawyer, Bull Housser LLP, Vancouver

of 74

SUPERVISED STUDENT PRESENTATIONS, PUBLISHED ABSTRACTS AND POSTERS (ALSO SEE PUBLICATION SECTION) (TRAINEES UNDERLINED) I encourage the students to submit abstracts to conferences for presentations/posters and to write reports/papers. Where available, I support trainees in applying for awards and travel funds. 2018 1. Foley R, Luth, W, Bieber M, Johnston W, Bubela T. (2018). Discussing trying and dying on Twitter:

depictions of non-standard care options for people with terminal cancer. 2018 Cancer Immunotherapy Summit. Banff, Alberta, Canada. November 27-30. [peer reviewed abstract selected for oral presentation]

2. Hik F, Tingling A, Hutchinson J, Delisle JS, Bubela T. (2018). A Global Landscape of Combinatorial Cancer Biotherapeutic Clinical Trials. 2018 Cancer Immunotherapy Summit. Banff, Alberta, Canada. November 27-30. [peer reviewed abstract selected for travel award to F Hik]

3. Di Francesco D, Garrone J, Hutchinson J, Atkins H, Bubela T. (2018). A Global Landscape of Oncolytic Virus Clinical Trials. 2018 Cancer Immunotherapy Summit. Banff, Alberta, Canada. November 27-30. [poster presentation]

4. Mahjoub R, Bubela T, MacDonald IM, McCabe C (2018). A novel model of value-based reimbursement for Precision Medicine with an illustrative application to choroideremia gene therapy. 40th Annual North American Meeting, Society for Medical Decision Making. Montreal, Quebec, Canada. October 13-17, 2018. [oral presentation, peer reviewed]

2017 1. Kowal S, Bubela T. (2017). Parental decision-making in pediatric trial enrolment: Recommendations for

informed consent in juvenile type 1 diabetes research. Canadian Journal of Diabetes, 41(5): S13. [published abstract]

2. Kowal S, Bubela T. Parental decision-making processes in pediatric trial enrollment: Recommendations for informed consent in juvenile type 1 diabetes research. 20th Annual Diabetes Canada/ Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings, Edmonton, Canada. November 1-4, 2017. [oral presentation]

3. Kowal S, Bubela T. Parental perspectives of pediatric clinical trials. Alberta Vision Net Research Day, Edmonton, Canada. [oral presentation]

4. Foley R, Mansour Y, Bubela T. Fighting for the “right to try”: An evaluation of right to try legislation in the US and potential applications in Canada. Till and McCulloch Meetings 2017, Mont-Tremblant, Canada. November 6-8, 2017. [poster presentation]

5. Foley R, Mansour Y, Bubela T. Fighting for the “right to try”: An evaluation of right to try legislation in the US and potential applications in Canada. Summit for Cancer Immunotherapy, Gatineau, Canada. June 25-28, 2017. [poster presentation]

6. Moir M, Luth W, Johnston W, Bubela T. Canadian newspaper coverage of ALS and assisted death. ALS Canada Research Forum. Toronto, Canada. April 29-May 1, 2017. [invited poster presentation]

2016 1. Moir M, Luth W, Johnston W, Bubela T. Canadian Newspaper Coverage of ALS and Assisted Death. 27th

Annual International ALS/MND Symposium. Dublin, Ireland. December 7-9, 2016 [poster presentation] 2. Moir M, Luth W, Vail C, Johnston W, Bubela T. Portrayals of ALS patients and end of life issues: Media

analysis post Carter V. Canada. 27th Annual International ALS/MND Symposium. Dublin, Ireland. December 7-9, 2016 [poster presentation]

3. Luth W, Moir M, Johnston W, Bubela T. Preparing For End-of-life After Carter: A Review Of End-of-life Experiences And Perspectives Of People With ALS, Their Families, And Health Care Providers. 27th Annual International ALS/MND Symposium. Dublin, Ireland. December 7-9, 2016 [poster presentations]

4. Breckenridge Z, Bubela T. Cellular immunotherapies: Lessons in clinical translation. Cancer Research Institute of Northern Alberta Research Day 2016. Edmonton, Canada. November 12, 2016 [poster presentation].

of 74 5. Breckenridge Z, Bubela T. Implementation and Delivery of Adoptive Lymphocyte Therapy in Canadian

Medical Centres. 2016 Till & McCulloch Meetings. Whistler, Canada. October 24-26, 2016 [poster presentation].

6. Breckenridge Z, Bubela T. Adoptive Immunotherapy: Next steps in translation. Summit for Cancer Immunotherapy. Halifax, NS. June 26-29, 2016 [poster presentation]

7. Moir M, Luth W, Lee A, Johnston W, Bubela T. A Patient Oriented Approach to Developing End of Life Clinical Communication Tools in an Era of Legal Reform on Physician Assisted Death: A Case Study of ALS. Patient Oriented Research Summer Institute, 2016: Connecting, Engaging & Capacity-Building, Calgary, AB. May 2-4, 2016 [poster presentation]

2015 1. Breckenridge Z, Bonter K, Lea K, Bubela T. The Global Landscape of Cellular Immunotherapy Clinical Trials.

2015 Till & McCulloch Meetings. Toronto, ON. Oct 26-28, 2015 [peer reviewed abstract selected for oral presentation; awarded Top Abstract]

2. Breckenridge Z, Bonter K, Lea K, Bubela T. The Global Landscape of Cellular Immunotherapy Trials. Insights: Focus on Public Health. Edmonton, AB. Oct 28, 2015. [poster presentation]

3. Geary J, Bubela T. Global perspectives on participating in the International Barcode of Life Project. 6th International Barcode of Life Conference, Guelph, Ont, Aug 18-21, 2015. [peer reviewed abstract selected for oral presentation, published in Genome 58(5): 219].

4. Bubela T, Geary J, Bieber M, Luth W, Hik D. Diffusing barcoding: the global spread of a good idea. 6th International Barcode of Life Conference, Guelph, Ont, Aug 18-21, 2015. [peer reviewed abstract selected for oral presentation, published in Genome 58(5): 201].

5. Kowal S, Bubela T, The Ethics of Pediatric Clinical Trials of Novel Bio-Therapeutics for Genetic Retinopathies. Ophthalmology Research Day 2015. Edmonton, AB. May 29, 2015 [oral presentation]

6. Geary J, Bubela T, Applying institutional logics theory to understand how community heteriogeneity impacts establishing successful commons: A case study of the International Barcode of Life Project. International Association for the Study of the Commons Biennial Conference, Edmonton, AB. May 25-29, 2015 [oral presentation]

7. Breckenridge Z, Bonter K, Lea K, O’Keefe C, Bubela T, The Global Clinical Trial Landscape of Cellular Cancer Immunotherapy. Canadian GE3LS and Health Services & Policy Research Conference: Integrated Approaches to Opportunities and Challenges in the Genomics Era, Vancouver, BC. April 18-21, 2015 [poster presentation]

8. Kowal S, Engaging in Community-Driven Participatory Research as a Graduate Student: What I Wish I Would Have Known, School of Public Health, University of Alberta, SPH 623: Qualitative and Community-Based Research Approaches (Prof: Dr. Kate Storey), March 11, 2015. Edmonton Alberta [Invited Lecturer]

2014 9. Kowal S, Jardine C, Bubela T, Foreign-Born Women’s Experiences with Informed Consent during

Immunization, University of Alberta, School of Public Health, INSIGHTS '14, Edmonton, AB. Nov 12, 2014 [oral presentation]

10. Kowal S, The Role of Nurses in Newcomers’ Experiences During Pregnancy and Early Childhood, Faculty of Nursing, McMaster University, HTH SCI 2RR3: Social Determinants of Health (Prof: Diana Sherifali), October 16, 2014. Hamilton Ontario [Invited Lecturer]

11. Kowal S, Jardine C, Bubela T, The Impact of Community Based Participatory Research Qualitative Inquiry Outcomes, Engagement Scholarship Consortium 2014 Meeting, Edmonton AB, October 7-8, 2014 [oral presentation, peer reviewed]

12. Kowal S, Clarke D (2014) Communicating Genomic Risk in Primary Health Care: Challenges and Opportunities for Providers. Health Science Inquiry, 5(1):43-45 [graduate journal publication, peer reviewed Winner: Best Submission – Expedited review in Medical Care Awarded to Stephanie Kowal and Derek Clark]

13. Kowal S, (2014) Primary Care Networks: Community-Focused Primary Health in Alberta. Health Science Inquiry, 5(1): 29-31 [News Report]

of 74 14. Fung, ME Atkins H, Bubela T. Evaluating the Outcomes of Stem Cell Clinical Trials, International Society for

Stem Cell Research 12th Annual Meeting, Vancouver, BC, June 18, 2014 [Poster Presentation]. 15. Kowal S, Engaging in Community-Driven Participatory Research as a Graduate Student: What I Wish I

Would Have Known, School of Public Health, University of Alberta, SPH 623: Qualitative and Community-Based Research Approaches (Prof: Dr. Kate Storey), May 16, 2014. Edmonton Alberta [Invited Lecturer]

16. Kowal S, Jardine C, Bubela T, “That’s how the nurse did it, how she decided which vaccines”: Immigrant mothers’ experience with informed consent during immunization in Edmonton, Alberta. Canadian Public Health Association Annual Conference, Toronto, ON, May 26-29, 2014 [oral presentation, peer-reviewed].

17. Kowal S, Jardine C, Bubela T, “Maybe if I had a family doctor, they would have suggested vaccines”: Foreign-Born Women’s Experiences with Immunization Risk Communication in Edmonton, Alberta. Canadian Public Health Association Annual Conference, Toronto, ON, May 26-29, 2014 [oral presentation, peer-reviewed].

18. Kowal S, Jardine C, Bubela T, Immunization Decision-Making Processes of New Immigrant Pregnant Women and Mothers in Edmonton: Implications for Vaccination Information and Campaign Development. Presentation for Surveillance and Assessment, Communicable Disease, and Immunization Branches of Alberta Health, Edmonton AB April 1, 2014, [Invited Presenter]

19. Kowal S, New Immigrant Women’s Vaccination Decision-Making Process: Implications for Vaccination Information and Campaign Strategies, Global Health Awareness Week, Edmonton AB, March 21, 2014 [oral presentation, invited speaker]

20. Kowal S, Jardine C, Bubela T, "If They Tell Me to Get It, I'll Get It. If They Don't...": New Immigrant Women's Relationship with Canadian Vaccination Information, Fourth International Conference on Health, Wellness and Society, Vancouver BC Mar 14-15, 2014 [oral presentation, peer-reviewed, Graduate Student Association Professional Development Grant - $500]

21. Tang K, Kowal S, Kongats K, Lukasewich M, Atkey K, Creating healthier Communities through Paricipatory Research : A Pecha-Kuch Style Presentation, University of Alberta International Week, Edmonton AB, January 27-31, 2014 [Workshop Coordinator/Presenter, peer reviewed]

22. Kowal S, (2014) The Current State of Child Poverty in Canada: Statistics and Responses. fACTivist, Winter Edmonton Social Planning Council Quarterly Newsletter [News Report]

2013 23. McGetrick JA, Bubela T, Hik D. Expert Assessment of Geographic Information Science (GIS) for Health

Communication in Circumpolar Natural Resource Development. ArcticNet Science Meeting, Halifax Nfld. December 11-13, 2013 [oral presentation, peer-reviewed].

24. McGetrick JA, Bubela T, Hik D. Balancing Traditional Knowledge with Scientific Evidence: Multi-stakeholder Consideration of Health Impacts in the Co-Management Setting. ArcticNet Science Meeting, Halifax Nfld. December 11-13, 2013 [poster presentation, peer-reviewed].

25. Fung ME, Atkins H, Bubela T. Evaluating the outcomes of stem cell therapy clinical trials. Till & McCulloch Meeting 2013, Banff, AB. October 23-25, 2013. [poster presentation, Winner Best Poster Prize - $500 to Moses Fung]

26. O’Keefe C, Atkins H, Bubela T. Enhancing translational stem cell research: innovative models for multi-sectorial collaboration. . Till & McCulloch Meeting 2013, Banff, AB. October 23-25, 2013. [poster presentation].

27. Geary J, Camicioli E, Bubela T. The public face of barcoding: How iBOL and DNA barcoding are represented in newspapers from around the world. The 5th International Barcode of Life Conference. Kunming, China, October 27-31, 2013. [oral presentation, peer-reviewed]

28. Guebert J. Prospects and Possibilities for the 2013 G8 Lough Erne Summit: Trade, Transparency, Tax and Terrorism. Queen’s University Belfast, Belfast, Northern Ireland, June 14, 2013. [invited panelist, oral presentation]

29. Kowal S, Jardine C, Bubela T. Transition, Trauma, and Information: Immigrant Women’s Relationship with Immunization Risk Communication, Society of Risk Analysis Annual General Meeting, Baltimore, MD,

of 74 December 9-12, 2013. [Oral presentation; Society of Risk Analysis (US) International Student Award - $150; Profiling Alberta’s Graduate Students Award - $1000]

30. Kowal S, Jardine C, Bubela T. Immunization Risk Communication for New Immigrant Women in Edmonton, National Forum on Public Health Education and Research, Edmonton Alberta, November 13, 2013. [poster presentation Winner Best MSc Poster Prize - $100 to Stephanie Kowal]

31. Kowal S, Jardine C, Bubela T. “If I have the recommendation from a doctor, I would take it and if there is none, I won’t.”: Immigrant women’s perspectives of vaccine risk communication in Edmonton Alberta, Women and Children’s Health Research Institute Research Day, Edmonton, Alberta, November 6, 2013. [oral presentation]

32. Kowal S, Jardine C, Bubela T. Immunization Risk Communication for New Immigrant Women in Edmonton, Academic Women’s Association Fall Social and Bente Roed Award Recipient Presentation, Edmonton, Alberta, October 10, 2013. [invited oral presentation as the Bente Roed Award Winner]

33. Kowal S. Immigrant Women’s Relationship with Immunization Risk Communication: Addressing Inequity in Health Information Delivery. Campus Alberta Student Conference on Health, Banff, Alberta September 6-7, 2013. [oral presentation]

34. Kowal S. Stories of Change Panel – Tips for Students to Win Grant Money, University of Alberta School of Public Health 2013 Orientation, Edmonton, Alberta, September 3, 2013. [invited panellist, oral presentation]

35. Kowal S. Ethnically Diverse Perspectives of Child Bodies in Relation to Immunization Uptake: Empirical Evidence from Various Immigrant Populations in Edmonton, Alberta, University of British Columbia-Okanagan, Faculty of Creative and Critical Studies Graduate Conference: Renewing/Reknowing the Body, Kelowna, British Columbia, May 3-5, 2013. [oral presentation]

36. Luth W, Jardine C, Bubela T. When pictures waste a thousand words: Analysis of the 2009 H1N1 Pandemic on Local Television News. Canadian Public Health Association 2013 Annual Conference: Moving Public Health Forward: Evidence, Policy, Practice, Ottawa Convention Centre, Ottawa, ON, June 9-13, 2013. [oral presentation]

37. McGetrick JA (2013) Logical Framework Analysis to Improve Health Communication for Natural Resource Development in Canada’s Northern Territories. International Journal of Circumpolar Health 72(S1): 1005-1007. [extended Abstract]

38. McGetrick JA, Bubela T, Hik D. Expert Assessment of Geographic Information Science (GIS) for Health Communication in Natural Resource Development of the Canadian Arctic. 2013 Arctic Science Summit Week: The Arctic Hub Regional and Global Perspectives. Krakow, Poland. April 13-19, 2013. [poster presentation, Awarded Outstanding Poster Prize; Profiling Alberta’s Graduate Students Award - $830]

39. McGetrick JA, Bubela T, Hik D. Content Analysis of Health Impacts in Multi-stakeholder Dialogue for Public Hearings in the Northwest Territories. Circumpolar Students Association Northern Research Day. Edmonton, Alberta. March 28, 2013. [oral presentation]

40. Mishra A, Bubela T, Bieber M. Access to High-Throughput Phenogenomics Resources: International User Survey of Mouse Resources. Beyond The Genome BioMed Central Conference, University of California San Francisco, California. October 1-3, 2013. [poster presentation, peer-reviewed]

2012 41. Benjaminy S, MacDonald I, Bubela T. Hope in Sight: Ocular Gene Transfer Risk Communication. Insights

Conference, School of Public Health, University of Alberta, Edmonton, Alberta, November 14, 2012. [oral presentation, peer-reviewed]

42. Benjaminy S, Bubela T, Bieber M, MacDonald I. Hope and Hype in Sight: Multi-Stakeholder Perspectives on Ocular Gene Therapy. American Society of Human Genetics conference. San Francisco, California, November 2012. [poster presentation; peer-reviewed; Graduate Student Association Professional Development Grant - $500]

43. Benjaminy S, MacDonald I, Bubela T. Hope in Sight: Ocular Gene Transfer Risk Communication. American Society of Bioethics and Humanities Annual Meeting, Washington DC, October 20, 2012. [oral presentation, peer-reviewed; Profiling Alberta’s Graduate Students Award - $1,100]

of 74 44. Benjaminy S, Bieber M, MacDonald I, Bubela T. Media Representations and Patient Perspectives of Ocular

Gene Transfer Clinical Trials. American Society for Bioethics and Humanities conference. Washington, DC, October 2012. [poster presentation; peer-reviewed]

45. Benjaminy S, Bubela T, Bieber M, MacDonald I. Hope and Hype in Sight: Multi-Stakeholder Perspectives on Ocular Gene Therapy Clinical Trials. Vision Science Symposium, University of Alberta, Edmonton, Alberta, June 6, 2012. [oral presentation, peer-reviewed]

46. Benjaminy S, Bubela T Bieber M, MacDonald I. Sustainably translating choroideremia gene transfer from bench to bedside: a genetic risk communication framework. Sixth International Choroideremia Research Foundation Conference. Boston, Massachusetts, June 2012. [oral presentation; Choroideremia Research Foundaton (US) Travel Award - $1,350]

47. Benjaminy S, Bubela T Bieber M, MacDonald I. Hope and Hype in Sight: Sensationalism in Choroideremia Gene Therapy. Association of Research in Vision and Ophthalmology conference, Fort Lauderdale, Florida, May 6-10, 2012. [poster presentation; peer-reviewed; Public Health Sciences Graduate Travel Award, University of Alberta - $1,000]

48. Benjaminy S, Bubela T, MacDonald I. A Cure in Sight? Multi-Stakeholder Perspectives on Ocular Gene Therapy Clinical Trials. Ethics of Genetics class, Department of Biological Sciences, University of Alberta, Edmonton, Alberta, February 15, 2012. [invited presentation]

49. Geary J, Bubela T. Access to Genetic Resources and Benefit Sharing: Implications for Research in Canada’s North. 15th International Congress on Circumpolar Health. Fairbanks, Alaska. August 5-10, 2012. [oral presentation]

50. Kowal S, Jardine C, Bubela T. Assessing Vaccination Risk Communication Needs for Pregnant Immigrant Mothers in Alberta, Canada, Society of Risk Assessment Annual General Meeting, December 9−12, 2012, San Francisco, CA, USA . [oral presentation; U Alberta, Department of Public Health Sciences, Public Health Science Travel Award - $1,000.00]

51. Kowal S, Jardine C, Bubela T Pregnant Women’s Decision Making Processes During the H1N1 Pandemic: Perspectives of a Threatening Virus and a Risky Response. Society of Risk Assessment Annual General Meeting. San Francisco, California, December 10, 2012. [oral presentation, Society of Risk Analysis (US) International Student Award - $350]

52. Kowal, S, Jardine, C, Bubela, T. Threatening Virus or a More Threatening Response?: Pregnant Women’s Vaccination Decision Making Processes during H1N1, University of Alberta, School of Public Health, INSIGHTS '12, Edmonton, Alberta, Nov 14, 2012. [Winner Best MSc Oral Presentation Prize - $100 Award to S Kowal]

53. Kowal S, Jardine C, Bubela T. Help Us Decide, or Leave Us Alone: Pregnant Women’s Perspectives on Pandemic H1N1 Vaccination Communications. Advancing Excellence in Gender, Sex and Health Research Conference. Montreal, Quebec, October 30, 2012. [oral presentation, Women and Children’s Health Research Institute Trainee Travel Award - $1,000]

54. Kowal S, Jardine C, Bubela T. H1N1 Health Risk Communication for Pregnant Women in Alberta, Canada. CIHR−Institute of Human Development, Child and Youth Health Scientific Forum: Promoting the Health and Well−being of Children and Youth. Edmonton Alberta. October 15, 2012. [poster presentation]

55. Kowal S, Jardine C, Bubela T. One Step to Beginning a Masters Level Community−Based Research Project, Community University Engagement Showcase IV: Celebrating 100 Years of Engaged Research. Edmonton, Alberta, May 25, 2012. [poster presentation]

56. Kowal S , Jardine C, Bubela T. Vaccine Knowledge Translation for Pregnant Women and Mothers in Immigrant Populations. Alberta Graduate Conference. Edmonton Alberta, May 3, 2012. [poster presentation]

57. Kumbamu, A. Sustaining the Indigenous Knowledge Commons. In Bubela T, Gold ER (eds) Genetic Resources and Traditional Knowledge: Case Studies and Conflicting Interests. (Williston, VT: Edward Elgar, 2012). [book chapter]

of 74 58. Li MD, Bubela T, Hafez M, Bieber M, Dacks L, Atkins H. Public Expectations Confront Clinical Realities for

Translational Stem Cell Research. Till & McCullough Meetings. Till & McCullough Meetings, Montreal Quebec, April 30-May 2, 2012. [poster presentation, Winner Best Poster Prize - $500 to MD Li]

59. Li MD, Reshef A, Dacks LA, Bieber M, Bubela T. Online Forum for Addressing Barriers to Translational Stem Cell Research. Till & McCullough Meetings, Montreal, Quebec, April 30-May 2, 2012. [poster presentation]

60. Luth W, Forcier E, Jardine C, Bubela T. When pictures waste a thousand words: 2009 H1N1 pandemic risk communication on Alberta TV news. INSIGHTS ’12: A Focus on Public Health, School of Public Health, University of Alberta, Edmonton, Alberta. November 14, 2012. [oral presentation, peer-reviewed]

61. Luth W. From Foe to Friend: Is there a Place for Video Games in School-based Obesity Interventions? Poster presentation at the 4th Conference on Recent Advances in the Prevention and Management of Childhood & Adolescent Obesity, Halifax, Nova Scotia, October 26, 2012. [poster presentation, U Alberta, Department of Public Health Sciences, Public Health Science Travel Award - $1,000.00]

62. MacDonald I, MacLaren R, Seabra M, Benjaminy S, Bubela T. Gene Therapy Trials in Human Retinal Dystrophies: Choroidremia. American Academy of Ophthalmology Annual Meeting, Chicago, Illinois, November 19, 2012 [oral presentation]

63. McGetrick JA, Bubela T, Hik D. Public Hearings in the Northwest Territories: Improving Multistakeholder Dialogue through Health Impact Assessment Guidelines. INSIGHTS '12 A Focus on Public Health Research. Edmonton, Alberta. November 15, 2012. [oral presentation]

64. McGetrick JA, Bubela T, Hik D. Logical Framework Analysis: The Case for Geographic Information Systems in Northern Risk Communication. 15th International Congress on Circumpolar Health. Fairbanks, Alaska. August 5-10, 2012. [oral presentation; U Alberta, Department of Public Health Sciences, Public Health Science Travel Award - $1,000.00; Shell Enhanced Learning Fund (SELF) Grant, University of Alberta School of Energy and Environment ($2500)]

65. McGetrick JA, Bubela T Hik D. Logical Framework Analysis: The Case for Geographic Information Systems in Northern Risk Communication. 18th International Symposium on Society and Resource Management (ISSRM 2012): Linking the North and South: Responding to Environmental Change. Edmonton, Alberta. June 17-21, 2012. [poster presentation]

66. McGetrick JA. Risk Communication for Natural Resource Development in the Canadian Arctic. University of Alberta Political Science Graduate Students' Association Sixth Annual Research Days 2012: Intellectual Diversity in Political and Social Scholarship. Edmonton, Alberta, May 4-5, 2012. [oral presentation]

67. McGetrick JA. Communication Tools for Health Impact Assessment Circumpolar Students' Association 12th Annual Northern Research Day. Edmonton, Alberta. March 29, 2012. [oral presentation]

2011 68. Benjaminy S, Bieber M, Bubela T. From darkness to the limelight: Media representations of ocular gene

therapy. Insights Conference, School of Public Health, University of Alberta, Edmonton, Alberta, November 16, 2011. [oral presentation, peer-reviewed]

69. Benjaminy S, Bubela T, MacDonald I. Genetic Risk Communication in Light of Ocular Gene Therapy Clinical Trials. First International Choroideremia Symposium, Montpellier, France, September 22, 2011. [oral presentation; Choroideremia Research Foundation (Canada) Travel Award $3,100]

70. Geary J, Goodman K, Bubela T. Developing research agreements between northern Aboriginal communities and academic researchers: A case-study of the Canadian North Helicobacter pylori Working Group. International Network for Circumpolar Research: Annual Meeting. Oulu, Finland, June 13-17, 2011. [oral presentation]

71. Kumbamu, A. “Dispossession and Metabolic Rift in Indian Agriculture: The Dynamics of Adoption and Abandonment of Genetically Modified Cotton in Kadavendi, A South Indian Village. “ “Nature of Contradictions” conference at the University of Florida, Gainesville, Florida, March 29-April 2, 2011. [invited presentation]

72. Kumbamu, A. “Trust and Equity in Global Research Partnerships: Reflections from India on Access and Benefit Sharing” Participated and presented a paper at a PhytoMetaSyn research symposium in Toronto, Ontario, March 5-7, 2011. [oral presentation]

of 74 73. McGetrick JA, McGee, T. Disaster Risk Reduction in Developing Countries. INSIGHTS '11 A Focus on Public

Health Research. Edmonton, Alberta. November 16, 2011. [poster presentation] 2010 74. Hafez M, Atkins H, Bubela T. Forecasting stem cell therapies: A survey of novel clinical applications 2010

Stem Cell Network Annual General Meeting, Calgary, Alberta, November 22-25, 2010. [poster presentation]

2009 75. Bubela T, Strotmann A, Noble R, Morrison S. Commercialization vs. collaboration Policy Goals in Stem Cell

Research. Insights: A Focus on Public Health Research, School of Public Health, University of Alberta, Edmonton, Alberta, November 12, 2009. [oral presentation]

76. Strotmann A, Zhao D, Bubela T. A multi-database approach to field delineation. Paper submitted to The American Society for Information Science and Technology 2009 Annual Meeting, Vancouver, British Columbia, 2009. [paper and oral presentation]

77. Strotmann A, Zhao, D, Bubela, T. Author name disambiguation for collaboration network analysis and visualization. The American Society for Information Science and Technology 2009 Annual Meeting, Vancouver, British Columbia, November 6-11, 2009. [oral presentation]

78. Strotmann A, Zhao D, Bubela T. A multi-database approach to field delineation. International Society for Scientometrics and Informetrics 2009 Conference, Rio de Janeiro, Brazil, July 14-17, 2009. [paper and oral presentation]

79. Strotmann A, Zhao D, Bubela T. Field delineation or field delimitation for mapping sciences? read at the Canadian Association for Information Science Annual Conference, Ottawa, Ontario, May 28-30, 2009. [presentation]

80. Taylor B, Bubela T. Stakeholders in Canada’s Access to Medicines Regime. Canada’s Access to Medicines Regime: Hindrance or Hope? Workshop sponsored by The Initiative for Drug Equity and Access at the Leslie Dan Faculty of Pharmacy, University of Toronto and the Centre for Intellectual Property Policy at McGill University, Ottawa, Ontario, May 7, 2009. [oral presentation]

2008 81. Noble BR, Bubela T. Commercialization and Mouse Genomics Research in Canada. 4th Annual Joint

Biotechnology Workshop, Victoria, British Columbia, September 26-27, 2008. [oral presentation] 82. Ouelette C, Bubela T, Caulfield T. Popular representations of genetics research: Recommendations for

journalist-researcher relationships. The American Society of Human Genetics: 58th Annual Meeting, Philadelphia, Pennsylvania, November 11-15, 2008. [poster presentation]

83. Strotmann A, Zhao D. Bibliometric maps for aggregated visual browsing in digital libraries. Proceedings of The SIGIR 2008 Workshop on Aggregated Search, Singapore July 24, 2008. [oral presentation]

84. Taylor BG, Bubela T. 4th Annual Joint Biotechnology Workshop, Victoria, British Columbia, September 26-27, 2008. [oral presentation]

85. Zhao D, Strotmann A. Identification of emerging research fields via combined author co-citation analysis and author bibliographic coupling analysis", poster presentation at the 10th International Conference on Science and Technology Indicators. Abstract published in the conference proceedings, Vienna, Austria, September 17-20, 2008. [poster presentation]

86. Zhao D, Strotmann A (2008) Evolution of research activities and intellectual influences in Information Science 1996-2005: Introducing author bibliographic coupling analysis. Journal of The American Society for Information Science and Technology 59(13): 2070-2086. [paper]

87. Zhao D, Strotmann A (2008) Comparing all-author and first-author co-citation analyses of Information Science. Journal of Informetrics, 2(3): 229-239. [paper]

88. Zhao D, Strotmann A. Author Bibliographic Coupling - Another approach to citation-based author knowledge network analysis. Proceedings of The American Society for Information Science and Technology 2008 Annual Meeting, Columbus, Ohio, October 24-29, 2008. [oral presentation]

of 74 89. Zhao D, Strotmann A (2008) Information Science during the first decade of the Web: An enriched author

co-citation analysis. Journal of the American Society for Information Science and Technology, 59(6): 916-937. [paper]

2007 90. Kraus E, Bubela T. The “progress paradigm in Parliamentarian arguments in the Stem Cell Debates: a

systematic comparison between Hansard debates on Stem Cell Research and Reproductive Technology from the United Kingdom and Canada. 3rd Annual Joint Biotechnology Workshop, Victoria, British Columbia, September 21-23, 2007. [oral presentation]

91. Noble R, Bubela T, Orton N, Einsiedel E, Strotmann A. Examining Intellectual Property Concerns in the Field of Stem Cell Research. Stem Cell Network Annual General Meeting, Toronto, Ontario, November 7-8, 2007. [After a competitive selection process with a success rate of 1/5, Rhiannon Noble’s abstract was selected as a trainee presentation]

92. Noble R, Orton N, Bubela T, Einsiedel E. Downstream Effects of Patenting Biomedical Research Tools. 3rd Annual Joint Biotechnology Workshop, Victoria, British Columbia, September 21-23, 2007. [oral presentation]

93. Zhao D, Strotmann A. Large-Scale Social Networks and Bibliometric Analysis. Scientometric and Social Network Analysis Workshop hosted at the University of Calgary, Calgary, Alberta, September 20, 2007. [oral presentation]

94. Zhao D, Strotmann A (2007) Can citation analysis of web publications better detect research fronts? Journal of the American Society for Information Science and Technology, 58(9): 1285-1302. [paper]

95. Zhao D, Strotmann A. All-author vs. first-author co-citation analysis of the Information Science field using Scopus. Joining Research and Practice: Social Computing and Information Science - Proceedings of the American Society for Information Science and Technology (JASIS&T) 2007 Annual Meeting, Milwaukee, Wisconsin, October 19 - 24, 2007. [oral presentation]

2006 96. Chau M, Bubela T. Private Sector Representations of Genetic Testing. Second Annual Joint Biotechnology

Workshop, Victoria, British Columbia, September 16, 2006. [oral presentation] 97. Fernando K, Bubela T, Caulfield T. Regulatory Governance and Public Trust as represented through the

Media. The Advanced Foods and Materials Network (AFMNet) Second Annual Scientific Conference "Research, Results, Rewards: The Science and Beyond - Swifter, Higher, Stronger!", Calgary, Alberta, April 30, 2006. [poster presentation]

98. Hagen SD, Bubela T, Gold ER, Morin JF. Intellectual Property Governance and Not-State Actors: The Case of Bill C-9.Second Annual Joint Biotechnology Workshop, Victoria, British Columbia, September 16, 2006. [oral presentation]

99. Koper M, Bubela T, Caulfield T, Boon H. Media Portrayal of Conflicts of Interest in Biomedical Research. Second Annual Joint Biotechnology Workshop, Victoria, British Columbia, September 16, 2006. [oral presentation]

100. Koper M, Bubela T, Caulfield T. Media Portrayal of Conflicts of Interest in Herbal Remedy Clinical Trials. The Advanced Foods and Materials Network (AFMNet) Second Annual Scientific Conference "Research, Results, Rewards: The Science and Beyond - Swifter, Higher, Stronger!", Calgary, Alberta, April 30, 2006. [poster presentation]

101. Strotmann A, Bubela T. Measuring the Impact of Canadian Science Networks. Postdoc Research Day, University of Alberta, Edmonton, Alberta, April 7, 2006. [poster presentation]

102. Zhao D, Strotmann A (2006) Can citation analysis of web publications better detect research fronts? Journal of the American Society for Information Science and Technology, 58(9): 1285-1302. [paper]

2005 103. DeBow S. Stem Cells: The Politics behind the Law in Canada.Joint Biotechnology Trainee Workshop, Victoria,

British Columbia, November 19, 2005. [oral presentation] 104. Fernando K, Bubela T, Caulfield T. Public Trust and Confidence in Regulatory Governance as represented

through the Media. Joint Biotechnology Trainee Workshop, Victoria, British Columbia, November 19, 2005.

of 74 [oral presentation]

105. Fernando K, Bubela T, Caulfield T. Public Trust and Confidence in Regulatory Agencies as represented through the Media. 3rd National food Security Assembly Waterloo, Ontario, September 30-October 2, 2005. [poster presentation]

106. Koper M, Bubela T, Caulfield T, Boon H. Media Portrayal of Conflicts of Interest in Herbal Remedies. Joint Biotechnology Trainee Workshop, Victoria, British Columbia, November 19, 2005. [oral presentation]

107. Kurata C, Bubela T, Caulfield T. Unpacking the Justifications for the Canadian Ban on Therapeutic Cloning” American Society of Human Genetics Annual Meeting, Salt Lake City, Utah, October 24-29, 2005. [poster presentation]

108. Kurata C, Bubela T, Caulfield T. Unpacking the Justifications for the Canadian Ban on Therapeutic Cloning. Challenges in Regenerative Medicine Annual Conference, Toronto, Ontario, October 21-22, 2005. [poster presentation]

ENGAGED TEACHING

Engaged teaching is a centre-piece in the mission and educational plan of the School of Public Health. In addition to my regular course load, therefore, I have developed case-based learning materials for interdisciplinary courses and workshops on legal and ethical issues arising from research and development. In 2010-2011, I developed training case studies and instructor manuals on intellectual property law and commercializaton for the Canadian Intellectual Property Office to be deployed in post-secondary institutions across Canada. These narrative cases and supporting training material covered the creative arts, information technologies and software, innovations in engineering and the life sciences. As further examples, I developed and delivered the case-based training for trainees of one of Canada’s most successful Networks of Centres of Excellence (NCE), the Stem Cell Network (SCN). In addition to issues of intellectual property and commercialization, I have been a member of the SCN’s Training and Education Committee since 2008 and have participated in course development and delivery on regulatory and socio-ethical issues confronting stem cell researchers. I have since translated this expertise into the co-development of a workshop and training session on Collaborative Models for Genetic Epidemiological Research in Public Health: Engaging Researchers, Knowledge-Users, Communities and Research Participants presented for trainees at the Canadian Society of Epidemiology and Biostatistics 2013 Conference.

I have also been heavily engaged in developing training material to build research management, intellectual property law and commercialization in developing countries (e.g., Tanzania, South Africa, Botswana and Kenya), especially for innovation focused on global health. I have been engaged in multiple collaborations and consultations on this topic and have brought my significant research expertise in genetic resources, access and benefit sharing, and the governance of international research consortia to address practical issues in this arena.

Finally, my research on science communication has enabled me to develop courses and training material for researchers to assist them in knowledge translation activities with lay and policy audiences. I have also actively engaged in this area, developing and presenting in multi-stakeholder consultation workshops as well as addressing concerns and issues raised by patient communities and the general public in the media, through workshops, cafés scientifiques, and patient conferences. In 2014, I was invited to give two keynote presentations, to over 600 Grade 12 students in Toronto and Vancouver, respectively, about challenges in the commercialization and translation of regenerative medicine as part of the Stem Cell Talks series sponsored by Let’s Talk Science. I then moderated the discussion panels. I have continued with Stem Cell Talks in Vancouver in 2015 and 2016.

of 74

CAPACITY BUILDING - CANADA

June 9, 2017 Bubela T The clinical translation of cell therapies – neurological and auto-immune disorders. Let’s Talk Science / Stem Cell Talks (University of British Columbia). Invited keynote speaker and panel participant for 200 Vancouver –area High School Students.

February 24, 2017 Bubela T Translating Translation. Non-science challenges from bench to bedside for novel biotherapeutics. Invited speaker for Biology 30. Strathcona Composite High School. Edmonton, Alberta.

May 13, 2016 Bubela T The clinical translation of cancer immunotherapies. Let’s Talk Science / Stem Cell Talks (University of British Columbia). Invited keynote speaker and panel moderator for 200 Vancouver –area High School Students.

May 15, 2015 Bubela T Innovating for the Eye: The clinical translation of ocular biotherapeutics. Let’s Talk Science / Stem Cell Talks (University of British Columbia). Invited keynote speaker and panel moderator for 200 Vancouver –area High School Students.

May 16, 2014 Bubela T Hope, Hype and Stem Cell Tourism. Let’s Talk Science / Stem Cell Talks (University of British Columbia). Invited keynote speaker and panel moderator for 200 Vancouver –area High School Students.

March 7, 2014 Bubela T Hope and Hype in Stem Cell Research. Let’s Talk Science / Stem Cell Talks (MARS Innovation, Toronto). Invited keynote speaker and panel moderator for 400 Ontario High School Students.

June 3, 2014 Steering Novel-Biotherapeutics from Bench to Bedside: All you ever wanted to know about intellectual property and commercialization. Case-based workshop hosted by NorCOMM2 and the Institute of Medical Sciences, University of Toronto. Based on lecture material and case study below.

November 20, 2014 Repeated one day workshop in the Faculty of Medicine and Dentistry, University of Alberta

• T Bubela, L Nutter, A Khashayar Varkouhi, K Bonter, and S Benjaminy (2014) Steering Novel-Biotherapeutics from Bench to Bedside: Ocular Gene Therapy. Training Case Study;

• T Bubela, K Bonter, (2014) Steering Novel-Biotherapeutics from Bench to Bedside: Ocular Gene Therapy. Discussion Leader’s Guide.

June 24, 2013 Workshop and training session on: Collaborative Models for Genetic Epidemiological Research in Public Health: Engaging Researchers, Knowledge-Users, Communities and Research Participants. Canadian Society of Epidemiology and Biostatistics: CSEB 2013 Conference, St. John’s, Newfoundland. Developed content for two case studies on biobanks and associated data for studying the genetics of colorectal cancer with Amy Colquhoun and Lori Knowles on the legal, regulatory, ethical and commercialization issues. Participated in the workshop pilot at the School of Public Health, University of Alberta.

April 23-25 2013 Understanding Stem Cell Controversies: An Intensive Course on Regulatory and Socio-Ethical Issues. Stem Cell Network, Montreal, April 23-25, 2013. [invited speaker, chair and panellist at a course for science and social science trainees of the Canadian Stem Cell Network]

November 20, 2010 Delivery of 2 lectures and a ½ day workshop on intellectual property and commercialization of stem cell technologies for Stem Cell Network Trainees and Researchers. Case Study for training developed in collaboration with the Stem Cell Network and the Canadian Intellectual Property Office.

2010-2011 Development of training case studies and instructor manuals for the Canadian Intellectual Property Office:

1. Canadian Intellectual Property Office and the Canadian Stem Cell Network (2011) CellBioTherapeutics: Commercializing Stem Cell Research - Revised Discussion Leaders’ Guide in line with new EU case law.

of 74 2. Canadian Intellectual Property Office (2011) John Thomson’s Entrepreneurial Venture: Commercializing

the SuperSorter – Case Study and Discussion Leaders’ Guide 3. Canadian Intellectual Property Office (2011) Samantha Chang: IP Case Study – Edited Case Study and

developed Discussion Leaders’ Guide. 4. Canadian Intellectual Property Office (2011) Autopaint: IP Case Study – Edited Case Study and developed

Discussion Leaders’ Guide. 5. Canadian Intellectual Property Office (2011) Suki’s Enterprises: Who has ownership of software? – Edited

Case Study and developed Discussion Leaders’ Guide. October 29, 2010 Meeting with the Canadian Intellectual Property Office and the Stem Cell Network to

develop a training case study on the patentability, commercialization and ethics of stem cell research.

CAPACITY BUILDING - INTERNATIONAL

• Bubela T, Campbell B, Intellectual Property Management and Technology Transfer in the University and Institutional Research Setting Tanzania Commission for Science and Technology, Dar es Salaam, Tanzania, February 16-17, 2010. 2 day workshop.

• Bubela T, Campbell B, Intellectual Property Management and Technology Transfer in the University and Institutional Research Setting, Ikafara health Institute, Dar es Salaam, Tanzania, February 18, 2010

• For details see: The Innovation Partnership, “TIP’s Giving Back Program: Building Capacity in Innovation Management in Tanzania” online: http://www.theinnovationpartnership.org/data/documents/00000021-1.pdf

TANIA M. BUBELA - CURRICULUM VITAE · TANIA M. BUBELA - CURRICULUM VITAE Dean and Professor Faculty...

Documents

Transcript of TANIA M. BUBELA - CURRICULUM VITAE · TANIA M. BUBELA - CURRICULUM VITAE Dean and Professor Faculty...